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ABSTRACT
PERTURBATIONS IN PROTEIN DYNAMICS ASSOCIATED WITH LIGAND
BINDING TO THE BLOOD COAGULATION ENZYMES THROMBIN AND
FACTOR XIII
Thomas M Sabo, II
December 13, 2007
In blood coagulation, the serine protease thrombin is a multifaceted enzyme that
interacts with multiple proteins. Thrombin utilizes two anion binding exosites (ABE-I
and II) to supplement binding to fibrinogen and to the platelet receptor GpIbα, two
proteins instrumental in clot formation. Approximately 7% to 15% of the fibrinogen γ
chain exists as the highly anionic γ′ variant (410PEHPAETEYSDSLYSPEDDL427), which
has been shown to bind ABE-II. GpIbα possesses a similar anionic stretch of residues
(269DEGDTDLYSDYSYSPEEDTEG286); however, the exact destination of thrombin
binding is more ambiguous.

1D and 2D solution NMR have been employed to

characterize the structural features of the bound γ′ and GpIbα peptides. The results
indicate that the γ′ residues A414-L427 make significant contact with the enzyme, a turn is
present between residues YS422-D425, and there is a hydrophobic cluster involving YS418YS422. For the GpIbα peptide, NMR results suggest the peptide exists in an extended
conformation with residues D274-E285 contributing to binding.

Hydrogen deuterium

exchange (HDX) coupled with MALDI-TOF MS indicate that at a 20:1 peptide-enzyme
ratio both peptides are interacting with residues within ABE-II fragments. Both peptides
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affect the dynamics of HDX for regions not associated with ABE-II including ABE-I, the
autolysis loop, and the A-chain. Curiously, at 40:1 GpIbα peptide to thrombin, the
GpIbα peptide appears to interact with ABE-I, with unique allosteric consequences.
Thrombin also activates FXIII, and the resultant transglutaminase covalently crosslinks
fibrin through the formation of isopeptide bonds. Studies were performed to examine the
effects of activation and inhibition on the conformational dynamics of FXIII using
MALDI-TOF MS.

A peptide-based FXIIIa inhibitor has been developed with the

glutamine isostere 6-diazo-5-oxo-norleucine (DON).

The K9 DON peptide blocks

chemical modification of C409 within the catalytic core and promotes significant HDX
protection for the β barrel 1 fragment 526-546. These results suggest that inhibition of
FXIIIa leads to local and long-range effects on protein dynamics. Finally, thrombin
activation of FXIII appears to influence regions near the activation peptide, and Ca2+activated FXIII presents more evidence for the existence of additional Ca2+ binding sites.
Ultimately, these studies further detail the dynamic nature of thrombin and FXIII.
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CHAPTER I
INTRODUCTION
Overview of Blood Coagulation
One of the most precious physiological tissues exists in the fluid state. Blood
travels throughout the body and is maintained in the vasculature.

A multifaceted

substance, blood serves as a transport system for cellular components, proteins, nutrients,
hormones, and waste. Blood shuttles red blood cells to and from the lungs, where
hemoglobin loads oxygen for aerobic metabolism in cells and deposits the waste product
carbon dioxide. In the case of infection, blood transports white blood cells to the site of
the foreign invasion. The white blood cells then attack the threat. Thus, the vitality of
life clearly depends on maintaining blood in an unimpeded fluid state and in an enclosed
network of highways (the blood vessels) that connect even the most distant regions of the
organism (1, 2).
When a vascular breach or damaged tissue is present, circulating platelets and
proteins are ready to quickly seal the leak in a process termed coagulation. Unchecked
clotting, however, could potentially lead to a life threatening obstruction of blood flow,
termed thrombosis.

Through evolutionary processes, life has developed a tightly

regulated system of clot formation and degradation, involving cells, proteins, sugars,
electrolytes and other molecules. Further elucidation into the mechanisms of blood
coagulation will eventually open new avenues for treatment of hypertension, heart
disease, and hemophilia (1, 2).
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The classical view of blood coagulation as a cascade of events separated into two
pathways that converge with the activation of Factor X (FX) is presented in Figure 1.
Tissue damage leads to activation of the extrinsic, or tissue factor (TF), pathway (3, 4).
Physiologically, this pathway is the most prompt route for wound healing.

The

components of the intrinsic, or contact factor, pathway all reside within the circulating
plasma (5). Initiation of this branch of
coagulation requires more time for full
activation.

A few perplexing issues

exist regarding this model of blood
clotting.

The main quandary deals

with the absence of any blood clotting
deficiencies in patients with low levels
of FXII (6). However, FVIII and FIX
from

the

intrinsic

pathway

are

absolutely essential for coagulation,
Figure 1: Classical view of blood coagulation.
The cascade is separated into the intrinsic and
extrinsic pathways. Adapted from a poster by
Enzyme Research Laboratories, South Bend, IN.

since patients lacking sufficient levels
of these proteins in the plasma suffer
from hemophilia (7). Finally, a dearth

in FVII from the extrinsic pathway also produces severe clotting disorders illustrating
that the intrinsic pathway alone cannot support effective wound healing (8). These
observations exemplify the interrelatedness of both pathways and suggest that
coagulation should not be thought of as two separate conduits but a more integrated
process without clear pathway demarcations.
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Recent proposals from Hoffman
and Monroe attempting to rationalize
the

clinical

observations

contradicting the view of coagulation
as two pathways have developed the
cell-based model of haemostasis (9,
10). In this scheme, coagulation is
separated into three stages, initiation,
amplification, and propagation (11).
Figure 2 presents the extrinsic and
intrinsic pathways in terms of the
cell-based model of coagulation.
Regardless of whether this model or
Figure 2:
Blood coagulation according to
Monroe and Hoffman (9-11). The classical view of
blood coagulation separates the process into two distinct
pathways converging on the activation of FX. The cellbased model of blood coagulation emphasizes the
interrelatedness of both pathways as described in the
text. In this figure, procoagulation events are depicted in
relation to the cell surface on which they occur.

the classical views of the coagulation
cascade are accurate representations
of blood clotting, the complexity of
thrombus formation should be readily
apparent with a cursory glance at

Figures 1 and 2. In an effort to present blood coagulation with a fresh perspective, the
process of clot formation, regulation, and, ultimately, lysis will be discussed in terms of
the cell-based model of Hoffman and Monroe.
Proper synthesis of prothrombin, FVII, FIX, and FX calls for vitamin K which is a
cofactor in the conversion of glutamic acid to γ-carboxyglutamic acid (Gla) (12). These

3

proteins’ Gla domains reside at the N-termini and provide the site for interaction with the
surface of cell membranes involved with blood coagulation. Binding to the phospholipid
membranes has the additional requirement of calcium. Ca2+ serves to stabilize the Gla
domains of these vitamin K-dependent proteins and to bridge the negatively charged
phospholipid membrane to the negatively charged Gla domains of the proenzymes (13).
Without the Gla domains, successful initiation of blood coagulation is significantly
hindered.

In the following discussion of coagulation, productive activation and/or

function of prothrombin, FVII, FIX, and FX all require Ca2+ and a cell surface.
The initiation phase of clotting is characterized by the preparation of extravascular
cells for an appropriate response to tissue damage. TF bearing cells typically exist
outside the vasculature, i.e. subendothelial tissue.

TF is a transmembrane protein

formally known as FIII. It should be noted that TF also resides in the blood, although the
physiological significance of the circulating TF has yet to be determined (3). Even in the
absence of vascular injury, several clotting factors are able to diffuse into the
extravascular space. Some of the TF forms a complex with the serine protease FVIIa that
can successfully activate FIX and FX in small quantities (14).
The low levels of FXa are able to activate FV and FVII present on TF bearing cells
(15). The resulting prothrombinase complex (FVa/FXa) can convert prothrombin to
thrombin (IIa) (3). Like FXa, IIa also can activate FVII (16). These events explain the
basal level of active coagulation factors that are present in normal individuals.
Fortunately for proper haemostatic balance, once FXa diffuses from the TF bearing cell
and returns to the blood stream, antithrombin and the TF pathway inhibitor (TFPI)
inactivate the protease (17). An explanation for the lack of full blown clotting resides in
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the sizes of the FVIII/von Willebrand factor (vWF) complex and platelets which
effectively minimizes the amount of diffusion that can occur, maintaining these
coagulation factors in the vasculature (18).
Amplification of clotting commences when damage to the endothelium allows
platelets, which are circulating in the blood, to contact the exposed tissue. Platelets
adhere to collagen and other extracellular matrix components that are available at the site
of tissue damage (19).

Adhesion of platelets to the damaged tissue only partially

activates the blood cells. IIa activated by TF bearing cells during the initiation phase can
now cleave the protease activated receptors (PARs) leading to the activation of platelets
(20). FVIII/vWF binds to the platelet surface and activation of FVIII by IIa releases vWF
(18, 21). IIa also activates FV (22) and FXI (23) located on the platelet membrane. The
ability of IIa to activate FXI on the activated platelet surface alleviates the requirement
for FXII, high molecular weight kininogen (HK), and prekallikrein (PK) for FXI
activation (10). This point is highlighted because in the classical model of coagulation,
FXII, HK, and PK initiate intrinsic coagulation through activation of FXI (24). As
evident in the amplification phase, the small amount of available IIa primes the system
for full-blown thrombin activation and clot formation (9-11).
In the final phase of coagulation, a burst of IIa generation is evident as well as a
propagation of procoagulant activities through positive feedback mechanisms. The low
levels of FIXa from the initiation phase forms the tenase complex with FVIIIa on the
platelet surface (25-27). FXIa bound to the platelet membrane generates additional
activated FIX (28, 29). Since FXa produced on TF bearing cells is unable to effectively
travel to the platelets, the tenase complex activates FX on the platelet surface (9-11).
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FXa associates with FVa forming the prothrombinase complex, which catalyzes the
conversion of prothrombin to IIa (3). Monroe and Hoffman emphasize that the platelet
surface is the only cell adequately designed to support tenase and prothrombinase
complex formation concurrently (9-11). In hemophilia, deficient quantities of FVIII or
FIX on the platelet surface severely limit that amount of thrombin activated at the site of
injury (7, 30, 31). Though TF bearing cells can activate thrombin, this pathway is
insufficient in alleviating the loss of the tenase complex formation on platelets (9-11).
At the nexus of procoagulation and anticoagulation resides the most important
coagulation protein thrombin (32-34).

The procoagulant activities of thrombin are

multifaceted and numerous. Thrombin converts fibrinogen to fibrin which associates
non-covalently to form the soft clot (35). Stabilization of the growing fibrin clot is
provided by IIa-activated FXIII, a transglutaminase that forms covalent linkages between
neighboring fibrin molecules (36, 37), and thrombin-activatable fibrinolysis inhibitor
(TAFI), a metalloprotein that protects the growing clot from degradation (38).

In

addition, thrombin participates in procoagulant positive feedback by activating FV (22),
FVIII (18), and FXI (39). Finally as mentioned earlier, several platelet receptors are
cleaved by this serine protease leading to the activation of platelets (20).
Obviously, unchecked coagulation would be fatal due to the cessation of blood
circulation. The activation of the anticoagulant protein C (PC) by IIa is accelerated when
IIa encounters the glycoprotein thrombomodulin on the surface of endothelial cells (40).
Activated PC turns off IIa production by cleaving FVa and FVIIIa disrupting productive
tenase and prothrombinase complex formation (41). Inhibition of coagulation proteases
by the serpin antithrombin is another method for shutting down coagulation (42). The
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glycosaminoglycan (GAG) heparin enhances successful inhibition of these proteases with
antithrombin, with the acceleration of thrombin inhibition augmented up to 1000-fold
(43). Heparin cofactor II is another serpin that specifically targets IIa, with inactivation
improved in the presence of GAGs (44).
Clots exist as temporary solutions to repairing wounds and eventually degradation
occurs by the fibrinolytic system.

Tissue-type plasminogen activator (tPA) and

plasminogen are the major players in this process. Activation of plasminogen to plasmin
results from ternary complex formation between tPA, plasminogen, and fibrin (45).
Active plasmin proceeds to hydrolyze fibrin at specific sites within the clot, ultimately
leading to the dissolution of the clot (35). To prevent premature clot lysis, several
proteins inhibit the protease plasmin. α2-antiplasmin not only acts as an inhibitor of
plasmin, the protein also blocks the binding of plasminogen to the fibrin clot preventing
activation of the fibrinolytic protease (46).

FXIIIa acts to covalently crosslink α2-

antiplasmin into the growing clot another preventive measure against unwarranted
fibrinolysis (36). The serine protease plasminogen activator inhibitor type 1, when bound
to fibrin, inhibits tPA and thus plasminogen activation (47). As mentioned previously,
TAFI activated by the thrombin/thrombomodulin complex serves as another mechanism
for the prevention of clot lysis (38).
Only a brief summary has been presented of the processes that encompass blood
coagulation. The majority of the projects described in this dissertation focus on the
proteins located at the end of coagulation, specifically thrombin and FXIII. A more
detailed analysis of the relevant features associated with these proteins will be discussed
in the following sections.

With regard to thrombin, the research undertaken has
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examined peptide interactions at anion binding exosite II of this serine protease. These
peptides are derived from sequences that exist in fibrinogen and GpIbα. Therefore, a
more in depth view of these proteins will be presented in context to interactions with IIa.
The Most Important Coagulation Protease: Thrombin
Circulating in the blood stream and awaiting activation by the prothrombinase
complex is the 579-residue zymogen
prothrombin (48, 49).

Prothrombin is a

glycoprotein that is synthesized in the liver
and circulates in the blood stream at ~1.2
µM.

The zymogen possesses several

domains including an N-terminal Gla
domain, two kringle domains, and a
proteolytic domain that is dormant until
activation.

Within the Gla domain, 10

glutamic acids residues are converted to γcarboxyglutamic acid through vitamin Kdependent mechanisms. Kringle domains
are so named due to their resemblance to
Figure 3: Schematic of the conversion of
prothrombin to thrombin. Depicted are the
various IIa precursors and autolytic products.

the Danish pastry. These structures form
large loops that are stabilized by three
disulfide bonds.

Conversion of prothrombin to α-thrombin (IIa) proceeds through several proteolytic
steps (see Figure 3) catalyzed by the prothrombinase complex (FXa/FVa) in the presence
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of Ca2+ on either the platelet surface or on a TF bearing cell (reviewed in 49). FXa
hydrolyzes two peptide bonds, though the order of cleavage has yet to be established.
Proteolysis at R320-I321 results in meziothrombin with fragment 1.2 and the A-chain
associated to IIa’s proteolytic domain through a disulfide bond (C1-C122 in chymotrypsin
numbering, see below). Prethrombin 2 is formed when FXa first hydrolyzes R271-T272
leading to dissociation of fragment 1.2. When FXa cleaves the second bond, α-IIa is
produced with the A-chain associated to the B-chain through a disulfide linkage. Once
α-IIa possesses catalytic activity, autolysis of the A-chain residues R284-T285 yields
mature α-IIa. α-IIa is 37.5 kDa with six α-helices, two β-sheets, and four disulfide
bonds (50). One of the disulfide linkages is between the A and B-chains, while the
remaining disulfide bonds are all within the B-chain.
For ease of comparison to other members of the serine protease family, α-IIa
residue numbering is referenced relative to chymotrypsin (51). When describing residues
in loops that are unique to IIa or just single amino acid insertions that are not present in
chymotrypsin, a letter follows the number of the last common residue. For example, two
important loops are specific to IIa and begin from the last common residue shared
between the two proteases. The β insertion loop begins at 60 and continues with 60A,
60B, etc. The autolysis loop starts from 149, and continues from 149A, 149B, and so on.
The N-terminus of IIa’s A-chain possesses eight additional residues when compared to
chymotrypsin. Thus, A-chain numbering begins at 1H and continues 1G, 1F, etc. It
should be noted that bovine α-IIa lacks an autolytic site within the A-chain. Therefore,
bovine α-IIa possesses an additional 22 residues at the N-terminus when compared to
chymotrypsin and 13 residues when compared to human α-IIa.
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Figure 4: Structure of the serine protease thrombin (1PPB) (51). A. Location of the relevant features
of thrombin described in the text. The catalytic triad is in yellow, the 60 loop is in light brown, the
residues involved in the S4 site are orange, the autolysis loop is red, the Na+ binding loop is pink and
the A-chain is cyan. B. Location of ABE-I and ABE-II in relation to Y60a-Y60d (yellow). ABE-I is
orange and ABE-II is red.

The primary catalytic machinery of all serine proteases is conserved in the catalytic
triad of residues H57, D102, and S195 (Figure 4A) (52). With IIa, the promiscuity observed
with trypsin hydrolysis of anything containing an R or K at P1 (as long as a proline is not
present at P1′) is not evident.

The P nomenclature system assigns P1-P1′ as the
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hydrolyzable bond. Residues N-terminal to P1 are designated P2, P3, etc. and residues Cterminal to P1′ are P2′, P3′, etc. Sites within the enzyme that interact with substrate are
given the corresponding number, i.e. P2 binds to the S2 site in IIa.
IIa’s specificity is a result of the loops and residues that surround the catalytic triad
(reviewed in 48). IIa hydrolyzes the protein backbone primarily after R, although K and
F at the P1 position can also act as less efficient substrates. At the P2 position, IIa prefers
small and hydrophobic residues that can interact effectively with the 60-loop defined by
Y60A, P60B, P60C, and W60D (S2 site). The P3 position is not a determinant for specificity
since this residue does not interact with the IIa surface. The aryl binding site (S4 site) is
created by L99, I174, and W215 leading to a preference for hydrophobic, aromatic residues.
The γ-loop, or autolysis loop (149-149E), is a flexible, hydrophilic surface loop that is
involved in determining substrate specificity C-terminally to the scissile bond.
To this point, the discussion has focused on α-IIa, but several autolytic sites exist in
IIa (Figure 3) (reviewed in 49). Since α-IIa in vivo is rapidly inhibited by a multitude of
serpins, these forms of IIa probably do not have physiologic significance. α-IIa that is
isolated in solution over time will hydrolyze several bonds. The first such proteolytic
event leads to the generation of β-IIa. Cleavage of R77A-N78 exposes the peptide bond
R67-I68 to IIa hydrolysis resulting in the excision of the peptide I68-R77A. Further catalysis
of K149E-G150 in the flexible autolysis loop produces γ-IIa. It should be noted that bovine
β-IIa can be produced by autolysis; however, a non-conservative substitution of E for K
at position 149E prevents formation of bovine γ-IIa (51). These autolytic events do not
affect catalysis of small chromogenic substrates, but significantly reduces the amount of
fibrinogen that is converted to fibrin due to the disruption of fibrinogen binding (53).
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An important allosteric activator of IIa is sodium (54). The binding loop is located
near the S1 pocket (see Figure 4A). Na+ coordination involves the carbonyl groups of
R221A and K224 as well as four water molecules and the bound cation is situated 15 Å from
the active site (55). Additional stabilization of Na+ is provided by D221 and D222. When
Na+ is bound to IIa, the protease is referred to as being in the fast form defined by a more
open and rigid structure, while IIa lacking coordinated Na+ is in the slow form
characterized by a more closed and flexible structure (56). Procoagulation is favored by
the fast form, where cleavage of fibrinogen and PAR-1 are significantly enhanced in the
presence of Na+ (57). Cleavage of PC with thrombomodulin as a cofactor occurs with
greater ease in the slow form (58). Since the concentration of Na+ remains tightly
regulated at 140 mM in the blood circulation, the partition of fast and slow form IIa in
vivo will not deviate from a ratio of 3:2 based on the KD of 110 mM (54). Whether Na+
acts as an allosteric regulator physiologically is an open debate; however, bound Na+
does result in conformational and catalytic changes for IIa (54, 59).
Thrombin contains two exosites that are located on opposing faces of the serine
protease flanking the catalytic site (51) (Figure 4B). These highly electropositive patches
are termed anion binding exosites I and II (ABE-I and ABE-II). An exosite is a ligandprotein interface that is distinct from the residues involved in catalysis. Exosite functions
include guiding substrate orientation for catalysis that is more efficient and/or providing a
separate cofactor interaction site that either enhances or dampens enzyme reactivity.
Selected residues from ABE-I include K36, R67, R73, R75, R77A, K81, K109, K110, and K149E.
ABE-I aides in the activation of fibrinogen, PAR-1, FV, FVIII, and FXI, binds the
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inhibitors hirudin and heparin cofactor II, and interacts with thrombomodulin which
switches thrombin’s specificity toward the anticoagulant PC (34, 48).
Table 1: Sequences of Selected ABE-II Binding Sitesa,b
Fibrinogen γ′

408

GpIbα
FVIII

VRPEHPAETEYSDSLYSPEDDL427

269

DEGDTDLYSDYSYSPEEDTEG286
341

EEAEDYSDDDLTDSEM355

a

Anionic residues are in bold.
These human ABE-II binding sequences were taken from the following sources:
fibrinogen γ′ (60, 61), GpIbα (62), and factor VIII (63).
b

ABE-II is more electropositive than ABE-I and encompasses R93, R97, R101, R126,
R173, R175, R233, K235, K236, and K240. The glycosaminoglycan heparin interacts with
ABE-II and plays an important role in inhibition of thrombin by the serpins antithrombin
(64) and heparin cofactor II through ternary complex formation. FV and FVIII binding to
both ABE-I and ABE-II may serve to further enhance activation of these two cofactors
(65). A recent crystal structure of haemadin and thrombin demonstrates the necessity of
both ABE-II and the active site for this inhibitory interaction (66). On the surface of
platelets, the association of GpIbα with ABE-II accelerates thrombin activation of PAR-1
and FXI, while reducing the rate of fibrinopeptide A release from fibrin (67, 68).
Finally, a C-terminal variant of the fibrinogen γ chain (termed the γ′ chain) has been
demonstrated to bind to ABE-II (69, 70). Table 1 shows a selection of sequences from
proteins that interact with ABE-II.
In a significant number of the previously described ABE interactions, sulfonation
appears to be an important element in ligand binding to IIa. In 1954, Bettelheim first
reported the presence of sulfonation in a blood coagulant protein at Y6 of the bovine
fibrinogen Bβ chain (71). This modified residue probably aids in interaction of the Bβ
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chain with the extended active site region, and possibly ABE-II. Other well known
sulfonated ligands are the ABE-I binding active site inhibitor hirudin (72) and the ABE-II
targeting heparin sulfate (73). The ABE-II binding sequences of γ′ chain (60, 61), GpIbα
(62), and FVIII (63) all display an intense clustering of YS, D, and E (Table 1).
The conformational features associated with the interaction of the acidic C-terminal
tails of fibrinogen and GpIbα with ABE-II are described in later chapters. Both of these
proteins utilize ABE-II for recruitment of IIa to the site of vascular injury and clot
formation. In addition, the proteins may play a role as cofactors in the cleavage of IIa’s
target proteins. The following sections describe these two proteins in further depth.
Glycoprotein Ibα
Residing on the surface of platelets is the transmembrane receptor complex
GpIbα/β-GpIX-GpV (74-77).

The importance of this protein complex in blood

coagulation is highlighted in Bernard-Soulier syndrome, a bleeding disorder resulting
from either dysfunctional or low levels of GpIbα/β-GpIX-GpV.

Disulfide bonds

covalently link GpIbα (140 kDa) to GpIbβ (27 kDa) recently discovered to exist at a 1:2
ratio (78).

GpIX (22 kDa) is non-covalently associated with GpIbα/β.

The final

component of the receptor complex is GpV (82 kDa), which forms a 1:2 complex with
GpIbα/β-GpIX. GpIbα is a member of the leucine rich repeat (LRR) family (Figure 5).
The receptor also has the following structural components C-terminally to the LRR
domain: a couple of loop structures linked by a disulfide bond, a highly glycosylated
mucin-like stem, a transmembrane domain, and a cytoplasmic region (79, 80).
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Within the platelet receptor complex, the N-terminal region (1-290) of GpIbα is the
major site of ligand binding.

The macrophage antigen-I (Mac-I) (81) and the cell

adhesion molecule P-selectin (82) bind GpIbα leading to the recruitment of leukocytes to
a site of infection resulting in vascular inflammation. GpIbα interacts with FXI (83),
FXII (84), and HK (85, 86), bringing these proteins to the platelet surface and amplifying
coagulation. Adhesion of platelets to sites of damaged tissue is the primary role for
GpIbα binding to vWF under high-shear.

When vWF interacts with GpIbα, the

transmembrane complex is primed to begin intracellular signaling achieving an increase
in Ca2+ in the cytosol, degranulation, rearrangement of the cytoskeleton, and activation of
the platelet aggregating integrin αIIbβ3 (75, 77).

GpIbα assists thrombin in the

activation of PAR-1 (67) and FXI (83). GpIbα may also aid cleavage of GpV by
thrombin, though the exact function of GpV proteolysis has yet to be established. GpV
could sterically hinder thrombin binding to and activation of platelets (87, 88) and/or be
involved in the adhesion of platelets to collagen (89).

Figure 5: Structure of glycoprotein Ibα (1-266) (1P9A) (96). The highly anionic C-terminal tail
(269-286) is not modeled in this structure. The most prominent feature of the structure is the leucine
rich repeat domain that forms the curvature of the protein.
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Considerable interest has been directed toward understanding in more detail the
nature of the GpIbα-IIa interaction in solution (90). The sequence within GpIbα that is
responsible for binding thrombin has been localized to the C-terminus of the N-terminal
fragment (1-290) between residues (269DEGDTDLYSDYSYSPEEDTEGD287) (Table 1)
(91). Mutagenesis studies have identified the ABE-II residues R93, R97, R101, R233, K236
and K240 as playing a role in binding, while the ABE-I residues R67, R73, R75, R76, and
R77A did not appear to be involved in the interaction (23, 68, 92). In the mutagenesis
work, the indicated residues were usually mutated to alanine and the effect of the
mutation on the KD was determined.
Though the evidence for ABE-II as the primary destination for GpIbα is strong,
others have identified ABE-I as the site of interaction through competitive inhibition with
hirudin but not with heparin (93-95). Yet, heparin inhibits GpIbα binding to IIa’s ABEII and not hirudin (68). Adding to the confusion, two independent crystal structures of
IIa-GpIbα (residues 1-279/284) were published in Science (96, 97). The Dumas structure
displays GpIbα residues 269-279 exclusively interacting with ABE-II, while the Celikel
structure illustrates residues 269-284 binding to both ABE-II and ABE-I through IIa
dimerization. The reasons for the discrepancies in results have yet to be resolved.
The KD values calculated for this interaction are highly salt dependent, which is
characteristic of ABE-II binding. At 100 mM Na+, the KD ranges from 102 nM to 187
nM, while at 150 mM Na+ this value increases to 1 µM (68, 92). Li et al. calculated a salt
dependence of Γsalt = -4.2, which indicates at least 4 salt bridges for GpIbα-IIa (68). This
value is in good agreement with an independent assessment of the salt dependence for
GpIbα-IIa (98), as well as for the nonspecific ABE-II ligand heparin (99).
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The efficiency of thrombin catalysis is affected by GpIbα exosites binding. Release
of fibrinopeptide A (FpA) is noncompetitively inhibited by GpIbα (68), while PAR-1
hydrolysis is enhanced by GpIbα binding to IIa (67). Curiously, other groups have
attributed GpIbα inhibition of FpA hydrolysis to competitive inhibition at ABE-I (100,
101). Based on recent mutagenesis data involving IIa, it seems more likely that inhibition
is occurring through ABE-II and not ABE-I (68, 92). GpIbα leads to decreased catalysis
at R372 in FVIII presumably due to competition for binding at ABE-II (65). These
examples emphasize the importance of ligand binding to ABE-II on catalytic activity and
the allosteric nature of the interaction.
Though GpIbα plays an important role in platelet aggregation, the protein
fibrinogen provides an equally important function in clot formation.

Like GpIbα,

fibrinogen has been demonstrated to bind ABE-I and ABE-II. In this instance, solid data
exists illustrating that fibrinogen interacts with both exosites, perhaps simultaneously.
Fibrinogen
The large soluble glycoprotein fibrinogen (340 kDa) is a dimer comprised of three
domains (AαBβγA)2 existing as coiled coils in the shape of a dumbbell (35, 102) (Figure
6). The N-termini of all six polypeptide chains are located in the central E-region of
fibrinogen, supplying a low affinity binding site for thrombin via ABE-I (103). The Ctermini of the polypeptide chains reach laterally from the E-region to form the flanking D
regions. During coagulation, thrombin cleaves fibrinopeptides A and B from the Nterminus of α and β chains, respectively. This action converts fibrinogen to fibrin
(αβγA)2, initiating formation of the noncovalently associated soft clot.
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There are two variants of the γ chain C-terminus extending outward from the D
regions (104, 105). The γA chain terminates with four amino acids (408AGDV411) and
interacts with platelets through residues 400-411 (106). The γ′ chain results from a
mRNA splice variant due to alternative processing and replaces the last four residues of
the γA chain with an insertion of 20 amino acids (408VRPEHPAETEYSDSLYSPEDDL427)
(107, 108) (Table 1). About 7% to 15% of all fibrinogen exist as the γA/γ′ heterodimer as
opposed to the γA/γA homodimer (109, 110).

Figure 6: Schematic diagram depicting the structure of fibrinogen and clot formation. Thrombin
cleavage of fibrinopeptides A and B (orange and green) lead to soft clot formation and FXIIIa
catalyzes covalent intermolecular crosslinks making the clot more resistant to fibrinolysis.

Meh et al. demonstrated that the D-region of fibrinogen γA/γ′ contained a high
affinity binding site for thrombin with a KD of 0.26 µM (111). Further work implicated
the γ′ residues A414-L427 as essential to the high affinity interaction, although the exact
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location of the γ′ chain interface on thrombin was unclear (60). Subsequent competitive
fluorescent binding studies localized γ′ peptide binding to ABE-II with a KD in the 0.63–
2.2 µM range for residues V408-L427 (69, 70). Replacement of the YS with F in the γ′
region of fibrin abolishes IIa binding (69). A combination of heparin, hirudin fragments,
and DNA aptamers targeting ABE-I and II were employed to verify the site of interaction
(69, 70). An aptamer is a short oligonucleotide sequence (20-30 bases) that has been
selected to bind a target protein with high affinity (112).
The presence of elevated levels of the heterodimer γA/γ′ has been linked to
increased incidence of cardiovascular diseases. As with GpIbα, the γ′ chain decreases the
rate of FpA hydrolysis (113) in this case leading to a fibrin network that possesses many
more offshoots with thinner fibers (113, 114). Fibrin clots formed in this manner are less
susceptible to fibrinolysis (110, 113). Fibrin enhanced FXIII activation is slightly slower
when the γ′ chain binds to ABE-II (113) suggesting that the levels of γ′ chain variant
present in fibrinogen has a significant impact on the regulation of coagulation (115).
The γ′ chain of fibrinogen has also been demonstrated to be a carrier of plasma
Factor XIII (A2B2) via the FXIII B2-subunits (116). Like fibrinogen, IIa also activates
FXIII at the conclusion of procoagulation.

Several issues have yet to be resolved

regarding FXIII activation and substrate recognition. For instance, a high degree of
similarity exists between the structures of FXIII and FXIIIa (117-119). Therefore, the
conformational transition resulting from activation that enables FXIIIa to perform
catalysis is unclear. In the following section, the role FXIII plays in blood coagulation is
described in more detail, as well as some of the questions that need to be addressed in
relation to this transglutaminase.
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The Transglutaminase Factor XIII
FXIII (83 kDa) shares the same primarily β sheet architecture of the other known
transglutaminases (TGases) (119). The five principal structural elements of the TGase
family are depicted in Figure 7A: the activation peptide (1-37), the β sandwich (residues
38-183), the catalytic core (residues 184-515), and the β barrel 1 (residues 516-627) and
β barrel 2 (residues 628-731) domains. The active site architecture for both cysteine
proteases and TGases are quite similar, consisting of the catalytic triad C314, H373, and
D396 (FXIII numbering) (Figure 7B); however, the proposed mechanism of TGases is the
reverse of cysteine proteases (119, 120). The only TGase to exist as a dimer is FXIII,
with key interchain interactions between K113-D367′, K257-E401′, and R260-D404′ (Figure 7B).
FXIII circulating in the plasma possesses an additional dimer that serves a
regulatory function. Upon activation of FXIII by thrombin, the regulatory B2 subunits
dissociate from the catalytic A2 subunits in the presence of 1 mM Ca2+ (121). In the
platelets and the placenta, FXIII lacks the B2 subunits and is termed cellular FXIII (122).
The A2 dimer from plasma and cellular FXIII is equivalent in structure and function.
Catalytically competent FXIIIa is achieved when IIa cleaves the N-terminal
activation peptide at R37-G38 and at least 1 mM Ca2+ is present (referred to as FXIIIaIIa)
(123, 124).

FXIIIa catalyzes the formation of isopeptide bonds between Q and K

residues and the catalytic mechanism is illustrated in Figure 8 (125). These covalent
bonds act to stabilize the growing fibrin clot. Furthermore, FXIIIa aids in protecting the
clot from plasmin degradation through the incorporation of substrates, like α2 antiplasmin
(126), to the fibrin matrix. After proteolysis by IIa, the activation peptide remains noncovalently associated with FXIIIa and transverses both monomers (Figure 7A) (118). A
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secondary thrombin cleavage site is located near the division of the catalytic core and β
barrel 1 (127). Proteolysis of K513-S514 reduces the affinity of FXIIIa for Q and K
containing substrates, however the catalytic machinery of the TGase is not perturbed
(128). Curiously this cleavage has no effect on FXIIIa binding to fibrin (128).

Figure 7: Structure of the transglutaminase Factor XIII (1FIE) (118). A. FXIII depicted as the A2
dimer. Regions include the activation peptide (red), β sandwich (blue), catalytic core (green), β
barrel 1 (cyan), and β barrel 2 (orange). The catalytic triad (C314, H373, and D396) is in pink. The two
Q substrate recognition sites peptide 4 (β sandwich) and peptide 7 (catalytic core) are purple and
yellow respectively. The potential K substrate recognition site in β barrel 2 is light green. B.
Expanded view of the catalytic core and the dimer interface. Depicted in the figure are the active site
(violet), the Ca2+ binding site (yellow), and key interactions at the dimer interface (orange).
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Alternatively, high concentrations of Ca2+ (>50 mM) or of monovalent cations
(>150 mM) with 1 mM Ca2+ can non-proteolytically activate FXIII (referred to as
FXIIIaCa) (129, 130). Only one Ca2+ binding site (Figure 7B) has been observed (N436,
D438, A457, E485, and E490) with a KD of ~100 µM (117), though the existence of several
more low affinity sites has been supported by equilibrium dialysis (131) and
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Ca NMR

(132). In addition, several other cations have been demonstrated to interact with FXIII,
including magnesium, strontium, manganese, ytterbium, terbium, and zinc (117, 133,
134). In fact, Fox et al. solved a structure of FXIII with ytterbium bound at the dimer
interface chelated by D270 and E272 from both monomers (117).

Figure 8:
Proposed catalytic
mechanism of transglutaminases
(125). A. The active site thiol
attacks the side chain carbonyl of
the acyl donor glutamine.
B.
Formation of the first tetrahedral
intermediate. The primary amine
abstracts a proton from histidine
and leaves as ammonia.
C.
Formation of the acyl-enzyme
intermediate. D. The active site
histidine pulls a proton from the
donor lysine substrate, which then
attacks the carbonyl of the acylenzyme intermediate. E. Formation
of
the
second
tetrahedral
intermediate. In this case, the thiol
group leaves regenerating the
active site for the next crosslinking
reaction. F. The product of a
transglutaminase reaction is an ε(γglutamyl)lysyl crosslink.

Pinpointing FXIIIa substrate specificity remains an elusive goal. Investigations in
the past have focused on primary sequence specificity (135-137) and substrate access to
the active site for the Q-containing substrate (138). As far as the K containing substrate,
some work has examined sequence specificity surrounding the reactive lysine residue
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(139, 140). In addition to the primary amine in the side chain of K, most other primary
amines will complete the TGase reaction (141). The absence of a primary amine will
lead to deamidation in the presence of water (137, 142, 143).

These studies have

ultimately reached the conclusion that determinants for substrate specificity not only exist
near the reactive residues, but also further away from the catalytic triad in potential
exosites. An ideal substrate for FXIIIa, or any TGase, would probably be located within
a pliable region of a protein, such as surface loops or sequences near the N- or Cterminus that can reach into the deeply buried catalytic core (138, 144).
Several prospective FXIIIa exosites have been proposed. Two potential Q substrate
exosites named peptides 4 (72-97) and 7 (190-230) are located within the β sandwich and
the catalytic core, respectively (Figure 7A) (145). Peptides derived from these sequences
competitively inhibit Q substrate catalysis. Within the β barrel 2, the antibody 5A2
targets residues 646-658 and acts as a competitive inhibitor of K substrate incorporation.
Such β barrel 2 residues may thus be part of a K substrate exosite (146).
Interestingly, alkylation of C314 by a small molecule like iodoacetamide (IAA)
occurs only after activation (124, 147-149). Yet, the X-ray structures of the zymogen
(119), FXIIIaIIa (118), and FXIIIaCa (117) are lacking in significant RMSD deviations
(118). These observations led Yee et al. to hypothesize that the inactive and active
conformers exist in equilibrium (117). Since the inactive conformer is favored during
crystallization, FXIIIa interaction with a substrate or inhibitor may favor crystallization
of the active conformer (117).
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Research Goals
A common thread is shared by all projects described in the following chapters.
Specifically, the research focuses on the implementation of solution-based methods to
better characterize the conformational features associated with ligand binding to the
proteins thrombin and FXIIIa. With that in mind, these investigations can be segmented
into two separate projects. The first endeavor examines peptide binding to thrombin’s
ABE-II, which can be further broken down into studies involving the complexes γ′ chain
(410-427)-IIa and GpIbα (269-286)-IIa.

The second project aims to explore the

inhibition of FXIIIa with a newly developed peptide based inhibitor, perhaps yielding
new insight into FXIIIa substrate recognition.
Rationale for Studying Peptide Binding to Thrombin’s ABE-II
One of the original treatments to promote anticoagulation is the administration of
heparin, which interacts at ABE-II (73, 150-152) and enhances antithrombin (AT) (64)
and heparin cofactor II (153) inactivation of thrombin. Heparin is used clinically to treat
myocardial infarction, atrial fibrillation, and deep-vein thrombosis. Unfortunately, the
presence of heparin can lead to inhibition of a multitude of other coagulation proteins
including FXa (which is also a therapeutic target of heparin) (154), FIXa (155), FXIa
(156), FXIIa (157) and vWF (158). In addition to anti-coagulation activities, heparin also
binds to circulating plasma proteins (159) and endothelial cells (160). Furthermore,
heparin has been shown to promote bone loss (161) and induce thrombocytopenia (low
levels of circulating platelets) (162). These heparin side effects vary from individual to
individual; therefore levels of heparin dosage must be carefully monitored during
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treatment (163). The difficulties in administrating heparin have led to the development of
several heparin-derived drugs and other anticoagulants (164).
Peptides provide a potential route for specifically targeted therapeutic utility. Drugs
designed from naturally occurring protein ligands of thrombin could avoid many of the
side effects resulting from heparin treatment (163).

The efficacy of peptide-based

anticoagulants has been demonstrated with the ABE-I binding inhibitors hirudin and
bivalirudin (165, 166). At the present time, a peptide-based anticoagulant that targets
ABE-II has not been developed. By examining the conformational features associated
with γ′ peptide (410-427) and GpIbα (269-286) binding to ABE-II, an ABE-II targeting
peptide with anticoagulant properties may be developed employing the unique structural
elements characteristic of these complexes.
The work described in Chapter IV details the γ′ peptide (410-427)-IIa interaction
utilizing NMR and MALDI-TOF MS (167). At the time this research was initiated, a
crystal structure demonstrating the interaction of the γ′ peptide with IIa had not been
reported, though the binding site was localized to ABE-II (69, 70). The length of the γ′
peptide substitution for γA in fibrinogen is twenty amino acids. Therefore, once bound to
thrombin, the γ′ peptide may potentially adopt secondary structural elements, i.e. helix
formation, turn structures etc., not favored when the peptide is free in solution.
From thrombin’s perspective, the residues within ABE-II that provide the γ′ peptide
interface had not been elucidated.

Crystal structures of heparin (168), prothrombin

fragment II (169), GpIbα (96, 97), and haemadin (66) binding to ABE-II provide an
important starting point for predicting where the γ′ peptide interacts at ABE-II. All
structures highlight R93, R101, and K240 as essential ABE-II binding residues, suggesting
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that the γ′ peptide also utilizes these positively charged residues when binding to
thrombin. Another aspect of ABE-II binding that remains to be further explored is
whether an allosteric connection exists from ABE-II to ABE-I. Some reports suggest
such a pathway is present in thrombin (70, 170), while other work appears to dismiss
such a possibility (171). Since thrombomodulin binding to ABE-I has been demonstrated
to perturb the dynamics of deuterium incorporation at ABE-II (172, 173), perhaps the
reverse is true for ligand binding to ABE-II.
With those questions in mind, research was initiated to further explore the γ′
peptide-IIa relationship. The project implemented 1D line broadening NMR and 2D
transferred NOESY NMR (detailed in Chapter II) to describe the ligand protein
interaction from the γ′ peptide’s perspective.

Using these techniques, the important

protons that contact thrombin’s surface were identified in addition to several key
secondary conformational features associated with γ′ chain binding to IIa. By using
MALDI-TOF MS and hydrogen deuterium exchange (HDX) (discussed in Chapter III),
the effects of the γ′ peptide on the dynamics of HDX for IIa were examined. These
experiments were performed to more accurately localize γ′ peptide binding within ABEII and to observe potential allostery associated with ligand binding to ABE-II.
Chapter V focuses on the interaction between GpIbα and IIa.

Two crystal

structures of GpIbα bound to IIa were solved simultaneously (96, 97). As discussed
earlier in the chapter, thrombin’s interaction with ABE-II appears to be similar in both
structures, while the second IIa binds at differing interfaces on GpIbα. The anionic Cterminal tail in the Dumas et al. structure ended at YS279 due to insufficient electron
density to model these residues (96). Conversely, the Celikel et al. structure terminates at
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T284, with the C-terminus spanning both thrombin molecules and interacting with ABE-II
and ABE-I in an extended conformation (97). The Celikel structure suggests that the Cterminal fragment of GpIbα may induce dimerization of thrombin. Due to the high
degree of similarity between the ABE-II binding sequences of GpIbα and the γ′ peptide
(see Table 1), perhaps these anionic, sulfonated regions share conformational elements
that direct these residues to interact with ABE-II.
As with the γ′ peptide, research was performed to study the GpIbα (269-286)-IIa
interaction in further detail utilizing NMR and HDX coupled with MALDI-TOF MS. 1D
and 2D NMR work demonstrate that GpIbα (269-286) and the γ′ peptide adopt differing
conformations when bound to ABE-II.

HDX coupled with MALDI-TOF MS was

performed in order to distinguish between ABE-II versus ABE-I binding of the GpIbα
peptide, as well as to characterize allostery associated with GpIbα interactions with IIa.
Finally, further work was then carried out with analytical ultracentrifugation to observe
whether the γ′ peptide or the GpIbα peptide could dimerize IIa in solution.
Rationale for Studying Peptide Inhibition of Factor XIIIa
Examining FXIIIa in solution is a difficult task, since the active TGase is mostly
insoluble by nature (as is the soft clot that FXIIIa covalently crosslinks).

This

insolubility perhaps explains the difficulties in obtaining a structure of the active FXIIIa
(117). As mentioned earlier in the chapter, structures have been solved for FXIIIaIIa (118)
and FXIIIaCa (117), though without significant RMSD deviations from the zymogen
(119).

Many studies have demonstrated that activation of FXIII must lead to a

conformational change that has been undetected in the reported X-ray structures (124,
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147-149). Fortunately, sufficient quantities of FXIIIaIIa and FXIIIaCa remain in solution
in order to probe the conformational changes associated with activation (174, 175).
These observations have led to the hypothesis that irreversible inhibitor binding to
FXIIIa may capture the TGase in an active conformation (117). Inhibited FXIIIa could
potentially be utilized to detail previously unobserved features of FXIIIa substrate
recognition and, indirectly, activation.

Recently, irreversible inhibitors have been

developed for TGase 2 based on natural Q-containing substrate sequences for the enzyme
(176). One of the reported peptide inhibitors of the TGase incorporated a glutamine
isostere 6-diazo-5-oxo-norleucine (DON) in place of the reactive glutamine. A wellcharacterized substrate for FXIIIa is the K9 peptide (177). The DON moiety has been
incorporated into the K9 peptide in order to study the conformational features resulting
from inhibitor binding to FXIIIa.
Perturbations in FXIIIa dynamics were further explored by inhibition with K9 DON
or iodoacetamide (IAA) (Chapter VI) (178).

The investigations rely primarily on

MALDI-TOF MS methodology (Chapter III). HDX, limited proteolysis, and differential
chemical modification were the strategies used to study the conformational changes
associated with FXIIIa inhibition, as well as build upon the earlier work investigating
FXIII activation (174, 175). The FXIIIa inhibitors K9 DON and IAA both displayed
similar perturbations in protein dynamics for regions distant from the active site, perhaps
indicating the location of exosites within the TGase. These experiments may also have
provided evidence for a potential interaction site for K9 DON within the catalytic core.
Though these are low-resolution studies, highly valuable glimpses are being provided on
FXIIIa allostery and the presence of putative FXIIIa exosites.
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CHAPTER II
NUCLEAR MAGNETIC RESONANCE TECHNIQUES:
1D LINE BROADENING AND 2D TRANSFERRED NOESY
One of the most powerful tools to study molecular structure and dynamics, ligandreceptor interactions, and chemical kinetics is nuclear magnetic resonance spectroscopy
(reviewed in 179). Through the application of an external magnetic field, a nuclear spin
becomes excited, ultimately allowing the detection of perturbations in electronic
environment that are quite subtle. In order to achieve an excited state, radio waves
irradiate the sample indicating that excitation requires small amounts of energy.
Consequently, the signal to noise in an NMR spectrum is low, thus requiring an
abundance of material and multiple scans to enhance resolution. One beneficial aspect of
the low energy transition is the long lifetime of nuclear spin excitation, which ranges
from msec to sec. It is this feature of an NMR experiment that produces very narrow
spectral signals and permits the observance of molecular motion over a large time scale.
Most importantly, the long lifetime of nuclear spin excitation confers the ability to
transfer resonance energy from one spin to another spin. As relaxation occurs, the energy
released by the nuclear spin is measured as a free induction decay (FID), which is
converted to a plot of intensity versus frequency by Fourier transform.
The magnetization that is experienced by the nucleus is primarily affected by the
density of electrons surrounding the nuclear spin (reviewed in 179). Application of an
external magnetic field also causes electrons to precess resulting in the creation of a
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magnetic field that opposes the applied field. This phenomenon leads to shielding of the
nuclear spin and is termed chemical shift. Larger electron density equates to lower
resonance frequencies of the observed nuclear spin. Therefore, the measured frequency
of a nuclear spin not only depends on the type of nuclei studied, but the electronic
environment in which the nuclear spin resides, whether due to bonding or proximity.
For amino acids, typical chemical shifts for the observed protons depend on the
atom and position of the group within the residue. Since nitrogen is more electronegative
than carbon, a backbone amide proton will possess a chemical shift at ≈ 8 ppm. The
proximity of Hα to the backbone nitrogen results in a resonance at ≈ 4 ppm, while Hδ
from leucine resonates further upfield at ≈ 1 ppm.

This example illustrates the

fundamental complexity of 1D spectra for peptides and proteins due to overlap of
multiple resonances for similar protons.

In order to resolve the spectra of larger

polypeptides, NMR experiments are performed in multiple dimensions, where multiple
chemical shifts aide in assigning the resonances for the observed peaks.
As with any transition from a ground state to an excited state, energy is eventually
released as the system reestablishes equilibrium (reviewed in 179). In NMR, the nuclear
spins that are excited experience two types of relaxation. The first relaxation process is
termed spin-lattice relaxation, whose time constant is T1. As energy transfers from the
excited nuclear spin to the environment, or lattice, the original Boltzman population
distribution is regenerated as the magnetic moment of the spins are realigned along the
static magnetic field. For proteins, the time scale for T1 relaxation is around a second,
while for smaller molecules, like peptides, T1 times range from 10 to 100 seconds.
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Transverse relaxation, with a time constant of T2, does not involve reestablishing
thermal equilibrium or demoting excited spins to the ground state (reviewed in 179). T2
relaxation describes the agitation of nuclear spin phase coherence. Three processes
dephase transverse magnetization. First, inhomogeneity of the magnetic field within the
sample affects the precessional frequency of the excited spins depending on the spatial
position of the spin within the inhomogeneous field.

To minimize inhomogeneity,

modern instruments possess shim coils that serve to increase the homogeneity of the
magnetic field. The second way for transverse relaxation to occur is due to the existence
of anisotropic electron density that envelops the nucleus (Chemical Shift Anisotropy).
Thus, the alignment of the nuclear spin within the magnetic field will actually determine
the actual field that is experienced by the spin due to variations in electron shielding. The
final type of transverse relaxation is spin-spin relaxation, which describes dipolar
coupling between two magnetic dipoles in close proximity.
For protons, dipolar coupling is the primary means for transverse relaxation
(reviewed in 179). Thus, molecular motion and, subsequently, molecular weight play an
important role in dipolar coupling. The rotational correlation time (τc) refers to the
average time a molecule in solution rotates 1 radian, which is about 1 nsec/2.6 kDa.
When the resonance frequency (ω) associated with the coupled spins is much slower than
τc (ωτc<<1), isotropic tumbling is observed, the dipolar coupling contribution to the spin
energy is zero, and splitting of resonance lines are not observed.

This situation is

observed for small molecules in solution. For larger molecules, like proteins, the time
required to rotate 1 radian is much longer, resulting in shorter T2 lifetimes (ωτc>>1) and
presenting a serious impediment for the transfer of magnetization between spins. Despite
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the longer τc, proteins tend to possess rotational frequencies on the order of 108 Hz, thus,
tumbling in solution is sufficiently fast to subvert the splitting of the resonance lines
(dipolar coupling is averaged).
Differences in rotational correlation times (τc) between proteins and peptides can be
exploited to obtain structural information regarding peptide interactions with a protein
(reviewed in 180, 181-184). In the 1D spectrum of a peptide interaction with a protein,
line broadening of the spectral signal for the nuclei being observed is an indication of
contact between that atom and the protein surface. Conformational information can be
obtained by performing a 2D transferred NOESY experiment where 2 protons within 5Å
display a cross peak which can then be employed to determine structural features of the
bound peptide. A majority of the NMR work described in the subsequent chapters deals
with implementing these two techniques to describe the conformational features
associated with two peptides interacting with thrombin’s anion binding exosite II.
Protons (or
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P nuclei of phosphorylated peptides) that contact the protein surface

(and thus contribute to the binding interface) can be discerned by comparing the 1D
spectra of the free peptide versus the bound peptide.

Equation 1 illustrates the

relationship between T2, ωτc, and the difference in resonance linewidth (πΔvi) (180).
Within Equation 1, g = 0.1γi2γj2(h/2π)2(µ0/4π)2 and the distance between protons is rij.
Peptides with less than 18 amino acids lack significant secondary structure and tumble
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(1)

rapidly when free in solution (ωτc approaches 1). In the 1D 1H or 31P spectra of the free
peptide, well-defined, narrow spectral peaks result from a longer T2 time (180, 184).
When examining the bound state, the peptide concentration is in molar excess to the
protein and the koff has to be sufficiently fast to allow the peptides with secondary
structural information to rejoin the free peptides in solution. Upon interacting with the
surface of an enzyme, the peptide now adopts a conformation with distinct secondary
structural features. Nuclei that interact with the enzyme surface experience an increase in
τc leading to ωτc >> 1. The decrease in the T2, coupled to differences in chemical shift
arising from the nuclei experiencing a new magnetic environment, lead to line
broadening of the peaks in the 1D spectra. Nuclei that do not interact with the surface of
the protein display similar spectral linewidths as observed with the free peptide (185).
Figure 9 presents an example of a 1D
1

H line broadening experiment.

that

contact

the protein

Protons

surface are

broadened relative to the spectra of the free
peptide. In this example, several residues
are not involved in the binding interface,
particularly the G (~8.65 ppm) and T (~8.2
ppm) residues, and are illustrated by peaks
that remain sharp and well resolved in the
absence and presence of the protein.
Conversely, the Y (~7.83 ppm) residue is
broadened in the presence of the protein.
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Figure 9: Example of line broadening in 1D
NMR spectra.
The top spectrum is free
unphosphorylated GpIbα (269-286) and the
bottom spectrum is of the peptide bound to IIa.

Due to the overlapping resonances of protons in a 1D spectrum, 2D TOtal
Correlation SpectroscopY (TOCSY) NMR is performed in order to assign chemical shifts
of similar protons within a peptide. TOCSY NMR takes advantage of a spin lock pulse,
which enables the connectivity for
an entire spin system to be
visualized within the 2D spectrum.
Carbonyls within amide bonds
demarcate the spin systems of
amino

acids

in

a

peptide.

Therefore, each residue will have a
Figure 10: Fingerprint region from a 2D TOCSY
spectrum. The spectrum is of unphosphorylated GpIbα
(269-286) interacting with bovine IIa. On the far left of
the spectrum is an example of a spin system for an E
residue (9 ppm).
The backbone amide’s spin is
correlated with the α (4.4 ppm), β (2.0 ppm), and γ (2.4
ppm) proton resonances for this particular E residue.

unique

set

correlations

of

proton-proton

flowing

from

the

backbone amide proton to the side
chain protons. Figure 10 displays

the amide to aliphatic proton region frequently referred to as the “fingerprint” region.
Cross-peaks representing protons with unique chemical shifts yet are neighbors due to
scaler coupling (through bond interactions) appear on opposite sides of the diagonal (for
an example of an entire spectrum see Figure 11, which is similar to the layout of a
TOCSY spectrum). By assigning the resonances in the 2D TOCSY, the 1D spectrum (the
diagonal) becomes rather straightforward to identify.
In addition to line broadening, another NMR technique provides information
concerning the conformational features associated with peptide binding: 2D transferred
Nuclear Overhauser Effect SpectroscopY (trNOESY).
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A typical spectrum obtained

during

a

2D

experiment

illustrated in Figure 11.

is

Along

the diagonal is the 1D spectrum of
the peptide, while crosspeaks
representing

NOEs

between

protons flank the diagonal.

An

NOE develops due to a transfer of
Figure 11: 2D transferred NOESY spectrum. The
spectrum is of the γ′ peptide interacting with bovine IIa.

magnetization

between

two

protons through space, resulting in
cross-relaxation. Since dipolar coupling depends on the distance between the protons
(relaxation rates are proportional to 1/r6), only protons within 5Å will result in a NOE
peak. Equation 2 relates the relaxation rate between protons (σ) to the interproton
distance (r). Thus, NOE intensity can be implemented to calculate a structure for the
peptide interacting with a protein (186).
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The 2D trNOESY NMR experiment also profits from the variations in τc resulting
from molecular weight between a peptide and a protein. Once again, a free peptide (of
less than 18 residues) possesses τc values of approximately 10-10 sec leading to ωτc ≤ 1.
This situation equates to NOEs that are both small and positive or approach zero. The
binding of the peptide to a larger protein (τc > 10-8 sec) means ωτc >> 1 and the NOEs are
large and negative, dominating the 2D spectrum. Interaction of the peptide with the
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protein surface may result in a defined conformation for the peptide. For a successful
experiment, the peptide must be in molar excess to the protein (~10:1). The koff should
be sufficiently quick for the peptide to rejoin the free peptide population, allowing
another peptide to bind to the protein.

If these conditions are met, then reliable

information regarding the bound state of the peptide will be obtained (Figure 12).
In instances where the peptide binds too tightly to the enzyme, line broadening and
NOEs will not be observed in the spectra. This situation results in less buildup of
magnetization intensity within the free peptide population since the peptide remains

Figure 12: Summary of the 1D line broadening and 2D transferred NOESY techniques. When free
in solution, a peptide possesses very little secondary structural features due to lack of constraining
factors, such as a protein in which to interact. This situation results in ωτ c ≤ 1 and longer transverse
relaxation (T2) times. The 1D spectrum will display very sharp peaks and the 2D trNOESY will lack
the presence of many discernable NOEs. Introduction of the binding partner, in this case a larger
protein, leads to the peptide interacting with protein. Thus, those protons that contact the protein
surface adopt the solution characteristics of the larger macromolecule, i.e. ωτ c >> 1, shorter T2 times,
and large negative NOEs. The peptide now assumes the secondary characteristics associated with
binding to the protein. If the koff for the peptide is sufficiently fast, then the peptide will take a
“memory” of the bound conformation to the free peptide population. This rejoining with the free
peptide population results in 1D line broadening for protons that contact the protein surface and a
weighted average of the NOES of the free and bound ligands in the 2D trNOESY spectrum.

36

bound to the protein. A variety of measures can be implemented to circumvent these
situations (reviewed in 184). First, since koff is dependent on temperature, raising the
temperature may weaken the interaction enough for the bound peptide to dissociate from
the protein and retain the characteristics of the bound conformation.

Another method

involves manipulating the ionic strength or the pH of the solution, which could interfere
with binding to protein enough to increase koff. Larger ratios of peptide to enzyme (up to
50:1) create a situation where more peptide is competing for the protein-binding site, thus
increasing dissociation.

Finally, modifying the residues within the peptide, such as

removing phosphorylation from a phosphotyrosine or substituting an F for a Y, may
achieve a similar effect as raising the temperature. Increasing koff too much may result in
the disappearance of NOEs and line broadening as well, because the rate of interaction
with the protein is now faster than the detection limits of the NMR experiment.
Spin diffusion resulting from intermolecular relaxation with the protein can
interfere with interpretation of NOEs. In this case, distances between protons appear to
be shorter due to dipolar coupling with protein protons leading to spin diffusion across
the protein surface. A direct outcome of spin diffusion is a peptide structure that is quite
compact when compared to the actual conformation of the ligand. Increasing the peptide
to protein ratio may circumvent this situation.

Another way around this potential

problem is by decreasing the mixing time for the NMR experiment, which discourages
indirect transfer of magnetization from the protein to the peptide and thus the appearance
of an artificial NOE or an increase in NOE intensity.

A comparison of NOEs from

spectra acquired at a range of mixing times should display a linear dependence for NOE
intensity with mixing time length (184).
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The ultimate advantage of these two NMR techniques, 1D line broadening and 2D
trNOESY, rests in the ability to observe, in solution, the conformational characteristics of
a ligand bound to a protein. In X-ray crystallography, a static snapshot of a system is
captured which could potentially be deceptive with regard to structural information.
Crystal packing effects within a lattice, or between neighboring protein molecules, could
potentially influence the solved structure and constrain the conformation of a bound
ligand. These techniques can observe transient interactions that may not be able to be
crystallized due to weak KD values.
As of this writing, NMR structures of IIa and FXIII have not been published. The
most probable reason for this absence is due to the need of large amounts of isotopically
labeled protein, which are required to obtain the NMR structure. Without a reliable
E.coli expression system, trNOESY NMR experiments provide a means to observe IIaligand or FXIIIa-substrate interactions in solution with no requirement for large amounts
of protein. A glance at the literature reveals that these NMR techniques have been
employed to gather an extensive amount of information regarding ligand interactions
with IIa’s active site and anion binding exosite I (185, 187-199). As for FXIIIa, NMR
work has focused on examining the interaction of the FXIIIa substrates K9 and α2antiplasmin binding to the active site (137, 200). For the first time, the conformational
features associated with peptide binding to IIa’s anion binding exosite II have been
elucidated in solution and are described in the subsequent chapters (167).
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CHAPTER III
MATRIX ASSISTED LASER DESORPTION IONIZATION TIME-OF-FLIGHT MASS
SPECTROMETRY AND HYDROGEN DEUTERIUM EXCHANGE
As discussed in the previous chapter, NMR is a powerful tool for high-resolution
structural analysis.

However, serious drawbacks to this technique include the

requirement for large amounts of material and the potential for macromolecules to
possess poor solubility in solution. A typical 2D trNOESY experiment may take upwards
of 24 hours to complete and demand a sample prepared to the highest degree of purity.
An important complementary method for the characterization of protein structure and
dynamics that alleviates many of the prerequisites for a successful NMR experiment is
Matrix-Assisted Laser

Desorption-Ionization

Time-of-Flight

Mass Spectrometry

(MALDI-TOF MS). Whereas in NMR µM to mM concentrations of material are needed
to collect a spectrum, MALDI-TOF MS proves to be a much more sensitive technique
with detection limits reaching pM levels. MALDI-TOF MS tolerates small amounts of
impurities, has short preparation/analysis times, and detects large macromolecules (>300
kDa). In this chapter, the basics of the MALDI-TOF MS experiment will be detailed
from the preparation of a sample to the acquisition of a spectrum, followed by a
discussion of how hydrogen deuterium exchange (HDX) can be monitored with MALDITOF MS.
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MALDI-TOF MS Theory and Instrumentation
As the name implies, mass spectrometry detects molecules based on molecular
mass. More precisely, the signal obtained reflects the mass to charge ratio (m/z) of the
observed ion. A typical MS experiment is broken down into three parts: ion production,
ion transmission, and ion detection (201). Figure 13 depicts a schematic of a Voyager
DE (Delayed Extraction)-PRO MALDI-TOF MS instrument (Applied Biosystems). The
following description pertaining to the theory and operation of the Voyager DE-PRO
MALDI-TOF MS is adapted from the Voyager Biospectrometry Workstation User Guide
provided by Applied Biosystems, unless referenced otherwise.

Figure 13: Schematic of a MALDI-TOF mass spectrometer. The red line is the path of the laser beam
and the blue line is the path of the ions traveling in reflector mode. The figure is adapted from the
Voyager Biospectrometry Workstation User Guide (Applied Biosystems).

Preparation of the sample is the first step in performing a MALDI-TOF MS
experiment. Sample ionization proceeds with the assistance of the matrix. The choice of
matrix depends on the composition of the material, i.e. protein, nucleic acid, or lipid, and
the molecular weight of the substance studied. The Voyager DE PRO is equipped with a

40

N2 laser with a wavelength of 337 nm, therefore the matrix must absorb at 337 nm. Table
2 presents a list of matrices most frequently employed in the projects described in this
dissertation. These compounds are dissolved in a volatile, acidic solvent. A typical
solution for α-CHCA consists of 1:1:1 acetonitrile:0.1 % trifluoroacetic acid:ethanol at a
concentration of 10 mg/mL. Sample is mixed with matrix at a 1:1 ratio and allowed to
dry on a stainless steel plate. After the matrix and sample co-crystallize, the plate is
inserted into the mass spectrometer.
MALDI-TOF MS acquisition consists of the laser firing, the matrix absorbing the
laser’s energy, the sample ionizing, the ions traveling to the detector, and the instrument

Table 2: Common Matrices Used with MALDI-TOF MS
Matrix
Structure

Application

HO
C
HC

3,5-Dimethoxy-4-hydroxy
cinnamic acid (Sinapinic
Acid)

O

CH

Peptides and Proteins
>10 kDa
H3CO

OCH3
OH

HO
C

α-cyano-4hydroxycinnamic acid
(α-CHCA)

HC

O

C

Peptides and Proteins
< 10 kDa

CN

OH
O
C

OH

CH

trans-4-hydroxy-3methoxycinnamic acid
(Ferulic Acid)

HC

Peptides and Proteins
3-10 kDa
CH3
O
OH

41

displaying the molecular mass of the ions in a spectrum (202). The laser fires coherent,
high-density energy (337 nm) at a rate of 3 nsec per pulse. An attenuator controls laser
intensity, with a prism directing the beam to the sample plate. An excess of matrix over
sample facilitates efficient sample ionization and desorption, as well as dissuades
decomposition of the sample due to radiation, thus the process is termed “soft” ionization
(203). It should be noted that ionization refers to the transfer of a proton from the matrix
to the sample (204). Hence, analytes are recorded as m/z values and not mass.
Once irradiated, a plume of gaseous material is ejected (desorption) from the
surface of the sample plate (204, 205). Within this plume, a mixture of matrix, sample
ions, and buffer components are in a dense cloud. The next step is to apply a potential
(20 kV) between the sample chamber and the variable voltage grid. Ions accelerate
through the field-free flight tube, desirably with the same kinetic energy and in a straight
path. Since KE=1/2mv2, smaller ions will reach the detector before larger species. A
guide wire within the flight tube possesses a potential of ~1% of the accelerating
potential and serves to focus the ions into a more coherent path to the detector.
The system is maintained under a high vacuum (10-6-10-8 torr) for a few reasons.
At atmospheric pressure, gaseous molecules will collide with the ions produced from
desorption. Collisions of this nature result in the ions experiencing decreases in the
kinetic energy and deviating from a straight path to the detector. These molecular
interactions ultimately lead to errors in m/z determinations. Another consideration is that
constant bombardment of the ion detectors with molecules from the atmosphere will
reduce sensitivity. Finally, the possibility exists for electrical arcing within the source
chamber since the high voltages required for ion transmission to the detector could cause
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molecules within the air to momentarily conduct current. Therefore, after inserting the
sample plate into the instrument, the sample chambers must be evacuated of nearly all
gaseous molecules for proper instrument functioning and maintenance. Located at the
opposite end of the instrument is the linear detector. The purpose of this device is to
count the number of ions (intensity) that reach the detector and the time the ions arrive
(drift time) at the detector. Signals recorded by the detector are sent to a digitizer for
conversion to a mass spectrum displaying a plot of the intensity versus m/z (206, 207).
The drift time (t) is converted to m/z using Equation 3, where KE is kinetic energy, s is
drift distance, and z is ionic charge.
1

"
%2
m
t = s$
'
# 2 * KE * z &

(3)

Equation 3 highlights the necessity of similar KE and drift distance values for
accurate m/z determinations.

!

An initial delay in the application of the accelerating

potential is quite important for a few reasons (208). If the potential is not immediately
applied, these plume components will drift apart and the initial ionization energy within
the sample molecules will dissipate to the surroundings. Therefore, introduction of 20
kV to the system will be less likely to induce fragmentation within the less dense plume.
Second, initial ionization will randomly impart varying degrees of energy to the ejected
species. Acceleration of the ions immediately following ionization yields an uneven
distribution of KE, skewing the detected m/z values for the observed species (209).

In

order to avoid these issues, a delay of 100-200 nsec is implemented before engaging the
accelerating potential (delayed extraction) (210, 211). This delay ensures that the ions
will traverse the field free tube at the same time and with the same KE.
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Within the Voyager DE PRO, another type of detection involves ion reflection.
Before reaching the linear detector, the ions are reflected by a single-stage gridded mirror
(evenly spaced electrodes) that uses a uniform electric field to direct the ions to the
reflector mode detector (212). In conjunction with delayed extraction, this process serves
to minimize initial differences in KE (213). Ions with higher KE will penetrate deeper
into the ion mirror, while ions with the same m/z but lower KE will not travel as far
within the ion mirror. Thus, variations in m/z due to KE are minimized. Reflector mode
significantly improves mass accuracy and signal resolution when compared to linear
detection. The upper limit for reflector mode ion detection is 10,000 m/z. The reason for
this threshold is related to peak broadening resulting from the metastable decay of higher
MW ions (214). This type of broadening is greater than broadening associated with KE
variation, thus resolution is not enhanced in reflector mode.
Applications of MALDI-TOF MS
As previously described, MALDI-TOF MS primarily measures the mass of
molecules.

This technique has been utilized to observe conformational changes in

protein dynamics that result from conversion of a zymogen to an active enzyme or of a
ligand binding to a protein. The three principal methods for probing variations in protein
dynamics with MALDI-TOF MS are chemical modification, limited proteolysis, and
hydrogen deuterium exchange (HDX).
Differential chemical modification of specific amino acid residues was first
implemented in our laboratory as a valuable tool for observing FXIII dynamics in 2004
(175). In this method, the protein is exposed to an amino acid modifying reagent,
digested with a protease, and analyzed with MALDI-TOF MS. For example, unactivated
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and activated FXIII are both introduced to N-ethylmaleimide (NEM), which specifically
modifies cysteine residues (215).

FXIII possesses nine cysteines and once labeled,

increases the m/z value of the monitored digest fragment by 125.1 Da (Figure 14). By

Unmodified Fragment

NEM Modified
Cysteine Fragment

Figure 14: NEM modification of cysteine as detected by MALDI-TOF MS. FXIIIa is treated with
NEM for 60 minutes, digested with trypsin, and analyzed with MALDI-TOF MS. The unmodified
fragment represents 327-333 (729.39 m/z). C327 is modified with NEM adding 125.1 m/z to the tryptic
peptide (854.45 m/z)

comparing the reaction of NEM with cysteine in zymogenic versus activated FXIII,
information is obtained about the solvent accessibility of cysteine, which is then
extrapolated to deduce conformational changes within the transglutaminase. Similarly,
acetic anhydride reacts with available lysine residues providing complementary structural
information (216, 217). An increase of 42 Da is observed in the mass spectrum (Figure
15). Further detail concerning this methodology will be discussed in chapter VI.
Conformational changes can also be detected by proteolytically digesting the
protein for only 30 minutes and recording the appearance and abundance of ions in the
mass spectra (218).

Such limited proteolysis provides a glimpse of peptide bond

accessibility for the proteases chymotrypsin and trypsin. If one fragment appears in the
45

digest of the zymogen and is absent in the digest of the activated form of the enzyme,
then it is inferred that a conformational change has rendered this peptide bond less
accessible to hydrolysis in the active form. Once again, the utility and implementation of
this technique is presented in chapter VI.

Unmodified
Fragment

AA Modified
Lysine
Fragment

Figure 15: Acetic Anhydride modification of lysine as detected by MALDI-TOF MS. FXIIIa is
treated with AA for 60 minutes, digested with trypsin, and analyzed with MALDI-TOF MS. The
unmodified fragment represents 704-715 (1307.69 m/z). K704 is modified with AA adding 42 m/z to
the tryptic peptide (1349.69 m/z)

An important technique for observing perturbations in protein dynamics that does
not rely on chemical modification of amino acids is hydrogen deuterium exchange
(HDX). HDX within proteins has been studied for nearly a half a century (219). The
method exploits differences in the rate of chemical exchange for backbone amide protons
in proteins. Half-lives ranging from milliseconds to years is possible for amide protons
in proteins due to secondary and tertiary structure, protein flexibility, and protein
mobility (220-223). Equation 4 relates the rate of chemical exchange to the concentration
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of acid and base present in solution (224). Typical rate constants for polyalanine are kH =
41.7 M-1 min-1, kOH = 1.12 x 1010 M-1 min-1, and kH2O = 3.16 x 10-2 M-1 min-1 (224).

kex =k H [ H + ] + kOH [OH " ] + k H 2O

(4)

The rate of chemical exchange is highly dependent on pH and temperature. At a pH
of 2.5, the rate of proton exchange is at a minimum. More acidic conditions (pH < 2.5)

!

lead to catalysis occurring through proton addition and a more basic environment (pH >
2.5) promotes proton abstraction (220). In addition, exchange is much slower at 0 °C
than at 25 °C. Therefore, HDX quench conditions refer to dropping the pH to 2.5 at 0 °C
where the exchange rate for backbone amide protons ranges from 30-120 minutes (225).
A few factors influence the rate of backbone amide proton exchange that are
intrinsic to the protein (220-223). First, the degree of solvent accessibility for the proton
is an important consideration. Surface-exposed amides are more available for deuterium
exchange than protons buried within the interior of the protein. Hydrogen bonding, along
with secondary and tertiary structural elements, involving the proton will provide
stabilization against exchange, further slowing the rate of deuterium incorporation.
Protein dynamics influence deuterium exchange to a high degree (Figure 16) (226228). Through fluctuations in protein structure (temporary protein unfolding), a deeply
buried proton may become briefly exposed to solvent. Therefore, the rate of protein
unfolding (ku) and refolding (kf) will play a role in proton solvent accessibility. A
smaller fluctuation event could be the momentary disruption of a H-bond leading to
deuterium exchange. In this instance, the rate of opening (kop) and closing (kcl) of local
protein structure need to be considered when following deuterium exchange (229).
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Figure 16: Pathways of protein backbone amide proton exposure (229). The top route
illustrates a local unfolding event, whereas the bottom pathway depicts complete unfolding of the
protein followed by deuterium exchange.

Two different types of deuterium exchange regimes describe the kinetic extremes of
the HDX continuum (221, 228). In EX1 exchange, once the proton becomes solvent
exposed, deuterium exchange immediately occurs. The observed rate of exchange is
equal to the rate describing the opening of the particular structural element within the
protein (kobs = kop). The time for the protein to reversibly refold, or close, (kcl) is slower
than deuterium exchange. At the other extreme, EX2 exchange refers to the situation
where protein refolding after solvent exposure is faster than the rate of deuterium
exchange.

Thus, an equilibrium exists between the solvent accessible and properly

folded protein states (kobs = kop/kcl*kex). Since the observed rate is proportional to the rate
of exchange, the EX2 regime is sensitive to pH changes. Unless the rate of protein
unfolding is dependent on pH, the EX1 regime is independent of pH. Most protons
within a protein reside somewhere between the two exchange states.
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The Komives laboratory described the first applications of HDX with MALDI-TOF
MS in 1998 (230, 231). Figure 17 illustrates the general protocol for the technique.
Since all three projects described in this dissertation employ HDX methodology, the
general protocol will be discussed in this chapter with the relevant features associated
with each specific project detailed in the following chapters.

Figure 17: Protocol for the hydrogen deuterium exchange experiment. In this schematic, a protein
and peptide interact leading to protection from deuterium at the peptide-protein interface. After
binding, a conformational change occurs at the purple fragment blocking exchange for several
interior protons. The exchange is quenched by acidification and a decrease in temperature.
Disulfides within a protein can be reduced with TCEP at the quench conditions. The protein is
hydrolyzed with pepsin and then analyzed with MALDI-TOF MS.

HDX can be utilized to examine conformational changes associated with the
conversion of a zymogen to an activated state. Additionally, the technique may be
applied to study the consequences of ligand binding to a protein.

The Komives

laboratory was the first to implement HDX to study solvent accessibility at a proteinprotein interface (231). With such an HDX experiment, the ligand should be bound to
the protein, ideally, for the entire course of the deuterium exchange (173, 231). Thus, the
KD describing the strength of the ligand-protein interaction, as well as, the concentration
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of the binding partners, will determine the lifetime of the complex. In other words, the
more time the ligand and protein spends apart directly affects protein deuterium
incorporation at the binding interface. Equation 5 illustrates the equation that calculates
the percentage of ligand (L) bound to protein (R) given the molar concentrations of both
components and the KD are known (173, 231).

%Bound =

L + R + KD ±

(L + R + K D )

2

" 4LR

(5)

2R

For a typical HDX experiment, the protein is exchanged into the desired buffer and
lyophilized. Initiation of deuterium exchange occurs when the protein is reconstituted in

!

D2O. Next, the samples are incubated in a desiccator at room temperature for 1 minute or
10 minutes. The exchange is quenched by lowering the temperature to 0 °C and
acidification to pH 2.5. Under the quench conditions, immobilized pepsin is introduced
to the sample and digested for 10 minutes. Unlike the proteases chymotrypsin and
trypsin, pepsin is most active at acidic pH conditions.

Also, pepsin’s specificity

determinants differ from chymotrypsin and trypsin (232). Whereas chymotrypsin and
trypsin hydrolyze peptide bonds after specific residues, pepsin relies on secondary and
tertiary structural elements when cleaving proteins (223). Though predicting where
pepsin cleaves proteins is a difficult prospect, proteolysis always yields the same
fragments from digest to digest, even with similar proteins from different species (233).
At this point, it should be noted that others have employed a range of time points
from 30 seconds to 10 minutes when studying HDX (172-174, 230, 231, 233, 234). The
data were then fitted to an exponential equation that classifies protons as either fast or
slow exchangers. The fitted equation yields values for the rate of proton exchange and
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the maximum amount of deuterium incorporation for the particular class of protons (fast
or slow). Since the peptides examined in this HDX method consist of a multitude of
backbone amide protons, assigning rate constants for individual amide protons is a
difficult task. Furthermore, classifying protons as either fast or slow exchangers does not
serve to advance a clearer understanding of the differences between protein states.
Therefore, the HDX technique may be considered as more of a qualitative method to
determine variations amongst several unique protein states. Observing differences in
HDX for a protein at an initial time point (1 minute) and a longer time point (10 minutes)
enables ligand binding interfaces to be deduced, as well as more transient deviations in
HDX resulting from allostery due to ligand binding or activation of the protein.
Since thrombin possesses four disulfide bonds (51), both a reducing and nonreducing digest was necessary to produce maximal sequence coverage.

Tris (2-

carboxyethyl) phosphine hydrochloride (TCEP HCl) can efficiently reduce disulfide
bonds in acidic conditions on ice (235) and does not interfere with pepsin hydrolysis of
the protein (167, 234).

Once pepsin hydrolysis has proceeded for 10 minutes,

centrifugation at 4 °C separates the digest from the immobilized pepsin. Finally, 10 µL
aliquots are immediately frozen in liquid nitrogen and are stored at –70 °C.
MALDI-TOF MS analysis of the digested protein is the next step. A frozen HDX
aliquot of the protein is thawed, immediately mixed with an equal volume of 10 mg/mL
α-CHCA matrix and then 0.5 µL spotted onto a chilled stainless steel MALDI plate. The
spotted MALDI plate is dried under a moderate vacuum and is inserted into the MALDITOF MS. The amount of time required for the plate to dry is roughly equivalent to the
time needed for the MALDI-TOF MS to cycle through the eject protocol and accept the
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plate for analysis. The entire procedure takes about five minutes of time, limiting the
amount of hydrogen back exchange.
The spectra are collected in the reflector mode with 256 laser shots per spectrum to
maximize signal to noise ratios. Since pepsin’s cleavage patterns are difficult to predict,
peptide fragments within a mass spectrum require identification, primarily through post
source decay (PSD) sequencing (236). Briefly, PSD is a technique that leads to peptide
fragmentation within the MS through ionization with higher laser intensity and collisions
with gas molecules introduced into the ion source. The resulting fragments are detected
by the MS. By matching the m/z values to theoretical fragments obtained from a known
potential peptide sequence, identification of a particular peptide is achieved and
differences in deuteration states can be localized to specific regions within the protein.
Thrombin peptides derived from a peptic digest without TCEP treatment were
previously identified by Croy and co-workers (233). These assignments were verified in
the current studies by in-house PSD sequencing. Peptides obtained from the reduction of
IIa by TCEP were also identified in-house with additional assistance from Julia Koeppe
(University of California at San Diego) (167, 234). Brian T. Turner, Jr. identified peptic
fragments from the digest of FXIII (174).

The program Data Explorer (Applied

Biosystems) was used to analyze the spectra. Calibration of the spectra involved two
reference peptides produced from the digest with pepsin.
Within the mass spectrum, compounds appear as an isotopic cluster. The first peak
in the envelope represents the compound with only the dominant isotopes
14

N. Since the natural abundance of

13

12

C,

16

O, and

C is 1.1% (237), the next peak in the cluster

correlates to the probability of the compound possessing a single 13C. The third peak in

52

the cluster is the compound with two 13C atoms. The monoisotopic peak will dominate
the cluster, until analyzing a compound with at least 100 carbon atoms, at which point the
likelihood of the presence of a

13

C atom is greater than the molecule without

13

C. The

atoms oxygen and nitrogen also possess naturally
occurring isotopes; however,

18

O (0.2%) and

(0.4%) have lower abundances than

13

15

N

C (1.1%) (237).

Since oxygen and nitrogen do not appear as frequently
in peptides as carbon, these O and N isotopes will not
contribute to the isotopic profile as visibly as 13C.
Introducing a peptide to deuterium will also serve
to increase the m/z by the amount of deuterium
Figure 18: Isotopic envelope for a
peptide after 0, 1, and 10 minutes of
deuteration.
Mass
spectra
representing residues 85-99 of
bovine thrombin (1317.73).
A.
Undeuterated fragment. B. One
minute of deuteration. C. Ten
minutes of deuteration.

incorporated into the peptide.

Deuterium is 1 Da

heavier than hydrogen, which is reflected in the shift of
the isotopic cluster to the right. Figure 18 displays
three time points from zero to ten minutes of

deuterium incorporation. As longer time points are observed, the peptide will incorporate
more deuterium, eventually reaching a plateau.
Once the spectra are collected, the amount of deuterium incorporation must be
calculated. Equation 6 has been developed to quantify the amount of deuterium uptake
for each peptide observed in the spectra, where Im represents the average mass of the
isotopic cluster (also termed centroid), xi is the intensity and mi is the mass of peak i. The
summation encompasses all peaks in a cluster that have signal to noise ratios of at least
two. By subtracting the undeuterated centroid from each deuterated centroid, the amount
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of deuterium incorporated into the peptide is quantified. At least three spectra were
collected per trial and three trials were run for each time point under each condition.

#
&
%
(
n
% xi (
Im = "%
(mi
n
i =1 %
(
% " xi (
$ i =1 '

(6)

Quantification of differences in deuteration between different protein states was
calculated with !
Equation 7, where D is the amount of deuterium incorporated in the
different protein state, Dref is the amount of deuterium incorporated for reference protein
state, and Hex is the theoretical maximum number of exchangeable protons within the
indicated peptide, assuming 100% deuteration. Only % differences more than ±4.5% are
considered significant (174, 238, 239).

# D " Dref &
%Difference = %
( *100%
$ Hex '

(7)

Hex can be divided into three categories. The first type is backbone NHs, calculated

! number of prolines and the N-terminal residue from the total amino
by subtracting the
acids in the peptide. The next two types rely on the final % of D2O in solution under
quench conditions (~4.5%). The N-terminus and C-terminus possess four exchangeable
protons. Finally, 12 residues contain side chain protons that can exchange for deuterium:
R(5), K(3), H(2), N(2), Q(2), C(1), S(1), T(1), Y(1), W(1), E(1), and D(1).

The

following is an example for calculating Hex for the IIa fragment 173-181 (RIRITDNMF).
The total number of NHs is nine. From this, the N-terminal residue is subtracted, leaving
8 exchangeable backbone protons. At the termini reside four protons. To these protons
are added the amount of exchangeable side chain protons: 2R (10 Hs), 1T (1 H), 1D (1
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H), and 1N (2 H). The termini plus side chain Hs equal 18, which is multiplied by the
residual % of deuterium in solution under quench conditions: 18 x 0.045 = 0.8. Add 0.8
and 8 to arrive at Hex = 8.8 for 173-181 of IIa.
Back exchange from deuterium to hydrogen resulting from humidity, temperature,
quench solutions, and matrix accounted for a 50% loss of deuterium during analysis.
This percentage was determined by performing the HDX protocol on a small model
peptide. Experiments were performed within the same week to minimize HDX variations
resulting from temperature and humidity fluctuations. In addition, a dehumidifier has
been installed in the MALDI-TOF MS room. Thus, the amount of back exchange is
essentially constant for each individual peptide, verified by the low standard deviation for
three independent trials. Only differences in HDX between two states of the protein are
desired, therefore a correction for deuterium loss was not necessary.
Mass spectrometry provides an important tool for studying protein structure. In the
case of FXIII, MALDI-TOF MS probes conformational changes that result from
activation and inhibition that otherwise would have gone undetected in the absence of the
corresponding crystal structures. The difficulties in crystallizing FXIIIa are detailed in
Chapter I. As for thrombin, HDX coupled with MALDI-TOF MS has identified sites of
peptide interaction at ABE-II and variations in protein dynamics independent of the
ligand interaction site. These variations in protein dynamics that occur due to peptideprotein interactions may go undetected in crystal structures. The relative ease in sample
preparation, instrument operation, and data analysis further enhances the accessibility of
this technique to researchers around the world. MALDI-TOF MS will continue to be an
essential method in detailing protein structure and dynamics for years to come.
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CHAPTER IV
CONFORMATIONAL ANALYSIS OF γ′ PEPTIDE (410-427) INTERACTIONS WITH
THROMBIN ANION BINDING EXOSITE-II
Introduction
The thrombin anion binding exosites are highly electropositive patches that flank
the catalytic triad of this serine protease (Figure 4B) (51). Binding to these exosites can
modulate thrombin specificity or act in the recruitment of inhibitors (34, 240). At the
time this research was undertaken, a crystal structure illustrating γ′ peptide binding to
thrombin’s ABE-II had not been solved. As a result, the conformation the peptide
adopted upon binding to thrombin and the exact ligand interface on the surface of
thrombin were unknown.
X-ray structures of ligands interacting with ABE-II have been reported in the
literature (66, 96, 97, 168, 169). Figure 19 displays the residues that form ABE-II and
some of ligands bound to ABE-II (it should be noted that the views of IIa are different
than Figure 4. The structures are flipped 90° on the z-axis and rotated 180° relative to the
horizontal plane for a head on view of ABE-II). The structures illustrate two unique
modes of ABE-II interactions. In the first set of structures, prothrombin fragment II
(169) and haemadin (66) are illustrated reaching toward R97, R173, and R175. Both of
these proteins utilize secondary structural elements while binding to IIa. Alternatively,
GpIbα (96, 97) and heparin (168) bind to a groove formed by R93, R101, K236, and K240 in

56

an extended conformation. Due to the high degree of sequence similarity to GpIbα,
perhaps the γ′ peptide binds to ABE-II in a similar fashion (Table 1).
Differing perspectives exist regarding the transmission of allostery resulting from
ABE-II binding. Though allosteric communication from ABE-II to the active site is a
fairly well accepted concept (67, 68, 113), more ambiguous is the linkage amongst ABE-I
and ABE-II (70, 170, 171). Hydrogen deuterium exchange (HDX) experiments provide a
method to observe the regions of thrombin influenced by ligand binding and enhance the
understanding of how allosteric changes are transmitted from ABE-II throughout the
protease.

Previous HDX work with the ABE-I binding protein thrombomodulin

demonstrated that deuterium exchange for several regions within thrombin is affected,
suggesting allostery from ABE-I to ABE-II (172, 173). With γ′ peptide binding to ABEII, maybe HDX could detect a reverse pathway from ABE-II to ABE-I.
The research described in this chapter examines the γ′ peptide’s interaction with
IIa’s ABE-II. 1D and 2D NMR experiments were carried out to observe, in solution, the
structural features the γ′ peptide adopts upon interacting with IIa’s ABE-II. Furthermore,
the individual residues within the γ′ peptide that contact the enzyme’s surface could be
detected. In another series of studies, HDX monitored by matrix-assisted laser desorption
time-of-flight mass spectrometry (MALDI-TOF MS) was used to characterize the effects
of γ′ peptide binding on the solvent accessibility of IIa’s surface. Additional coverage of
IIa was obtained through the use of the reducing agent TCEP, which enabled the
monitoring of previously unseen regions of thrombin. In these NMR and MS studies,
phosphotyrosines, which do not sacrifice binding affinity, were prepared instead of the
acid labile sulfotyrosines present in the fibrinogen γ′ chains (69, 241).
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Figure 19: Modes of ligand binding to ABE-II. In the 1PPB structure, key ABE-II residues
are labeled and color-coded. The orange residues interact with all ligands depicted in this
figure. The blue residues form a groove that is utilized by heparin and GpIbα. The
polypeptides prothrombin fragment 2 and haemadin reach toward the yellow residues, skirting
the ABE-II binding groove formed by the blue residues.
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Our findings describe the γ′ peptide-thrombin relationship from the perspective of
both the peptide and the enzyme. γ′ peptide binding to ABE-II causes the ligand to adopt
significant secondary structure when compared to free peptide in solution. Interactions at
ABE-II also have allosteric consequences on the rate of deuterium exchange for regions
unaffiliated with the ligand-protease interface. Fresh analysis of the results obtained in
this investigation (167) will be compared to the crystal structure recently published by the
Di Cera lab (242).
Materials and Methods
Synthetic Peptides. SynPep (Dublin, Ca) and Research Genetics, Inc (Huntsville,
Al) synthesized peptides based on residues 410-427 (PEHPAETEYDSLYPEDDL) of the
human fibrinogen γ′ chain. Four variants of this sequence were prepared (Table 3).
MALDI-TOF measurements on an Applied Biosystems Voyager DE-Pro mass
spectrometer were used to verify the peptide m/z values. The concentrations of the
peptides in solution were determined by quantitative amino acid analysis (AAA Service
Laboratory, Boring, OR).
Table 3: γ′ Peptides Used in IIa Binding Studies
YP418 YP422
YP418 Y422
Y418 YP422
Y418 Y422

410

PEHPAETEYPDSLYPPEDDL427
410
PEHPAETEYPDSLYPEDDL427
410
PEHPAETEYDSLYPPEDDL427
410

PEHPAETEYDSLYPEDDL427

Thrombin Preparation. The isolation and purification of thrombin from bovine
plasma barium sulfate eluate (BSE) (Sigma) was performed as previously described by
Trumbo and Maurer (243).

The purified thrombin solution was concentrated with

Amicon Ultra-15 centrifugal filter units (Millipore) in an Allegra 21R Centrifuge
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(Beckman Coulter) run at 4000 rpm and 4 °C. The concentration of the activated
thrombin was determined using the extinction coefficient of E1% = 19.5 (244), then
aliquoted and frozen at –70 °C for future use.
Bovine IIa was used as the enzyme during the course of this work, while peptides
derived from the fibrinogen γ′ chain were based on the human sequence. Human and
bovine IIa exhibit a high degree of sequence conservation (87% identical) (51).
Important regions where there are no differences include the active site, the Na+ binding
site, the β-insertion (Trp60D) loop, ABE-I, and ABE-II. As for the γ′ chain, the bovine γ′
sequence terminates at residue 419 (111), while the human sequence possesses an
additional eight residues (60, 61). In this case, a peptide derived from the bovine γ′ chain
may not accurately portray human γ′ chain binding to IIa. The interaction of the human γ′
peptide with bovine IIa should not be influenced by the minor differences between the
species. Supporting this statement is an HDX study, where PPACK inhibition of human
and bovine IIa affected HDX in a similar manner for analogous peptides from both types
of IIa (233). In addition, 2D trNOESY NMR examining the structural features adopted
by fibrinopeptide A (193, 196, 245, 246) and a PAR1 peptide (185) bound to bovine IIa
were in agreement with the corresponding human IIa X-ray structures (247, 248).
1

H and 31P NMR Sample Preparation and Analysis. Approximately a 1:10 ratio of

IIa to peptide was maintained for each complex studied. Sample preparation and analysis
procedures similar to those of Trumbo and Maurer were employed (190). Selective
features are summarized here. Each 400 µl NMR sample contained 1.5 mM peptide and
either zero or 151-162 µM IIa. The samples were buffered in 25 mM H3PO4, 150 mM
NaCl, 0.2 mM EDTA, pH 5.6 and 10% D2O (NMR buffer).
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Human gamma-IIa

(Haematologic Technologies, Inc.) at 56 µM was buffer exchanged into the NMR buffer
and concentrated to 153 µM via ultracentrifugation. With addition of the YP418YP422
peptide, the final ratio of gamma-IIa to peptide was 11:1 in 10% D2O.
All 1H NMR experiments were performed on either a Varian Inova 800 MHz
spectrometer equipped with a triple resonance probe and pulsed-field triple axis gradients
or a Varian Inova 500 MHz equipped with a triple resonance probe and pulsed-field zaxis gradients. 2D transferred NOESY experiments of the enzyme-peptide complexes
were run at 15 or 17 °C with 32 transients, 512 t1 increments, a mixing time of 400 ms,
and a spectral width of 8006 Hz or 5006 Hz. Spectra were processed using FELIX2000
software (Accelerys, San Diego, CA) on a Silicon Graphics Octane workstation. For 31P
NMR, spectra were recorded on a Varian Inova 500 MHz equipped with a 5 mm
broadband probe tuned to 202.4 MHz.

The spectra were referenced to the peak

corresponding to H3PO4 (0.00 ppm).
HDX Sample Preparation.

Aliquots of 100 µL, 142-150 µM IIa were buffer

exchanged with Amicon-Ultra 4 units (10,000 MWCO) and diluted into 75 mM NaCl,
12.5 mM NaH2PO4, pH 6.5 (HDX Buffer). The final target concentration of IIa for all
HDX preparations was from 20-25 µM. D-Phe-Pro-Arg-chloromethyl ketone (PPACK)
inhibited IIa was prepared by adding 5 µL of 11 mM PPACK to a thawed IIa sample
diluted to 545 µL with the HDX buffer (resulting in a 4:1 ratio of PPACK to IIa). The
PPACK-IIa solution was incubated at 37 °C for at least 30 minutes. An assay involving
the chromogenic substrate S2238 was employed to establish that IIa was inactivated by
PPACK. Following inactivation, PPACK-IIa was buffer exchanged in the same manner
as active IIa. For samples containing the γ′ peptide, 25 µL of 480 µM γ′ peptide in dI
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H2O was added to 24 µL of the buffer exchanged IIa (20-25 µM). The aliquots of the
buffer-exchanged IIa, with and without the peptide, were evaporated to dryness using a
SpeedVac unit (Savant). The dry aliquots were stored at -70°C.
HDX Experiments. Dry aliquots of IIa or YP418YP422 peptide-IIa were allowed to
come to room temperature before beginning the experiment. 12 µL of 99.996% D2O
(Cambridge Isotope Laboratories) were added to the aliquot yielding the final
concentrations: 40-50 µM IIa/PPACK-IIa, with or without 1000 µM γ′ peptide, in 150
mM NaCl, 25 mM NaH2PO4, pH 6.5. The samples were incubated in a desiccator at
room temperature for 1 minute or 10 minutes. An initial set of HDX experiments were
performed with varying concentrations of the γ′ peptide (150-1500 µM) to determine the
target peptide concentration and to address potential non-specific binding interactions.
Since IIa possesses four disulfide bonds, both a reducing and non-reducing digest
was necessary to produce maximal sequence coverage.

Adding 114 µL of 0.1%

trifluoroacetic acid (TFA) (on ice) acted to acidify (pH 2.5) the solution and quench
HDX. Immediately, 66 µL was transferred to a tube of activated pepsin bound to 6%
agarose (Pierce Chemical). To the remaining quenched IIa, 6µL of 1 M TCEP (Tris (2carboxyethyl) phosphine hydrochloride, Pierce Chemical) was introduced, quickly
vortexed, and the entire solution added to another tube of activated pepsin.

After

deuteration was quenched, the entire process of splitting IIa into a non-reducing and
reducing pepsin digest took 30-40 seconds. Digestion occurred on ice for 10 minutes.
Centrifugation at 4 °C separated the digest from the pepsin and 10 µL aliquots were
immediately frozen in liquid nitrogen and stored at -70 °C.
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HDX Analysis. A frozen HDX aliquot of IIa, with or without peptide, was thawed,
immediately mixed with an equal volume of 10 mg/mL α-cyano-hydroxycinnamic acid
matrix (Aldrich) in 1:1:1 ethanol/acetonitrile/0.1% TFA, pH 2.2, and then 0.5 µL spotted
onto a chilled stainless steel MALDI plate. The spotted MALDI plate was dried within a
SpeedVac unit (Savant) and inserted into the MALDI-TOF MS. The amount of time
required for the plate to dry was roughly equivalent to the time needed for the MALDITOF MS to cycle through the eject protocol and accept the plate for analysis. The entire
procedure took about five minutes of time, limiting the amount of hydrogen back
exchange. The spectra were collected in the reflector mode over a mass range of 8003500 m/z with 256 laser shots per spectrum. Peptides obtained from the peptic digest of
IIa were previously identified. New coverage obtained by reducing the disulfides in IIa
with TCEP was identified in-house and independently verified.
The program Data Explorer (Applied Biosystems) was used to analyze the spectra.
Calibration of the spectra involved two reference peptides, one with the singly protonated
monoisotopic mass of 888.4943 Da (residues 46-52) and the other with the singly
protonated pentaisotopic mass of 2106.1505 Da (residues 85-99).

The amount of

deuterium uptake by each peptide and the % difference in deuteration relative to IIa was
quantified as described by Sabo et al. (167) and discussed in Chapter III.
Results
One-Dimensional Line Broadening NMR. One-dimensional proton NMR spectra of
the different fibrinogen γ′ peptides were obtained in the absence and presence of IIa. The
appearance of resonance broadening in the spectra is indicative of peptide protons
coming in direct contact with the IIa surface. Figure 20 illustrates the extensive binding
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interactions observed for the YP418YP422 peptide. Widespread line broadening is observed
for the entire 1D spectrum, including the NHs spanning residues H412 to L427, the β, δ, and
ε protons of YP418 and YP422, the β protons of D419, D425, and D426, and the β, γ, and δ
protons of residues L421 and L427. Only three observable proton resonances in Figure 20
remain unchanged with the addition of the enzyme: P410 β, E411 NH, and H412 δ.

Figure 20: Line broadening for the γ′ (YP418YP422) peptide in the presence of thrombin. A. 1D NMR
spectrum for 1.5 mM peptide in solution. B. 1D NMR spectrum for 1.5 mM peptide in the presence of
0.162 mM thrombin. All NMR samples are in 25 mM H3PO 4, 150 mM NaCl, 200 µM EDTA, and 10%
D2O, pH 5.6 (NMR Buffer). All observable protons make extensive contact with the surface of
thrombin except P410 β, E411 NH, and H412 δ.

To assess the contributions that each YP makes to the interaction with IIa, singly
phosphorylated peptides were also analyzed.

The spectrum for the YP422 peptide

indicates broadened peaks for several residues (Figure 21).

These spectra provide

evidence that phosphorylation at a single Y is sufficient to promote binding of the γ′
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peptide to IIa. The absence of the phosphate at Y418, however, abrogates enzyme contact
for at the least the protons: H412 NH, A414 NH and β, T416 γ, Y418 ε, and L421 γ and δs.

Figure 21: Line broadening for the γ′ (YP422) peptide in the presence of thrombin. A. 1D NMR
spectrum for 1.5 mM peptide in solution. B. 1D NMR spectrum for 1.2 mM peptide in the
presence of 0.122 mM thrombin. The experimental conditions are the same as in Figure 27. In
contrast to the previous figure, several residues experience a decrease in line broadening including
the observable protons of H412, A414, T416, Y418, and L421.

With the YP418 peptide, the appearance of much weaker enzyme binding is evident
when examining the spectra in Figure 22, suggesting that most protons are not contacting
the surface of the enzyme. The only significant amount of line broadening that can
unambiguously be assigned is observed for the following protons: A414 β, E417 NH and
β′, Y418 δ and ε, and D419, D425, and D426 βs. The amide region of the YP418 spectra also
displays broadening for a peak that includes the NH of H412, A414, and E424, indicating
that all three of these amide protons are contacting the surface of thrombin. To complete
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the series, 1D spectra of the unphosphorylated peptide were obtained which lacked any
line broadening in the presence of thrombin (data not shown).

Figure 22: Line broadening for the γ′ (YP418) peptide in the presence of thrombin. A. 1D NMR
spectrum for 1.5 mM peptide in solution. B. 1D NMR spectrum for 1.5 mM peptide in the presence of
0.151 mM thrombin. The experimental conditions are the same as in Figure 27. A significant reduction
in line broadening occurs in the absence of phosphorylation at Y422. Residues displaying contact with
the enzyme include H412, A414, E417, Y418, E424, L427, and the aspartate βs.

Two-Dimensional Transferred Nuclear Overhauser Effect NMR. For the γ′ peptides
representing YP418YP422, YP418, and YP422, between 135-155 inter-residue NOEs were
observed in the presence of IIa displaying similar structural features. Appendix A lists
the chemical shifts associated with each residue in all four γ′ peptides. In addition, interresidue NOEs for the YP418YP422, YP418, and YP422 peptides are compiled in Appendix B.
By removing both phosphates from the peptide, 26 inter-residue, nearest neighbor NOEs
were identified in the presence of IIa, which is quite similar to the NOESY of the free
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phosphorylated peptides (data not shown). This significant decrease in NOEs suggests
that phosphorylation of at least one Y residue is required for interacting effectively with
IIa. Such an effect is in agreement with the 1D line broadening studies.

A
B

Figure 23: Representative spectra of key γ′ peptide NOEs in the presence of thrombin. A. βturn between residues Y422-D425 from 2D trNOESY spectrum of the YP418 peptide (1.5 mM) in
the presence of IIa (0.151 mM). All three phosphorylated peptides exhibit this conformational
feature, while the turn is absent when analyzing spectra involving the unphosphorylated peptide.
B. The intense clustering of NOEs centered at the aromatic protons of both tyrosine residues.
The spectrum is from the 2D trNOESY of YP418YP422 peptide (1.5 mM) in the presence of IIa
(0.162 mM). The aromatic protons of Y418 are in close proximity to aliphatic protons from T416,
E417, D419, and L421, while the Y422 ring protons display NOEs with residues S420, L421, P423, E424,
and D425. When the unphosphorylated peptide is observed, the NOEs are no longer present.

Important structural information related to the conformation of all three
phosphorylated peptides bound to IIa are obtained through analysis of the trNOESY
spectra. Key through space interactions occurs between the H412 α-P413 δs protons, as

67

well as the Y422β-P423δs protons (see Appendix B). These NOEs are indicative of an
Xxx-Pro bond in the trans conformation (249). Figure 23A from the trNOESY spectrum
of YP418 displays a β-turn formed by residues Y422-E425. The principal NOEs for this turn
are between the P423α-E424NH, the P423α-D425NH, and the NHs of E424 and D425 (249).
The NOEs for the β-turn and the proline trans bonds were also present in the 2D
spectrum of the YP418YP422 peptide binding to γ-IIa (a form of IIa with an impaired ABEI, see Chapter I) (data not shown).

Examining the trNOESY spectrum for the

unphosphorylated peptide with native IIa reveals the existence of trans H412-P413, but the
absence of the required NOEs for the β-turn and the C-terminal trans bond.
A region displaying numerous proton interactions in the trNOESY spectra of the
three phosphorylated peptides is centered on the two aromatic Y residues (Figure 23B
and Appendix B). A hydrophobic cluster, or an intense grouping of aliphatic protons, is
present encompassing T416-D425. By including through space interactions between E424 α
and the aliphatic chain of L427, this cluster extends to the C-terminus of the peptide.
31

P NMR Studies. Phosphorous NMR spectra were collected for the YP418YP422,

YP418, and YP422 peptides with and without IIa in solution. These experiments were
performed to monitor the effects of peptide-IIa interaction on line broadening. The
YP418YP422 peptide displayed two resonances at -3.06 ppm and -3.14 ppm (Figure 24).
Addition of IIa resulted in a merging of both phosphorous signals into one peak with a
significant amount of line broadening. The singly phosphorylated peptides were also
analyzed to assess the contribution each individual YP makes to the 31P NMR spectrum.
The YP418 and YP422 peptide signals shift upfield and become slightly broader with the
introduction of IIa (data not shown).
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Figure 24: 31P 1D NMR spectra for
the γ′ YP418YP422 peptide in the
presence of thrombin. A. Spectrum for
1.5 mM peptide in solution.
B.
Spectrum for 1.5 mM peptide in the
presence of 0.162 mM IIa. Both
phosphotyrosines are contacting the
enzyme surface resulting in a slight
downfield shift of the broadened peak.

HDX Experiments:

Examining the Influence of the γ′ Peptide on the Solvent

Accessibility of Thrombin. Peptic digests of thrombin, with and without the reducing
agent TCEP, yielded fourteen quantifiable isotopic clusters encompassing 44% of
thrombin’s sequence (Figure 25). The presence of four disulfide bonds (C1-C122, C42-C58,
C168-C182, and C191-C220) limits the amount of sequence coverage attainable without
introducing a reducing agent. Peptides spanning ABE-1 (65-84), ABE-2 (85-99), the
autolysis loop (135-149D), and several residues involved in substrate specificity (L99 and
I174) are represented in the peptic digests. TCEP allowed additional coverage to be
obtained in the A-chain (-3 to 7), as well as a region encompassing W215 and the Na+
binding site (212-227). Appendix C lists the m/z values for the fragments obtained from
a peptic digest of thrombin.
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Figure 25: Sequence coverage from the peptic digest of bovine thrombin. The solid
black lines indicate quantifiable peptide clusters obtained without a reducing agent,
while dashed lines refer to peptides acquired in the presence of TCEP. This coverage
represents 44% of the total sequence and includes residues from both anion binding
exosites, the W148 loop, the Na+ binding site, and several residues involved in substrate
specificity (L99, I174, and W215). Residues in the catalytic triad are green. ABE-I
amino acids are blue and ABE-II residues are red.

IIa with or without the addition of 1 mM γ′ peptide was exposed to 100% D2O for
either 1 or 10 minutes. The concentration of 1 mM γ′ peptide provided at least 99.93%
occupancy of 40-50 µM IIa (KD = 0.68 µM) (69). Table 4 and Figure 26 present the raw
data representing total deuterium incorporation for IIa.

The fourteen quantifiable

peptides represent ten distinct regions within IIa (Figure 25). When analyzing IIa alone,
five of these regions were continuing to exchange for deuterium after 10 minutes: 85-99,
106-116, 173-181, 202-207, and 212-227. These residues span ABE-II, the Na+ binding
site, and the substrate specificity residues L99, I174, and W215. The other five segments,
representing ABE-I, the A-chain, and the autolysis loop, became saturated with
deuterium at 1 minute: -13 to -4, -3 to 7, 46-52, 65-84, and 135-149D. The continued
uptake of deuterium over the entire observed time range is specific to amide protons more
protected from the solvent, or partially solvent exposed. Conversely, almost complete
initial saturation of the peptide indicates a more solvent exposed region (229).
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Figure 26: Graphs of deuterium incorporation for IIa, PPACK-IIa, γ′-IIa, and γ′ PPACK-IIa. A. one minute
and B. ten minutes of HDX for IIa in the absence or presence of ligands. The bars in the graph correspond
to: IIa (purple), PPACK-IIa (magenta), γ′ peptide-IIa (green), and γ′ peptide PPACK-IIa (orange). The
asterisk symbol (*) located after 6 fragments on the x-axis refers to data obtained in the absence of TCEP
for fragments. Errors correspond to standard deviation of the mean for three independent experiments.

Differences in Deuteration for Thrombin versus γ′ Peptide-Thrombin.

The γ′

peptide imparts a significant amount of solvent protection (Table 5; Figure 26) in five IIa
peptides representing two regions within ABE-II. Peptides 85-94, 85-96, and 85-99 are
situated in the center of ABE-II. Peptides 173-180 and 173-181 involve peripheral ABEII residues and the substrate specificity residue I174. After ten minutes, differences in
HDX for these ABE-II regions significantly increase when compared to one minute
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(Table 5). For example, γ′ peptide binding within 85-94 leads to HDX protection of 0.5
deuterons at 1 minute (-5.6%), which increases to 1.6 deuterons at 10 minutes (-17.7%)
(Figure 27).
Table 4: Deuterium Incorporation for IIa, PPACK-IIa, γ′-IIa, and γ′ PPACK-IIa at
One and Ten Minutes
1 Minute
Theo.
Residues
Dmaxa
IIa
P-IIa
γ′ IIa
γ′ P-IIa
-13 to -4b
8.5
3.7 ± 0.1
3.4 ± 0.1
2.7 ± 0.1
2.3 ± 0.0
-3 to 7
16.9
5.3 ± 0.1
5.0 ± 0.1
2.8 ± 0.1
2.3 ± 0.0
46-52
6.6
0.4 ± 0.0
0.4 ± 0.0
0.3 ± 0.0
0.4 ± 0.0
65-84
21.8
10.5 ± 0.1
10.1 ± 0.2
7.2 ± 0.1
5.0 ± 0.1
85-94
8.8
1.4 ± 0.0
1.5 ± 0.1
0.9 ± 0.0
0.8 ± 0.1
85-96
10.9
2.2 ± 0.1
1.8 ± 0.1
0.9 ± 0.1
0.7 ± 0.0
85-99
15.2
4.4 ± 0.0
3.4 ± 0.1
1.9 ± 0.1
1.2 ± 0.0
106-113b
6.7
1.6 ± 0.0
1.5 ± 0.1
0.9 ± 0.1
0.9 ± 0.0
106-116b
9.8
2.0 ± 0.1
1.8 ± 0.1
1.3 ± 0.1
1.2 ± 0.1
135-149D
19.4
7.8 ± 0.1
6.8 ± 0.1
6.9 ± 0.0
4.9 ± 0.1
173-180b
7.8
1.7 ± 0.1
1.1 ± 0.1
1.1 ± 0.1
1.0 ± 0.1
173-181b
8.8
1.7 ± 0.1
1.1 ± 0.1
1.2 ± 0.1
1.1 ± 0.1
202-207b
6.8
2.3 ± 0.0
2.3 ± 0.0
1.4 ± 0.1
1.2 ± 0.1
212-227
15.9
3.4 ± 0.1
2.5 ± 0.1
2.4 ± 0.1
1.5 ± 0.1
10 Minutes
Theo.
Residues
Dmax
IIa
P-IIa
γ′ IIa
γ′ P-IIa
-13 to -4b
8.5
3.6 ± 0.1
3.7 ± 0.1
3.2 ± 0.2
3.1 ± 0.2
-3 to 7
16.9
5.3 ± 0.1
5.3 ± 0.1
4.3 ± 0.1
4.4 ± 0.1
46-52
6.6
0.4 ± 0.0
0.4 ± 0.0
0.4 ± 0.0
0.4 ± 0.1
65-84
21.8
10.4 ± 0.2
10.5 ± 0.1
9.7 ± 0.2
8.7 ± 0.2
85-94
8.8
2.6 ± 0.1
2.7 ± 0.1
1.0 ± 0.1
1.0 ± 0.1
85-96
10.9
3.7 ± 0.1
3.4 ± 0.2
0.9 ± 0.1
1.0 ± 0.1
85-99
15.2
6.4 ± 0.1
5.5 ± 0.1
3.0 ± 0.2
2.3 ± 0.1
106-113b
6.7
2.3 ± 0.0
2.3 ± 0.1
1.4 ± 0.2
1.3 ± 0.1
106-116b
9.8
2.8 ± 0.1
2.8 ± 0.1
1.8 ± 0.2
1.7 ± 0.1
135-149D
19.4
7.7 ± 0.1
7.3 ± 0.1
7.8 ± 0.1
6.4 ± 0.1
173-180b
7.8
2.6 ± 0.1
2.1 ± 0.1
1.2 ± 0.1
1.0 ± 0.1
173-181b
8.8
2.7 ± 0.1
2.1 ± 0.1
1.2 ± 0.1
1.0 ± 0.1
202-207b
6.8
2.6 ± 0.1
2.8 ± 0.1
2.2 ± 0.1
2.1 ± 0.1
212-227
15.9
4.0 ± 0.1
2.7 ± 0.1
3.7 ± 0.2
2.4 ± 0.1
a
The maximum number of exchangeable protons within the indicated peptide,
assuming 100% deuteration. This value accounts for all exchangeable backbone
amide protons and a slight fraction of N-terminal, C-terminal, and side chain
exchangeable protons that are dependent on the final percentage of D2O in solution
under quench conditions (approximately 4.5%). A fully deuterated peptide would
theoretically have acquired this amount of deuterons. bThe deuterium uptake for these
peptides was quantified from the non-reducing digests. All other peptides are from
the digests with TCEP. When isotopic clusters appear in both the TCEP and nonTCEP digests, the differences in deuteration are negligible when comparing similar
peptides. Certain peptides appear exclusively under non-reducing or reducing
conditions, hence the necessity of performing both types of peptic digests.
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Figure 27: Mass spectra of IIa
residues 85-94 after one and ten
minutes of HDX.
All D-on
experiments are in 150 mM NaCl,
25 mM NaH2PO3, pH 6.5 (HDX
buffer). A and F: the undeuterated
peak cluster, B and G: thrombin
spectrum in the absence of
ligands, C and H: PPACK
inhibited thrombin, D and I: γ′
peptide bound to thrombin, and E
and J: γ′ peptide bound to PPACK
inhibited thrombin. This peak
cluster contains the ABE-II
residue R93 and experiences a
significant degree of protection
from deuterium in the presence of
the γ′ peptide. This protection
from solvent is maintained over
the course of ten minutes.

In addition to the noted protection within the vicinity of ABE-II, the γ′ peptide also
shielded regions distant from ABE-II. Unlike the ABE-II fragments, these thrombin
segments lost some of their degree of protection as the incubation with D2O was
increased from 1 to 10 minutes.

Such thrombin segments are likely not becoming

completely solvent excluded in the presence of the γ′ peptide. The regions affected
include ABE-I (65-84 and 106-116), the A-chain (-13 to -4 and -3 to 7) and a nearby Bchain loop (202-207), the W215 region (212-227), and the autolysis loop (135-149D). See
Table 5 and also Figure 26. Figures 28B and 28D illustrate that within one minute the
isotopic cluster representing residues within ABE-I (65-84) underwent a -15.1%
difference in deuteration relative to free thrombin whereas the cluster for residues within
the W215 region (212-227) underwent a -6.3% difference. Fragment 46-52 of thrombin
remained insensitive to the γ′ peptide binding to ABE-II.
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Figure 28: Mass spectra of IIa
residues 65-84 and 212-227 after one
minute of HDX.
All D-on
experiments are in 150 mM NaCl, 25
mM NaH2PO3, pH 6.5 (HDX buffer).
A: the undeuterated peak cluster, B:
thrombin spectrum in the absence of
ligands, C: PPACK inhibited
thrombin, D: γ′ peptide bound to
thrombin, and E: γ′ peptide bound to
PPACK inhibited thrombin.

Differences in Deuteration Between PPACK-Thrombin and the γ′ Peptide-PPACKThrombin Complex. γ′ peptide binding to PPACK-IIa resulted in significant protection
from HDX for almost every IIa region (Tables 4 and 5; Figure 26). After 10 minutes of
HDX, the peptide 85-99 (2102.12 m/z) experiences a decrease in deuteration of -21.8% in
the presence of the γ′ peptide, a decrease of -5.5% with PPACK inhibition, and both
interacting together with IIa result in a decrease of -26.6% (Table 5). These additive
shifts lead to lower m/z values for the peptide as can be seen by comparing the isotopic
clusters of PPACK-IIa, γ′ peptide-IIa, and γ′ peptide-PPACK IIa (Figures 27 and 28).
Located adjacent to this ABE-II region is the fragment 173-181. This segment
encompasses several residues involved in substrate specificity (R173 and I174) and some
peripheral ABE-II residues (R173 and R175). When examining the results for one minute
of HDX, the binary and ternary complexes with IIa offer similar degrees of protection
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(between -5.9% and -7.1%) (Table 5). After ten minutes of HDX, differences are more
apparent. The γ′ peptide (-16.9%) appears capable of imparting an increasing degree of
protection over 10 minutes whereas PPACK’s affect remains at similar levels (-6.6%).
Another region of thrombin for which there are some time dependent trends in
deuteration involves residues 212-227 (Table 5). Shifts to this peptide’s isotopic cluster
can be followed in Figure 28. After one minute of HDX, both PPACK and the γ′ peptide
impart a similar degree of protection from solvent (-6.0% and -6.3%). Protection of the
ternary γ′-PPACK-IIa complex appears additive at (-12.1%). Similarities in protection
for the binary complexes, however, are lost within 10 minutes of HDX. PPACK-IIa now
exhibits protection of (-7.9%), whereas γ′ peptide binding no longer significantly affects
this region (-1.5%). Interestingly, the degree of protection of the ternary complex is still
roughly additive (-10.0%). Contrary to results for segment 173-181, it is the PPACK, not
the γ′ peptide, which dominates in hindering exchange for segment 212-227.
Two solvent exposed regions encompassing ABE-I (65-84) and the autolysis loop
(135-149D) present evidence of a synergistic effect involving the interactions of both
ligands (Table 5). After one minute of HDX, the presence of PPACK affords very little
HDX protection for 65-84 (-1.6%) (Figure 28C), whereas the γ′ peptide provides
significant protection (-15.1%) (Figure 28B). Interestingly, both ligands together offer
even more protection from solvent than an additive effect would suggest (-25.1%)
(Figure 28D). The same is true for the segment spanning 135-149D. The presence of
both these ligands appears to stabilize these surface regions of IIa, protecting the
backbone amides from exchange more effectively than either ligand acting alone.
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The peptides spanning residues -13 to 7, 106-116, and 202-207 experienced roughly
similar protection when the γ′ peptide bound to ABE-II in the presence or absence of
PPACK (Tables 4 and 5). PPACK’s sphere of influences must not extend to these
fragments. The A-chain peptides -13 to -4 and -3 to 7 incorporate an almost identical
amount of deuterium at one minute and after ten minutes display similar % differences
(ranging from -5.1% to -6.1%). Located in close proximity to the A-chain, the fragment
202-207 was also protected from solvent within ten minutes of deuteration by a
comparable amount to the A-chain (-6.1%). Finally, peptides 106-113 and 106-116,
containing several peripheral ABE-I residues, incorporated virtually identical amounts of
deuterium regardless of the presence of PPACK.

Table 5: Changes in % Deuteration for IIa, PPACK-IIa, γ′-IIa, and γ′ PPACK-IIa
Complexes at One and Ten Minutes Relative to Free IIaa
Theo.
P-IIa
γ′ IIa
γ′ P-IIa
Residues
Dmax b
1 min
10 min
1 min
10 min
1 min
10 min
-13 to -4c
8.5
-3.6
0.8
-11.3
-5.1
-15.9
-5.8
-3 to 7
16.9
-2.0
0.0
-15.0
-6.1
-18.2
-5.6
46-52
6.6
0.0
0.0
-0.2
-0.7
0.1
-0.6
65-84
21.8
-1.6
0.4
-15.1
-3.3
-25.1
-7.9
85-94
8.8
1.1
1.2
-5.6
-17.7
-6.2
-17.6
85-96
10.9
-3.9
-2.5
-12.3
-25.9
-13.4
-25.2
85-99
15.2
-6.3d
-5.5
-16.4
-21.8
-20.9
-26.6
106-113c
6.7
-1.6
-0.5
-10.0
-13.1
-10.8
-13.9
106-116c
9.8
-2.1
-0.6
-6.9
-10.0
-8.3
-11.2
135-149D
19.4
-5.5
-2.2
-4.6
-0.5
-15.2
-6.9
173-180c
7.8
-7.7
-7.0
-7.3
-18.6
-8.7
-21.3
173-181c
8.8
-6.6
-6.6
-5.9
-16.9
-7.1
-19.3
202-207c
6.8
0.5
2.9
-13.2
-6.1
-15.8
-6.1
212-227
15.9
-6.0
-7.9
-6.3
-1.5
-12.1
-10.0
a
The % change for a particular peptide is calculated by Equation 7 (Chapter III). bThe
maximum number of exchangeable protons within the indicated peptide, assuming
100% deuteration (Chapter III). A fully deuterated peptide would theoretically have
acquired this amount of deuterons. cThe deuterium uptake for these peptides was
quantified from the non-reducing digests. All other peptides are from the digests with
TCEP. When isotopic clusters appear in both the TCEP and non-TCEP digests, the
differences in deuteration are negligible when comparing similar peptides. Certain
peptides appear exclusively under non-reducing or reducing conditions, hence the
necessity of performing both types of peptic digests. dThe values in bold represent
significant changes in deuteration of greater than -4.5%.
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Discussion
The binding interface for the γ′ peptide has been localized to thrombin anionbinding exosite II through fluorescence studies (69, 70).

Additional information is

needed on the conformational features the peptide adopts upon binding and the
contribution each sulfotyrosine makes toward the thrombin interaction. There is also
interest in determining the residues within thrombin ABE-II that make contact with the
peptide and the possible long range effects associated with a binding event at this exosite.
The current work employs solution NMR methods and HDX coupled with MALDI-TOF
mass spectrometry to further describe the γ′ peptide-thrombin relationship (167). Since
the γ′ peptide-thrombin structure has been recently crystallized (242), the data in this
chapter will be compared to the X-ray structure when relevant to the discussion.
Analysis of NMR Data: Insight into the Structural Requirements for the γ′ Peptide
Interaction with Thrombin’s ABE-II.

One-dimensional (1D)

1

H and

31

P NMR

demonstrate that the YP418YP422 peptide makes significant contact with the IIa surface
(Figures 20 and 24). The NMR broadening effects are in agreement with observations
that truncation of the γ′ peptide from E411-L427 to A414-L427 decreases binding affinity
almost 4-fold whereas peptides lacking the N-terminal residues P410-T416 demonstrate no
observable binding to ABE-II (60, 69). The current work makes it possible to identify
individual protons on amino acids that participate in this binding. The consequences of
removing the phosphates were also screened using 1D 1H and 31P NMR line broadening.
Figures 21 and 22 demonstrate that both the YP418 and YP422 peptides are interacting with
IIa. The binding segment of the YP422 peptide exhibits more extensive contact with IIa
than the YP418 peptide, suggesting a more instrumental role for YP422 in anchoring the γ′
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peptide segment to thrombin. Although phosphorylation at either position is enough to
support the ABE-II interaction, the presence of both phosphates in the γ′ peptide
promotes more effective binding to IIa as evidenced by the increased line broadening.
Two-Dimensional (2D) trNOESY spectra supply critical information regarding the
conformational features the peptides adopt when interacting with thrombin. All three
phosphorylated peptides generate similar spectra illustrating that IIa-bound structural
characteristics are preserved as long as one YP is present. Key conformational features
for the bound γ′ peptides include a turn between residues Y422-D425 (Figure 23A), a trans
conformation adopted by both Xxx-Pro bonds, and a cluster of NOEs centered around the
aromatic rings of both Y residues (Figure 23B). The Y residues and their neighbors are
major contributors to establishing the bound structure. The results demonstrate the
requirement of at least one YP in the interaction of the γ′ chain and ABE-II.
2D NMR with Gamma-Thrombin:

The γ′ Peptide Targets ABE-II.

Previous

solution studies have demonstrated that the primary binding site for the γ′ peptide is
ABE-II (69, 70). Recent crystal structures of GpIbα and thrombin display interactions
occurring with both ABE-II and ABE-I (96, 97). GpIbα and the γ′ peptide have quite a
comparable clustering of YS, E, and D residues (Table 1). Therefore, 2D trNOESY NMR
spectra were obtained for the γ′ peptide in the presence of gamma-thrombin to address if
the peptide is interacting with ABE-I or influenced by this exosite. The gamma variant of
thrombin retains catalytic activity while possessing an impaired ABE-I due to cleavages
after residues R75/R77A and K149E (53). The spectra obtained were remarkably similar to
the spectra obtained for wild type thrombin, suggesting that the structural information
results from interactions at ABE-II (data not shown).
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Comparing the NMR data with the X-ray Crystal Structure. Before the X-ray
structure for this complex was solved, the NMR data predicted several conformational
features adopted by the bound peptide. One of these structural elements was a turn
conformation at the peptide’s C-terminus (YP422-D425) (167). The NMR work suggested
extensive interactions with every residue within the peptide with the exception of the first
three residues (P410, E411, and H412) (167). Figure 29 depicts the crystal structure of the γ′
peptide-IIa (242). The structure was reported at 2.4Å and is lacking sufficient electron
density to model residues P410, E411, H412, and L427 (242). The 1D NMR results (Figure
20) predicted a limited role for the γ′ peptide’s N-terminus in binding to IIa (167), which
is in agreement with the X-ray structure (242) and solution studies with truncated γ′
peptides (60, 69). As for L427, the NMR study suggests that this residue does contribute
to IIa binding (167), even though L427 is not modeled in the structure (242).
The 2D trNOESY experiments provided evidence for a trans configuration for the
two P amide bonds in the peptide (167). As mentioned, H412 was not modeled in the Xray structure, thus the H412-P413 bond is not present (242). However, the YP422-P423 bond
is in the trans configuration, forming the beginning of the turn structure that was also
predicted by the NMR data (Figures 23A and 29) (242). An additional feature of the 2D
trNOESY spectra was the presence of significant C-terminal interactions with the protons
spanning residues YP418-L427 (Figures 23B and 29; Appendix B) (167). The C-terminal
turn amongst residues YP422-D425 enables the peptide to bend back on itself, supporting
the extensive amount of NOEs observed for the aromatic ring of YP422 (242).
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Figure 29: Crystallographic views of the γ′ peptide bound to thrombin (I) (2HWL). A. The γ′ peptide
isolated from thrombin. The individual amino acids are labeled. YP418 is yellow. The trans bond between
YP422-P423 is light blue and the turn structure YP422-D425 is blue. B. Illustration of γ′ peptide induced
dimerization of IIa. The turn conformation is situated between the two symmetry related IIa monomers.

Analysis of HDX Results (I): Comparing the HDX data with the X-ray Crystal
Structure. HDX coupled with the MALDI-TOF MS was performed to gain further
insight on the location of the γ′ peptide interface with IIa.

Observed decreases in

deuteration could be the product of a restricted ensemble of conformations (protein
stabilization), a conformational change, or a ligand-protein interface. When examining
the HDX results, differences in deuteration at sites located within ABE-II are due
primarily to the shielding of backbone amides from solvent by the γ′ peptide. Regions
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distant from the γ′ peptide-IIa interface that display protection from the solvent are
probably experiencing a change in dynamics due to binding at ABE-II.
A number of mutagenesis studies and crystallographic structures have demonstrated
the importance of IIa residues R93, R101, and K240 in the binding of ligands to ABE-II (66,
73, 96, 97, 168, 169, 250) (Figure 19). As described in the introduction, ligand binding
to IIa appears to involve two separate ABE-II interfaces that both utilize residues R93,
R101, and K240 (Figure 19).

The HDX data present evidence that the γ′ peptide is

interacting with ABE-II residues within the fragments 85-99 and 173-181 (Table 5).
These results compare extremely well to the γ′ peptide-IIa X-ray structure, which
illustrates an ABE-II interaction similar to heparin and GpIbα (Figures 19 and 30A).
Specifically, the HDX data supports the observed electrostatic interactions between R93TS420γ′ and N179T-D419γ′ (Figure 30B). In addition, the residue R93 from a symmetry related
IIa interacts with both D425 and D426 (Figure 30B).

The authors also describe a

hydrophobic pocket formed by I162, V163, R165, F181 (part of peptide 173-181), A183, and
the disulfide C168-C182 into which the residues P413 and A414 insert (Figure 30B).
Unfortunately, lack of peptic digest coverage for many of the residues that bind the γ′
peptide prevented analysis of their contribution to the interaction, including the Cterminal helix 233-240.
There is evidence that binding of the γ′ peptide to IIa ABE-II reduces the rate at
which fibrinopeptide A (FpA) is released from fibrinogen and the chromogenic substrate
S2238 is hydrolyzed (113). Contact of the γ′ peptide with the thrombin regions 85-99
and 173-181 could explain the hindered release of FpA. Crystal structures of FpA (7-16)
and IIa demonstrate the importance of R97, E97A and I174 in orienting FpA in the active
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Figure 30: Crystallographic views of the γ′ peptide bound to IIa (II) (2HWL). A. View of the γ′ peptide
binding into the groove formed by ABE-II residues in a similar manner as heparin and GpIbα. B. Depiction
of key interactions detected by HDX and illustrated in the crystal structure. The orange fragment is 85-99
and the yellow fragment is 173-181. The catalytic triad is pink. The text contains descriptions of the
relevant features highlighted in this figure including the hydrophobic pocket (green) and the γ′ peptide (red).

site (248). HDX results indicate that regions containing these residues are protected from
deuteration in the presence of γ′ peptide. Since the crystal structure has identified the
residues R93, N179, and F181 as being involved in binding, perhaps the γ′ chain could be
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hindering the helical turn of FpA from optimally accessing the active site region through
an allosteric mechanism. The conformation of R97, E97A and I174 may be perturbed due to
allostery resulting from γ′ peptide binding, ultimately reducing the rate of catalysis (70,
170) (Figure 30B). A similar suggestion has been offered for the inhibition of fibrinogen
clotting activity by the chondroitin sulfate moiety of thrombomodulin (250).
Analysis of HDX Results (II): Determining the Consequences of Ligand Binding to
ABE-II on Several Key Regions of Thrombin. Binding of ligands (fibrinogen Aα, PAR-1,
thrombomodulin, and hirudin) to ABE-I has clearly been shown to affect reactivity
within the thrombin active site region (240). The reduced release of FpA from fibrinogen
in the presence of γ′ peptide-IIa (113) supports a linkage from ABE-II to the active site.
Conflicting reports address the existence of an allosteric linkage between ABE-I and
ABE-II (170, 171). The current studies provide evidence that ligand binding to ABE-II is
perturbing the rate of HDX at other distant sites. The HDX results suggest lines of
communication from ABE-II to ABE-I (Figure 31C), from ABE-II to a segment
containing W215 (Figure 31D), and from ABE-II to a region of the A-chain (Figure 31D).
Interaction of the γ′ peptide with ABE-II resulted in a segment of ABE-I
representing residues 65-84 to become more protected from solvent. A pathway from
ABE-II to ABE-I can be traced from L99 back toward residue L65 as seen in Figure 31B.
Electrostatic interactions between two anti-parallel β-strands, including contacts between
the residues E86-K107, K87-K107, and M84-K109 explain how an ABE-II binding event could
be relayed to the peripheral ABE-I region involving residues 106-113 (51) (Figure 31C).
A similar line of communication has been reported in a prior (233) and in our own HDX
study of PPACK inhibited thrombin. PPACK alone offers little protection for residues
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85-96 (Table 5), while the observed protection within 97-99 is in part attributable to
contacts with L99. These PPACK interactions are proposed to be transmitted to ABE-I
via the β-strand formed by residues 85-96 (233)

Figure 31: Correlating HDX results with X-ray structure of PPACK-IIa (1PPB). W60D is yellow. A.
ABE-II region 85-99 blue and 173-181 green. The additional ABE-II region not observed in the
present HDX study, 233-240, is in pink. B. The flexible solvent exposed regions 65-84 red and 135149D brown. Both PPACK and the γ′ peptide significantly stabilize the segments upon ternary
complex formation with thrombin. C. Line of communication from ABE-II, 85-99 blue, to ABE-I,
65-84 red and 106-116 purple. D. The A-chain. There are several electrostatic contacts between the
A-chain residues 1H -7 red and the B chain residues 202 -207 teal. Also represented are 85 -99 blue
and 212-227 green. The β-strand connecting 202-207 to 212-227 is orange.

Examining the γ′ peptide-PPACK-IIa complex reveals more information about sites
of distant influence. The ternary interactions resulted in a synergistic effect on the rate of
deuterium exchange for the solvent exposed regions 65-84 (ABE-I) and 135-149D
(autolysis loop) (Figure 31B). This suggests that simultaneous binding of γ′ peptide and
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PPACK to thrombin significantly stabilizes these portions of the protease. Effects on the
environment of 212-227 are also important to consider. The additive effect observed for
the ternary complex suggests that the two ligands may be independently influencing the
solvent accessibility of 212-227. The γ′ peptide could be affecting residues near W215
and/or other regions within the residues 212-227, while the D-Phe of PPACK is known to
exhibit beneficial interactions with W215 via a perpendicular aryl-aryl arrangement (51).
In addition to altering the deuterium exchange dynamics for regions involving
ABE-II, ABE-I, and the active site region, the γ' peptide also exhibits effects on a portion
of the thrombin A chain and a nearby B-chain fragment 202-207 (Figure 31D). As can
be seen in Figure 31D, a direct connection cannot be made from ABE-II to the A-chain.
Deletion of K9 from the A-chain has recently been shown to perturb the pKa of the
catalytic residue H57 slowing the catalytic activity of IIa (251). K9 contacts D1A which is
part of a segment that undergoes protection from solvent in the presence of the γ' peptide.
The γ' peptide decreases kcat values for the hydrolysis of the small chromogenic substrate
S2238 (113). Perhaps γ' peptide binding to ABE-II leads to a line of communication to
the A-chain and the nearby B-chain segment 202-207 through the active site.
HDX studies on the binding of ligands to thrombin have revealed both local and
long range effects (172, 173, 230, 233). The current work with the γ' peptide illustrate
lines of communication from ABE-II to ABE-I and from ABE-II to regions of the
extended active site. Studies with PPACK-IIa display connections from the active site to
similar regions of ABE-I and the edge of ABE-II (233). Binding of the thrombomodulin
fragment TMEGF45 to thrombin ABE-I has led to perturbations in deuterium exchange
within the 90s loop of ABE II (172, 173). A distinct linkage between ABE-I and ABE-II
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may also have been demonstrated in earlier work involving a mixture of γ' peptide, IIa,
and Fibrin 1 (fibrinogen lacking the γ' extension) (60). These different observations
support the concept of an inter-exosite linkage reported between the two ABE-II binding
ligands prothrombin fragment 2 and γ' peptide and the ABE-I (70, 170). On the contrary,
another study with hirudin and heparin ligands did not observe as significant a negative
allostery for the ABE-I/ABE-II connections (171). The HDX studies presented here
cannot evaluate the extent to which inter-exosite linkages affect enzyme function but they
can establish potential lines of communication between the sites.
Conclusions. In this investigation, interactions between a series of γ′ peptides and
thrombin were characterized using solution NMR and HDX coupled with MALDI-TOF
MS. 1D NMR results indicate that residues H412-L427 of the YP418YP422 peptide are
responsible for the primary sites of contact with the thrombin surface and illustrate the
importance of sulfonation at the Y422 position. Data from the 2D trNOESY spectra
demonstrate that the ABE-II bound γ′ peptide adopts significant secondary structure in
the presence of at least one phosphotyrosine. HDX results suggest that the γ′ peptide
interacts with thrombin ABE-II. In response to this binding, other regions of thrombin
also experience protection from deuteration including ABE-I, regions near the active site,
and a portion of the A-chain. Finally, thrombin can form a ternary complex with the γ′
peptide and PPACK generating an enzyme that is further stabilized from HDX.
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CHAPTER V
STUDYING GPIBα (269-286) PEPTIDE INTERACTIONS WITH THE THROMBIN
ANION BINDING EXOSITES
Introduction
GpIbα is part of a transmembrane receptor complex of glycoproteins on the surface
of platelets (74-77).

GpIbα serves a multitude of functions that include binding

coagulation proteins, adhering platelets to the site of damaged tissue, and aiding in the
recruitment of leukocytes to combat infection.

IIa interacts with GpIbα leading to

enhancements in the activation of PAR-1, FXI, and GpV (67, 83, 87). As mentioned in
Chapter I, GpIbα residues 269-286 share a similar clustering of anionic residues as found
in the γ′ peptide (410-427) (Table 1). The studies on γ′ peptide binding to IIa described
in Chapter IV were originally conducted due to the absence of a reported crystal structure
illustrating this interaction (167). In the case of GpIbα-IIa, two independent crystal
structures have been published pertaining to the binding of these proteins (96, 97). An
unresolved issue is why independent groups attribute GpIbα binding either to ABE-II
(68, 92) or to ABE-I (93, 101), while the γ′ peptide targets ABE-II (69, 70, 167, 242).
The X-ray structures involving GpIbα possess important similarities and
differences regarding the mode of IIa interaction (96, 97) (Figure 32). In the reported
structures, insufficient electron density prevented the modeling of GpIbα’s C-terminus.
The Dumas structure (1P8V) ends at Y279 (96), while the Celikel structure (1OOK)
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includes 5 additional residues (P280-T284) at the C-terminus (97). The N-terminus of
residues 269-286 appears to be rather flexible, adopting a turn conformation in 1P8V (96)
and a fully extended structure in 1OOK (97).

Though both groups report a 1:1

asymmetric unit, the proteins in symmetry related molecules display unique binding
interfaces. Both structures illustrate similar GpIbα interactions with ABE-II, but differ in
regard to the depiction of GpIbα binding to ABE-I. 1OOK shows the C-terminal tail of
GpIbα potentially dimerizing IIa through interactions with both exosites (97). In 1P8V,
the second IIa molecule binds to GpIbα at the C-terminal end of the leucine rich repeat
domain (in blue) through ABE-I (96).

1P8V

1OOK

Figure 32: Two views of GpIbα binding to thrombin. The crystal structures depict similar ABE-II
interactions but differ in the depiction of thrombin dimerization. In blue is GpIbα and the anionic Cterminal tail is in red. Thrombin in gold binds to the C-terminal tail, while thrombin in green binds at
different interfaces. The structure on the left is 1P8V (96), the structure on the right 1OOK (97).

The focus of this chapter is to further characterize the GpIbα-IIa interaction by
using peptides based on the sequence 269-286 (Table 6), perhaps the γ′ peptide and the
GpIbα peptide share similar characteristics when binding thrombin. For example, the Cterminal turn structure observed for the γ′ peptide (167, 242) is not being modeled in the
Dumas structure (1P8V), which ends at residue Y279 (96). The sequence of the γ′ peptide
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turn (422YSPED425), however, is very similar to the comparable C-terminal stretch of
residues in GpIbα (279YSPEE282) (Table 1). In addition, when the GpIbα peptide binds to
IIa there are comparable long-range allosteric effects observed as with the γ′ peptide. For
the GpIbα studies (as with the γ′ peptide), phosphotyrosines were substituted for the
naturally occurring sulfotyrosines without sacrificing binding affinity.

This type of

substitution has been reported to have a minimal effect on binding affinity (69, 241).
1D and 2D NMR experiments demonstrate that the GpIbα peptide binds to IIa in an
extended conformation, with a majority of the residues contacting IIa’s surface.
Additional work with HDX coupled with MALDI-TOF MS suggests a concentration
dependence in regard to the GpIbα binding interface on IIa. In addition, the HDX results
display allostery related to GpIbα interactions with IIa. GpIbα peptide binding to IIa
alters the dynamics of deuterium incorporation at sites unaffiliated with the binding
interface. Finally, analytical ultracentrifugation (AUC) was performed to observe the
behavior of thrombin when binding the GpIbα peptide or the γ′ peptide in solution.
Materials and Methods
Synthetic Peptides and Thrombin Purification. Bachem (King of Prussia, PA)
synthesized peptides based on residues 269-286 of GpIbα (Table 6). SynPep (Dublin,
CA) synthesized a peptide based on residues 410-427 of the human fibrinogen γ′ chain
variant (Table 3 in Chapter IV, only the YP418YP422 peptide).

MALDI-TOF MS

measurements on an Applied Biosystems Voyager DE-Pro mass spectrometer were used
to verify peptide m/z values.

The concentrations of the peptide in solution were

determined by quantitative amino acid analysis (AAA Service Laboratory, Boring, OR).
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Bovine IIa was purified as described by Trumbo and Maurer (243). The use of bovine IIa
in place of human IIa is justified in the Material and Methods of Chapter IV.
Table 6: GpIbα Peptides Used in IIa Binding Studies
269
YP276 YP278 YP279
DEGDTDLYPDYPYPEEDTEG286
269
YP276 Y278 YP279
DEGDTDLYPDYYPEEDTEG286
269
Y276 Y278 Y279
DEGDTDLYDYYEEDTEG286

1

H and 31P NMR Sample Preparation and Analysis. Approximately a 1:10 ratio of

enzyme to peptide was maintained for the complex studied. Sample preparation and
analysis were similar to those described by Trumbo and Maurer (190). Selective features
are summarized here. Each 400 µl NMR sample contained 1.5 mM peptide and either
zero or 150 µM bovine IIa. The samples were buffered in 25 mM H3PO4, 150 mM NaCl,
0.2 mM EDTA, pH 5.6 and 10% D2O.

1

H NMR experiments were performed on a

Varian Inova 500 MHz equipped with a triple resonance probe and pulsed-field z-axis
gradients. 2D transferred NOESY experiments of the enzyme-peptide complexes were
run at 17 °C with 32 transients, 512 t1 increments, mixing time of 400 ms, and a spectral
width of 5006 Hz. Spectra were processed using FELIX2000 software (Accelerys, San
Diego, CA) on a Silicon Graphics O2 workstation. For 31P NMR, spectra were recorded
on a Varian Inova 500 MHz equipped with a 5 mm broadband probe tuned to 202.4 MHz.
The spectra were referenced to the peak corresponding to H3PO4 (0.00 ppm).
HDX Sample Preparation. Thrombin was buffer exchanged into 75mM NaCl,
12.5mM NaH2PO4, pH 6.5 with an Amicon-Ultra 4 unit (10 kDa MWCO).

The

concentration of IIa for all HDX preparations varied between 20-25 µM. Enough GpIbα
peptide was added to achieve a 20:1 or 40:1 ratio during the HDX experiments. For the
γ′ peptide, only 40:1 ratios were examined during this investigation. The data reported
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for IIa alone and γ′ peptide-IIa (20:1) was previously published and discussed in Chapter
IV (167); inclusion in this chapter is purely for comparison to GpIbα results. The
aliquots of buffer-exchanged IIa with peptide were evaporated to dryness using a
SpeedVac unit (Savant). The dry aliquots were stored at -70°C.
HDX Experiments. Dry aliquots of γ′ peptide-IIa (40:1) or GpIbα-IIa (20:1 and
40:1) were allowed to come to room temperature before beginning the experiment. First,
12µL of D2O was added to the dry aliquot yielding the final concentrations: 40-50 µM
IIa, 1 mM or 2 mM GpIbα/γ′ peptide, 150 mM NaCl, 25 mM NaH2PO4, pH 6.5. The
samples were incubated in a desiccator at room temperature for 1 minute or 10 minutes.
After incubation, 114 µL of 0.1% TFA pH 2.5 (on ice) was added to quench the solution.
Next, 66 µL of the quenched solution was transferred to a tube of activated pepsin bound
to agarose. To the remaining 60 µL, 6 µL of 1 M TCEP-HCl in 0.1% TFA was added to
reduce the disulfides bonds of IIa and then immediately added to another tube of pepsin.
Digestion occurred on ice for 10 minutes. Centrifugation at 4°C separated the digest
from the pepsin and 8.2 µL aliquots were immediately frozen in liquid N2.
HDX Analysis. A frozen aliquot was thawed, immediately mixed with an equal
volume of 10 mg/mL α-CHCA matrix in 1:1:1 ethanol/acetonitrile/0.1% TFA, pH 2.2
and 0.5 µL spotted onto a chilled stainless steel MALDI plate. The plate was dried with
the SpeedVac (Savant) and inserted into the MALDI-TOF MS. This procedure should
consume around five minutes of time, limiting the amount of hydrogen back exchange.
The spectra were collected in the reflector mode over a mass range of 800-3500 m/z with
256 laser shots per spectrum. Peptides obtained from the peptic digest of thrombin were
previously identified (167, 233, 234).
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The spectra were collected and analyzed using Data Explorer (Applied Biosystems).
Calibration of the spectra involved two reference peptides, one with the singly protonated
monoisotopic mass of 888.4943 Da (46-52) and the other with the singly protonated
pentaisotopic mass of 2106.1505 Da (85-99). The amount of deuterium uptake by each
peptide and the % difference relative to IIa alone was quantified as described by Sabo et
al. and in Chapter III (167). At least three spectra were collected during each trial and
three trials were run for each time point under each condition.
Analytical Ultracentrifugation. IIa was inhibited with a two-fold excess of PPACK
for 30 min. An assay involving the chromogenic substrate S2238 was employed to
ensure that IIa was inactive. PPACK-IIa was then subjected to overnight dialysis with
150mM NaCl, 25mM phosphate, pH 7.4. The γ′ or GpIbα peptide was lyophilized and
reconstituted in the same buffer. A series of sedimentation velocity AUC experiments
ranging from 1, 2, 5, 10, and 20 times peptide to IIa (4.5-7.0 µM) in duplicate was
performed in a XL-A AUC (Beckman-Coulter). The parameters for each run were
60,000 rpm, 25°C, and 280nm. The data was analyzed with the program DC-DT+.
Results
1

H and 31P One-Dimensional Line Broadening NMR. 1D NMR experiments were

performed to determine which proton or phosphorous nuclei within the GpIbα (269-286)
peptide interact with IIa.

The first set of spectra collected examined GpIbα

(YP276YP278YP279) and displayed the absence of significant line broadening for the 1H 1D
NMR spectra of the peptide in the presence of IIa (data not shown). Similar results were
obtained when performing 31P 1D NMR (data not shown). These findings indicate that
the triply phosphorylated peptide binds too tightly to IIa’s surface. Thus, the transfer of
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information regarding peptide proton or phosphorous interactions with the protein back to
the free peptide population does not occur. The result is a 1D spectrum for the peptide in
the presence of IIa similar to the free peptide (see Chapter II for further explanation).
Since the GpIbα (YP276YP278YP279) peptide spectra did not display line broadening, a
doubly phosphorylated variant was synthesized. The GpIbα (YP276YP279) peptide still
interacts with IIa (demonstrated by the two crystal structures (96, 97)), but the absence of
one phosphotyrosine may sufficiently weaken the interaction for the appearance of 1D
line broadening. The spectra in Figure 33 focus on the amide region and do illustrate line
broadening in the presence of IIa. Most of the broadening encompasses residues D275YP279, while a modest amount of broadening is observed for residues E281-D283.
However, the line broadening is not extensive, with residues D269-D274 and T284-G286
appearing unchanged from the free peptide spectrum. Curiously, the 31P spectra do not
present evidence of line broadening (data not shown).

These results suggest two

possibilities. The peptide may be binding too tightly for the N- and C-terminal residues
to display line broadening or these residues are not involved in the interaction with IIa.
A final peptide was synthesized without any phosphotyrosines. Much more line
broadening is evident with the unphosphorylated peptide (Figure 33). The central portion
of the peptide spanning D274-Y279, E281, and D283 display a significant amount of line
broadening. The residues E282 and E285 show a modest amount of broadening. Finally,
the N-terminal residues D269-T273 and the C-terminal residues T284 and G286 do not appear
to be essential for the interaction of GpIbα (269-286) with IIa.
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B
D

Figure 33: Line broadening spectra for the GpIbα peptides in the presence of thrombin. All NMR
samples are in 25 mM H3PO4, 150 mM NaCl, 200 µM EDTA, and 10% D2O, pH 5.6. A. 1D NMR
spectrum for 1.5 mM YP276YP279 peptide in solution. B. 1D NMR spectrum for 1.5 mM Y P276YP279 peptide
in the presence of 0.148 mM IIa. The amide protons that display the most line broadening are D275-YP279.
A moderate amount of line broadening is evident for the NHs of E281-D283. Line broadening is not
observed for the amide protons of D269-D274 and T284-G286. C. 1D NMR spectrum for 1.5 mM
unphosphorylated peptide in solution. D. 1D NMR spectrum for 1.5 mM unphosphorylated peptide in the
presence of 0.150 mM IIa. The amide protons that display the most line broadening are D274-YP279, E281,
and D283. A moderate amount of line broadening is evident for the NHs of E282 and E285. Line broadening
is not observed for the amide protons of D269-T273, T284, and G286.

Two-Dimensional Transferred Nuclear Overhauser Effect NMR. For the triply
phosphorylated peptide, the 2D spectra of the free peptide were indistinguishable from
the spectrum with the peptide in the presence of the enzyme (data not shown). For the
doubly phosphorylated and unphosphorylated GpIbα peptides, the 2D trNOESY spectra
displayed only nearest neighbor NOEs in the presence of the enzyme. Appendix A has
tables for the chemical shift assignments of both the free and bound unphosphorylated
GpIbα. Only 2D NMR spectra in the presence of thrombin were collected for GpIbα
(YP276YP279) and these resonances are compiled in Appendix A.
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Figure 34: Representative spectra of GpIbα peptide NOEs in the presence of thrombin. 2D
trNOESY spectrum of the unphosphorylated GpIbα (1.5 mM) bound to IIa (0.150 mM). The top
panel illustrates the evidence for a trans Y279-P280 peptide bond. The bottom panels demonstrate that
GpIbα exists in an extended structure when bound to IIa due to the presence of only nearest neighbor
NOEs. The NOEs are color coded according to the corresponding residue.

Figure 34 presents some of the key features from the unphosphorylated GpIbα-IIa
2D trNOESY spectra. The presence of only nearest neighbor NOEs suggests that the
peptide adopts an extended conformation when binding to IIa. In addition, the Y279-P280
amide bond is in the trans conformation. With the GpIbα (YP276YP279) peptide, slightly
fewer inter-residue NOEs are observed in the presence of IIa when compared to
unphosphorylated GpIbα (data not shown). With the doubly phosphorylated GpIbα, a
trans conformation is also evident for the YP279-P280 peptide bond.
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HDX Experiments (I): Observing the Effect of the GpIbα (YP276YP278YP279) Peptide
on Thrombin’s Backbone Amide Solvent Accessibility.

In contrast to the NMR

experiments, the strong interaction between the GpIbα (YP276YP278YP279) and IIa is an
important asset when performing HDX (see Chapter III). Chapter IV describes the
sequence coverage obtained from a peptic digest of IIa with or without the aid of the
reducing agent TCEP (Figure 25). The fourteen fragments contain coverage for ABE-I,
ABE-II, the autolysis loop, the Na+ site, the A-chain, and residues involved in substrate
recognition and catalysis.
The GpIbα (YP276YP278YP279) peptide (1 mM) was incubated with IIa (50 µM) at
room temperature for one or ten minutes in the presence of 99.99% D2O. The KD for the
interaction of the GpIbα (269-286) peptide with IIa has not been determined. A previous
study found that GpIbα residues 265-285 bound to IIa with a KD of 5.9 nM (101). In
addition, the NMR results suggest that the binding of the GpIbα (269-286) peptide to IIa
is probably tighter than γ′ peptide (410-427) (KD = 680 nM) (69). Therefore, similar
HDX concentrations of the peptide and IIa (20:1) were used as described in Chapter IV.
The results for deuterium incorporation are compiled in Table 7 and Figure 35. The
GpIbα peptide significantly protects fragments spanning residues 85-99 (Figure 36) and
173-181 from deuterium. In fact, the protection from solvent, as represented by negative
% differences in Table 8, increases from one to ten minutes suggesting this peptide is
binding to ABE-II. These results are similar in magnitude to the effects of the γ′ peptide
on deuterium exchange at ABE-II (Table 8). Within one minute of deuteration, the
GpIbα peptide protects the fragment 85-99 by 2.7 deuterons (-17.3%) and the γ′ peptide
by 2.5 deuterons (-16.4%) (Figure 36B, C, and D). After 10 minutes of deuteration, the
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GpIbα peptide shields the same fragment from solvent by 3.7 deuterons (-23.9%) and the
γ′ peptide by 3.4 deuterons (-21.8%) (Figure 36 H, I, and J).

Figure 35: Graphs of deuterium incorporation for IIa, GpIbα-IIa, and γ′-IIa at 20:1. The bars in
the graph correspond to IIa alone (red), GpIbα-IIa (green) and γ′ peptide-IIa (blue). Errors
correspond to the standard deviation of the mean for three independent experiments.

As with the γ′ peptide, the GpIbα peptide protects regions within IIa unaffiliated
with binding at ABE-II. Most of these peptides are more shielded from deuterium within
one minute of exchange compared to ten minutes. These fragments are considered not to
be completely solvent excluded in the presence of the GpIbα peptide. The regions
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affected by GpIbα binding to ABE-II after one minute of deuterium exchange include the
ABE-I fragments 65-84 (-18.3%), 106-113 (-9.9%), and 106-116 (-7.2%), the A-chain
residues -13 to -4 (-17.8%) and -3 to 7 (-17.3%) and the nearby B-chain fragment 202207 (-15.6%), and finally the W215/Na+ binding site region 212-227 (-5.8%) (Table 8).
Table 7: Deuterium Incorporation for IIa, GpIbα-IIa, and γ′-IIa at One and Ten Minutes
1 Minute
Theo.
Residues
20:1
40:1
a
Dmax
IIa
GpIbα IIa
γ′ IIa
GpIbα IIa
γ′ IIa
-13 to -4b
8.5
3.7 ± 0.1
2.2 ± 0.1
2.7 ± 0.1
n/ac
2.2 ± 0.0
-3 to 7
16.9
5.3 ± 0.1
2.4 ± 0.1
2.8 ± 0.1
3.3 ± 0.0
2.1 ± 0.3
46-52
6.6
0.4 ± 0.0
0.4 ± 0.1
0.3 ± 0.0
0.4 ± 0.0
0.3 ± 0.0
65-84
21.8
10.5 ± 0.1
6.5 ± 0.3
7.2 ± 0.1
2.6 ± 0.1
5.6 ± 0.1
85-94
8.8
1.4 ± 0.0
0.9 ± 0.1
0.9 ± 0.0
1.1 ± 0.1
0.8 ± 0.1
85-96
10.9
2.2 ± 0.1
0.9 ± 0.2
0.9 ± 0.1
1.3 ± 0.1
0.7 ± 0.1
85-99
15.2
4.4 ± 0.0
1.7 ± 0.2
1.9 ± 0.1
2.1 ± 0.3
1.6 ± 0.2
106-113b
6.7
1.6 ± 0.0
0.9 ± 0.0
0.9 ± 0.1
n/a
0.8 ± 0.1
106-116b
9.8
2.0 ± 0.1
1.3 ± 0.1
1.3 ± 0.1
n/a
1.2 ± 0.1
135-149D
19.4
7.8 ± 0.1
7.3 ± 0.4
6.9 ± 0.0
3.3 ± 0.1
6.3 ± 0.0
173-180b
7.8
1.7 ± 0.1
1.0 ± 0.1
1.1 ± 0.1
n/a
1.0 ± 0.1
173-181b
8.8
1.7 ± 0.1
1.1 ± 0.1
1.2 ± 0.1
n/a
1.1 ± 0.1
202-207b
6.8
2.3 ± 0.0
1.2 ± 0.1
1.4 ± 0.1
n/a
1.2 ± 0.1
212-227
15.9
3.4 ± 0.1
2.5 ± 0.1
2.4 ± 0.1
2.5 ± 0.1
2.4 ± 0.1
10 Minutes
Theo.
Residues
20:1
40:1
Dmax
IIa
GpIbα IIa
γ′ IIa
GpIbα IIa
γ′ IIa
-13 to -4b
8.5
3.6 ± 0.1
3.2 ± 0.3
3.2 ± 0.2
n/a
3.3 ± 0.1
-3 to 7
16.9
5.3 ± 0.1
3.8 ± 0.4
4.3 ± 0.1
6.6 ± 0.1
4.0 ± 0.1
46-52
6.6
0.4 ± 0.0
0.4 ± 0.0
0.4 ± 0.0
0.6 ± 0.0
0.4 ± 0.0
65-84
21.8
10.4 ± 0.2
8.9 ± 0.5
9.7 ± 0.2
7.6 ± 0.1
9.6 ± 0.3
85-94
8.8
2.6 ± 0.1
1.2 ± 0.1
1.0 ± 0.1
3.1 ± 0.1
1.1 ± 0.1
85-96
10.9
3.7 ± 0.1
1.2 ± 0.2
0.9 ± 0.1
4.0 ± 0.1
1.2 ± 0.1
85-99
15.2
6.4 ± 0.1
2.7 ± 0.1
3.0 ± 0.2
6.2 ± 0.1
2.5 ± 0.1
106-113b
6.7
2.3 ± 0.0
1.3 ± 0.1
1.4 ± 0.2
n/a
1.4 ± 0.0
106-116b
9.8
2.8 ± 0.1
1.8 ± 0.1
1.8 ± 0.2
n/a
1.8 ± 0.1
135-149D
19.4
7.7 ± 0.1
7.5 ± 0.6
7.8 ± 0.1
8.2 ± 0.0
8.0 ± 0.1
173-180b
7.8
2.6 ± 0.1
1.3 ± 0.1
1.2 ± 0.1
n/a
1.3 ± 0.1
173-181b
8.8
2.7 ± 0.1
1.3 ± 0.1
1.2 ± 0.1
n/a
1.2 ± 0.1
202-207b
6.8
2.6 ± 0.1
1.6 ± 0.2
2.2 ± 0.1
n/a
1.7 ± 0.1
212-227
15.9
4.0 ± 0.1
3.6 ± 0.3
3.7 ± 0.2
5.4 ± 0.0
3.9 ± 0.2
a

The maximum number of exchangeable protons within the indicated peptide, assuming 100%
deuteration (Chapter III). A fully deuterated peptide would theoretically have acquired this
amount of deuterons. bThe deuterium uptake for these peptides was quantified from the nonreducing digests. All other peptides are from the TCEP digests. When isotopic clusters appear
in both the TCEP and non-TCEP digests, the differences in deuteration are negligible when
comparing similar peptides. Certain peptides appear exclusively under non-reducing or
reducing conditions, hence the necessity of performing both types of peptic digests. cThese
fragments were not able to be quantified in the non-reducing digest at 40:1 GpIbα to IIa.
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Figure 36: Mass spectra of residues 85-99 after one and ten minutes of HDX. All of the
D-on experiments are in 150 mM NaCl, 25 mM NaH2PO3, pH 6.5. A and G: the
undeuterated peak cluster, B and H: IIa spectra in the absence of ligands, C and I: γ′
peptide (1 mM) bound to IIa (50 µM) at a 20:1 ratio, D and J: GpIbα peptide (1 mM)
bound to IIa (50 µM) at a 20:1 ratio, E and K: γ′ peptide (2 mM) bound to IIa (50 µM) at
a 40:1 ratio, and F and L: GpIbα peptide (2 mM) bound to IIa (50 µM) at a 40:1 ratio. At
the ratio of 20:1, both peptides exhibit a similar degree of protection for these ABE-II
residues; however in spectrum J a small shoulder is present suggesting the presence of
two IIa populations. Increasing the amount of peptide completely abrogates protection
after ten minutes in the presence of the GpIbα peptide, while the γ′ peptide begins to
display a similar shoulder at ten minutes.

After ten minutes of deuteration, the two A-chain fragments lose some degree of
protection from solvent, with -13 to -4 down to -5.2% and -3 to 7 reduced to -8.6%;
however, the nearby B-chain fragment 202-207 is at a similar level compared to one
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minute (-14.1%). The ABE-I fragment 65-84 (-6.7%) also is reduced in the observed
amount of deuterium protection. The segments 106-113 (-13.7%) and 106-116 (-9.5%)
experience slight increases in protection at ten minutes. The W215/Na+ binding site
peptide 212-227 (-2.1%) ceases to be significantly protected from solvent after ten
minutes of deuteration. GpIbα binding does not change the dynamics of deuterium
exchange for the fragments 46-52 and 135-149D (the autolysis loop).
Table 8: Changes in % Deuteration for GpIbα-IIa and γ′-IIa at 1 and 10 Minutes Relative to Free IIaa
20:1
40:1
Theo.
Residues
GpIbα IIa
γ′ IIa
GpIbα IIa
γ′ IIa
b
Dmax
1 min
10 min
1 min
10 min
1 min
10 min
1 min
10 min
-13 to -4c
8.5
-17.8 d
-5.2
-11.3
-5.1
n/a
n/a
-17.3
-4.0
-3 to 7
16.9
-17.3
-8.6
-15.0
-6.1
-12.0
7.8
-19.1
-7.9
46-52
6.6
0.5
-0.5
-0.2
-0.7
0.8
3.0
-0.3
-0.2
65-84
21.8
-18.3
-6.7
-15.1
-3.3
-36.2
-12.7
-22.3
-3.8
85-94
8.8
-5.5
-15.3
-5.6
-17.7
-3.4
6.3
-6.3
-16.9
85-96
10.9
-12.4
-22.8
-12.3
-25.9
-8.2
2.8
-13.7
-22.8
85-99
15.2
-17.3
-23.9
-16.4
-21.8
-14.8
-1.1
-18.0
-25.7
106-113c
6.7
-9.9
-13.7
-10.0
-13.1
n/a
n/a
-11.0
-12.8
106-116c
9.8
-7.2
-9.5
-6.9
-10.0
n/a
n/a
-8.1
-9.5
135-149D
19.4
-2.5
-1.1
-4.6
-0.5
-23.2
2.3
-7.8
1.0
173-180c
7.8
-8.1
-17.6
-7.3
-18.6
n/a
n/a
-8.5
-17.6
173-181c
8.8
-6.3
-15.5
-5.9
-16.9
n/a
n/a
-6.4
-16.5
202-207c
6.8
-15.6
-14.1
-13.2
-6.1
n/a
n/a
-15.7
-12.2
212-227
15.9
-5.8
-2.1
-6.3
-1.5
-6.0
9.2
-6.5
-0.7
a
The % change for a particular peptide is calculated by Equation 7 (Chapter III). bThe maximum
number of exchangeable protons within the indicated peptide, assuming 100% deuteration. (Chapter
III). A fully deuterated peptide would theoretically have acquired this amount of deuterons. cThe
deuterium uptake for these peptides was quantified from the non-reducing digests. All other peptides
are from the TCEP digests. When isotopic clusters appear in both the TCEP and non-TCEP digests, the
differences in deuteration are negligible when comparing similar peptides. Certain peptides appear
exclusively under non-reducing or reducing conditions, hence the necessity of performing both types of
peptic digests. dThe values in bold represent significant changes in deuteration of greater than -4.5%.
e
These fragments were not able to be quantified in the non-reducing digest at 40:1 GpIbα to IIa.

When comparing the amount of deuterium incorporation for these fragments in the
presence of the GpIbα peptide to the γ′ peptide, very similar trends are observed for the
segments -13 to -4, -3 to 7, 106-113, 106-116, and 212-227. Differences do exist for two
peptides in regard to the amount of protection still present after ten minutes. The ABE-I
residues 65-84 (-6.7% for GpIbα vs. -3.3% for γ′) and the peptide 202-207 (-14.1% for
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GpIbα vs. -6.1% for γ′) are more protected at ten minutes by the GpIbα peptide than the
γ′ peptide (Table 8). In addition, the γ′ peptide exhibits protection from solvent for the
autolysis loop fragment 135-149D (-4.6%) after one minute, whereas the GpIbα peptide
does not appear to influence this region. These results suggest that GpIbα binding to IIa
has subtly different consequences on protein dynamics when compared to the γ′ peptide.
In Figure 36J, the isotopic cluster for residues 85-99 has an interesting feature not
observed with the other fragments in the peptic digest.

The cluster appears to be

expanded with a slight shoulder ending near 2115 m/z. This larger peak envelope was
observed consistently in each experiment when the concentration of GpIbα was 1 mM
and IIa was 50 µM (20:1 molar ratio). The results suggest the presence of two different
IIa populations exposed to deuterium during HDX. In order to test this theory, HDX was
performed on a higher ratio (40:1) of peptide (2 mM) to IIa (50 µM). Perhaps the newly
emerging second population of IIa would eventually dominate the results.
HDX Experiments (II): Examining the Influence of a Higher Peptide Concentration
on the Dynamics of Thrombin’s Deuterium Incorporation.

In HDX experiments with

40:1 GpIbα peptide to IIa, only the digests with TCEP presented reliable isotopic clusters
for quantification. Thus, the amount of deuteration for the fragments -13 to -4, 106-113,
106-116, 173-180, 173-181, and 202-207 was unable to be reported at this GpIbα peptide
concentration (2 mM). These problems were not encountered with the γ′ peptide and the
data for all fourteen peptides are presented in Tables 7 and 8. Figure 37 graphically
illustrates the data for HDX at 40:1 peptide to thrombin.
For the γ′ peptide, deuterium incorporation for the fragments representing ABE-II
residues 85-99 (Figures 36E and K) and 173-181 were similar at 2 mM peptide (40:1) as
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A-Chain

A-Chain

Figure 37: Graphs of deuterium incorporation for IIa, GpIbα-IIa, and γ′-IIa at 40:1. These
results are taken from the digests with the reducing agent TCEP. The bars in the graph
correspond to IIa alone (red), GpIbα-IIa (green) and γ′ peptide-IIa (blue). Errors correspond
to the standard deviation of the mean for three independent experiments.

at 1 mM peptide (20:1) (Table 8). Interestingly, Figure 36K displays the appearance of a
similar shoulder on the 85-99 isotopic cluster for 40:1 γ′ peptide-IIa that was observed
with the GpIbα peptide during the 20:1 experiments (Figure 36I). In fact, many of the
other fragments obtained from the non-reducing digests are analogous to the results for
GpIbα at 20:1. The A-chain residues -13 to -4 are initially protected to a greater degree
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(-17.3% for 40:1 vs. -11.3% for 20:1) and residues 202-207 maintain a steady difference
in deuterium incorporation over ten minutes (-15.7% at one minute to -12.2% at ten
minutes) (Table 8). The ABE-I fragment 106-116 is shielded from deuterium in a similar
manner at both peptide concentrations. The only significant difference between 40:1 γ′
peptide and 20:1 GpIbα peptide is apparent in the autolysis loop, where the γ′ peptide
protects residues 135-149D from deuterium after 1 minute of exchange.
GpIbα binding to IIa at a higher peptide concentration reveals a different
mechanism for peptide interaction. Figure 38 illustrates the one minute HDX spectra for
ABE-I residues 65-84. At 40:1 and one minute of HDX, the GpIbα peptide imparts a
dramatic amount of protection for 65-84 amounting to 7.9 deuterons up from 4.0
deuterons at 20:1 (Figure 38D and F; Tables 7). Even after ten minutes of deuteration,
the protection is 2.8 deuterons compared to 1.5 deuterons at 20:1. The γ′ peptide at both
HDX concentrations shows a significant amount of initial protection (Figure 38C and E),
which dissipates after ten minutes of deuteration. Examining the effect of GpIbα on
ABE-II, residues 85-94 are not shielded from HDX after one minute (-3.4%); however,
within ten minutes, these residues are more exposed to solvent (+6.3%). HDX in 85-96
and 85-99 reveal protection from solvent within a minute of deuterium exposure, but ten
minutes of HDX leaves these residues at similar levels to IIa alone (Figure 36H and L).
Three additional IIa regions display new responses to GpIbα peptide binding. Both
the A-chain fragment -3 to 7 and the W215/Na+ binding site peptide (212-227) are
shielded from deuterium within one minute (-12.0% and -6.0% respectively); however
ten minutes of deuterium exposure results in both of these regions becoming more
available for deuterium exchange when compared to IIa alone (+7.8% and +9.2%
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respectively) (Table 8). With the autolysis loop, 20:1 GpIbα peptide did not affect the
amount of deuterium incorporation relative to free IIa. By increasing the concentration of
the GpIbα peptide (40:1), the residues 135-149D are now protected by -23.2% within a
minute of deuterium exchange and that protection is abrogated after ten minutes (+2.3%).

Figure 38: Mass spectra of residues 65-84
after one minute of HDX. All D-on
experiments are in 150 mM NaCl and 25
mM NaH2PO3, pH 6.5. Panels: A. the
undeuterated peak cluster, B. IIa spectrum
in the absence of ligands, C. γ′ peptide (1
mM) bound to IIa (50 µM), D. GpIbα
peptide (1 mM) bound to IIa (50 µM), E. γ′
peptide (2 mM) bound to IIa (50 µM), and
F. GpIbα peptide (2 mM) bound to IIa (50
µM).

Analytical Ultracentrifugation.

AUC was employed to determine whether the

GpIbα peptide or the γ′ peptide induces dimerization of IIa in solution. In these AUC
trials, the concentrations of PPACK inhibited IIa spanned 4.7-7.0 µM. A series of
sedimentation velocity experiments were executed with a range of peptide to IIa molar
ratios varying from 1:1 to 20:1. Two trials with IIa alone were performed for comparison
to the peptide-IIa experiments. Table 9 presents the data for the average of two runs.
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Figures 39 and 40 illustrate the raw SV data used to construct the distribution of
Svedberg constants (S) for the trial examining the GpIbα peptide and IIa at a 2:1 ratio
and the γ′ peptide and IIa at 1:1, respectively.
The Svedberg constant measures the rate of sedimentation, which is related to the
size and shape of the molecule. It should be noted that this constant is not additive,
though molecular weight is additive. In other words, S values are affected by the amount
of surface area exposed to solvent. Thus when two proteins interact, the surface area is
decreased leading to a non-additive increase in the S constant. The calculated Svedberg
constants for the peptide binding to the enzyme range from 3.2-3.3, compared to 3.1 for
IIa alone. The slight increase in molecular weight with increasing peptide concentration
coupled with the slight increase in S values seem to propose that the peptides bind to IIa
but appear not to instigate protein dimerization.
Table 9: Analytical Ultracentrifugation Data
Sedimentation Coefficient (S)
IIa alone
3.11 ± 0.00
GpIbα peptide:IIa
1:1
3.19 ± 0.02
2:1
3.18 ± 0.01
5:1
3.27 ± 0.05
10:1
3.25 ± 0.02
20:1
3.22 ± 0.01
γ′-peptide:IIa
1:1
3.19 ± 0.02
2:1
3.22 ± 0.03
5:1
3.23 ± 0.03
10:1
3.27 ± 0.01
20:1
3.28 ± 0.01
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Molecular Weight (kDa)
36.2 ± 0.3
37.3 ± 0.0
37.5 ± 0.9
37.9 ± 0.7
37.2 ± 1.1
38.1 ± 1.4
39.3 ± 1.0
38.6 ± 0.4
39.9 ± 0.2
39.9 ± 0.6
40.9 ± 0.7

Figure 39: Sedimentation velocity AUC of GpIbα peptide (14 µM) and IIa (7 µM).
Analysis was performed at 280 nm, 20 °C, and 60,000 rpm in 150 mM NaCl, 25 mM
phosphate, pH 7.4. Top Panel: Raw data set for the sedimentation velocity run examining
this interaction. Bottom Panel: The apparent Svedberg constant distribution centered at 3.2
S with the residuals resulting from a global fit of the data using the DCDT+ program.
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Figure 40: Sedimentation velocity AUC of γ′ peptide (4.7 µM) and IIa (4.7 µM).
Analysis was performed at 280 nm, 20 °C and 60,000 rpm in 150 mM NaCl, 25 mM
phosphate, pH 7.4. Top Panel: Raw data set for the sedimentation velocity run
examining this interaction. Bottom Panel: The apparent Svedberg constant distribution
centered at 3.2 S with the residuals resulting from a global fit of the data using the
DCDT+ program.
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Discussion
GpIbα binds to IIa, however, the literature presents evidence for interactions at both
anion binding exosites. Though mutagenesis data strongly suggest that GpIbα binds
exclusively at ABE-II (23, 68, 92), binding studies display interactions at both exosites
(68, 93, 95, 98, 101). Adding to the ambiguity, two crystal structures of GpIbα-IIa
illustrate similar interactions at ABE-II for one IIa molecule, while a symmetry related
IIa binds to GpIbα through ABE-I at different GpIbα interfaces (96, 97) (Figure 32).
The studies described in this chapter use solution NMR, HDX coupled with MALDITOF MS, and AUC to investigate the interaction of the GpIbα peptide with thrombin.
The results will be described in terms of the crystal structures when applicable (96, 97).
Analysis of NMR Data: the GpIbα Peptide Binds to Thrombin in an Extended
Conformation.

Initially, NMR experiments were performed with the triply

phosphorylated GpIbα peptide. The 1D spectra did not display line-broadening and the
2D trNOESY lacked the presence of inter-residue NOEs. These results indicate that the
koff for this peptide is too slow for these types of NMR experiments (see Chapter II). In
order to sufficiently weaken the interaction and observe the trNOESY effect, the GpIbα
peptide was dephosphorylated, first at Y278, then at all three Y residues. Conflicting
accounts exist regarding the interaction of unphosphorylated variants of GpIbα and IIa.
One report describes unphosphorylated GpIbα as unable to bind to thrombin (252), while
another group demonstrated competitive inhibition of FVIII hydrolysis by IIa in the
presence of unphosphorylated GpIbα peptide (residues 268-282) (65).

The present

investigation supports the observation that unphosphorylated GpIbα can effectively
interact with IIa.
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The NMR results from both GpIbα (YP276YP279) and the unphosphorylated GpIbα
peptide can be used to describe the two different conformations of the GpIbα residues
269-277 in both X-ray structures (Figure 41A) (96, 97). The residues D269-T273 of the
GpIbα peptide do not display line broadening suggesting that these residues do not
contribute to IIa binding. Also, the 2D trNOESY spectra do not support the existence of
a turn conformation present in the Dumas structure (1P8V) between residues D274-D277
(96). Thus, the N-terminus of this peptide probably exists as a flexible portion of the
GpIbα protein, able to adopt both of the conformations observed in the two structures.
Curiously, these results are at odds with a prior study focusing on the inhibition of
IIa binding to platelets and glycocalicin by GpIbα based peptides (101). The group
showed that residues E270-T273 are important for inhibiting platelet and glycocalicin
interactions with IIa (101). Yet, both X-ray structures show that D269-T273 does not make
electrostatic contacts with residues from thrombin (96, 97). Another study demonstrated
that residue D269-G271 are not essential for GpIbα binding (98). The present data and the
X-ray structures (96, 97) seem to deemphasize D269-T273 as important for binding IIa.
The 2D trNOESY data in conjunction with the 1D NMR appear to support the
Celikel structure (1OOK) more so than the Dumas structure (1P8V). The Celikel X-ray
crystal (1OOK) displays the residues 269-284 in an extended conformation sandwiched
between two thrombin monomers (Figure 41B) with a trans conformation for YP279-P280
(Figure 41A) (97). Electrostatic interactions are observed for residues D274-T284 with
both ABE-I and ABE-II (Figure 42) (97).

Presumably, residues P280-G286 are too

disordered in the Dumas structure (1P8V) to be effectively modeled (96); yet the NMR
data displays significant interactions with thrombin for several of the residues within this
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sequence. Assuming the Celikel structure (1OOK) is an accurate representation of a
potential mode of GpIbα-IIa binding (97), the 1D line broadening support the possibility
of GpIbα binding to both exosites of thrombin in an extended conformation through
dimerization of the protease.

Figure 41: Crystallographic views of GpIbα bound to thrombin (I). A. Representation of
the GpIbα peptide isolated from thrombin. The peptide on the left is from 1OOK and the
structure on the right is from 1P8V. The individual amino acids are labeled. The trans bond
between YP279-P280 in 1OOK is in light blue. Residues experiencing line-broadening in the
1D NMR spectra are in blue. B. Illustration of GpIbα peptide induced dimerization of
thrombin in 1OOK. The data suggests this structure more accurately represents the NMR
results. The C-terminus of GpIbα is in an extended conformation and residues D274-T284
interact with both ABE-II and ABE-I of opposing thrombin monomers.
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Analytical Ultracentrifugation: γ′ Peptide and GpIbα Peptide is Unable to Induce
Dimerization of Thrombin. To explain the NMR observations (167), dimerization of IIa
appears to be a necessary requirement. (Figures 29B in Chapter IV and Figure 41B) (97,
242).

These observations led to AUC being performed with the two peptides and

PPACK-IIa (PPACK is an active site inhibitor).

It should be noted that the HDX

experiments demonstrate that the γ′ peptide interacts effectively with PPACK-IIa (Table
5) (167) and that the GpIbα X-ray structures were solved with PPACK-IIa (96, 97). The
AUC results do not depict dimerization of PPACK-IIa by either peptide. The S values
calculated for PPACK inhibited bovine IIa (3.1) and PPACK-II in the presence of the
peptides (3.2-3.3) match those previously determined for the exact same form of IIa (3.3)
in a similar buffer (253). The same study shows a fragment of thrombomodulin with a
similar molecular weight to IIa binding to the serine protease and increasing S from 3.3 to
4.2 (253). Thus, IIa dimerization would lead to an increase in the S value.
An important discrepancy exists between the AUC studies and the NMR/X-ray
investigations. For the NMR/X-ray work, higher concentrations of thrombin are required
(100-150 µM) (96, 97, 167, 242) whereas in the AUC experiments the concentration of
IIa was much lower in order to avoid saturation of the uv-vis detector. For example, 4.7
µM IIa leads to an optical density of 0.41. Thrombin dimerization by these peptides may
also have a IIa concentration dependence. In the future directions section of chapter VII,
additional experiments are detailed that could independently confirm IIa dimerization by
the peptides, including the measurement of diffusion coefficients by NMR.
Analysis of HDX Results (I): GpIbα (269-286) Behaves in a Similar Manner to the

γ′ peptide (410-427) when Binding to Thrombin. At a ratio of 20:1 GpIbα peptide to IIa,
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the HDX data illustrate very comparable effects to the γ′ peptide (167) on IIa deuterium
exchange. The GpIbα peptide appears to bind to IIa’s ABE-II based on the deuterium
protection for fragments 85-99 and 173-181 over the course of ten minutes (Figure 42).
Several residues within these two fragments have been demonstrated to be involved in
the interaction by mutagenesis and the X-ray crystallography (68, 92, 96, 97). Two
residues from the mutagenesis studies are present within 85-99 that reduce GpIbα
binding when mutated to alanine: R93 and R97 (68, 92) (Figure 42). While R97 does not
appear to interact with GpIbα in the crystal structures, IIa R93 is depicted as being
prominent residue in binding to YP279 at the C-terminus of both GpIbα crystals (96, 97).
In addition, the structures display the importance of IIa N179 in binding to GpIbα D277,
which is within fragment 173-181 (96, 97). Unfortunately, the coverage from the peptic
digest does not include a majority of the residues that bind GpIbα at ABE-II, such as
R101, R126, R165, R233, K235, K236, and K240 (not shown in Figure 42).
Several studies have found that GpIbα binding to IIa has consequences on catalysis.
Increases in the rate of IIa catalysis for FXI (23), PAR-1 (67), and GpV (254) are
observed when IIa interacts with GpIbα.

Conversely, IIa bound to GpIbα

noncompetitively inhibits the rate of fibrinopeptide A release and catalysis of small
chromogenic substrates suggesting an allosteric mechanism transmitted by ABE-II ligand
binding to the active site (68). Similar results are described for the ABE-II ligands γ′
peptide (113) and the chondroitin sulfate moiety of thrombomodulin (255). The residues
R97, E97A, and I174 play important roles orienting and binding FpA for catalysis (248)
(Figure 42). These residues are within the fragments 85-99 and 173-181 that contain
residues involved with binding to GpIbα and display large decreases in % deuteration.
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Interestingly, R97 does not play a direct role in GpIbα binding to IIa, but when mutated to
alanine results in an 8-fold increase of KD (92). Therefore, the binding of GpIbα to ABEII is allosterically linked to at least one residue, R97, involved in IIa catalysis of FpA.
As with the γ′ peptide, GpIbα is affecting the rate of deuterium exchange for sites
distant from ABE-II. Explanations for how allostery is transmitted from ABE-II binding
to these regions are discussed in Chapter IV (167). It should be noted that several reports
have described allostery resulting from glycocalicin binding to ABE-II. Two ABE-I
ligands have been demonstrated to display a reduced affinity for IIa when glycocalicin
binds to ABE-II: hirudin (256) and PAR-1 (257). The reduced amount of deuterium
exchange for the ABE-I regions 65-84 and 106-116 once a ligand binds to ABE-II
illustrates a linkage between the two exosites and supports the observed non-competitive
inhibition observed for these ABE-I ligands.
A few important differences exist between GpIbα and the γ′ peptide deuterium
protection at 20:1. The first variation is that GpIbα does not affect the autolysis loop’s
(135-149D) rate of HDX after one minute, whereas the γ′ peptide provides a slight
amount of protection. In addition, the GpIbα peptide provides slightly more protection
for the A-chain residues -13 to -4 at one minute. These two regions are highly flexible.
The fragment -13 to -4, in addition to being present only in bovine IIa, is not modeled in
X-ray structures of bovine IIa binding to the ligands FpA and hirudin (258, 259). Thus,
these observations for the fragment -13 to -4 may be of little physiologic relevance. With
the autolysis loop (135-149D), residue W141 has been postulated to connect ABE-I to the
active site (233); however the significance of the γ′ peptide’s slight amount of protection
for this region may just be a result of stabilizing this pliable loop to a small degree.
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The most striking variation between the two peptides is the shoulder visible at
higher m/z for the isotopic cluster representing residues 85-99 when GpIbα interacts with
IIa (Figure 36K).

This suggests the presence of two different populations of IIa

exchanging for deuterium. After ten minutes of deuterium exchange, residues 65-84 still
show 1.5 deuterons (-6.7%) of protection for GpIbα. In addition, the fragment 202-207
does not appear to significantly change in the amount of deuterium incorporation
compared to one minute of exchange (-15.6% vs. -14.1%). These longer observed effects
for these regions coupled with the observation for 85-99 could be a consequence of a
small fraction of GpIbα binding to ABE-I. Once bound to ABE-I, the interaction may
have a negative allosteric effect on ligand binding to ABE-II. Thus, residues 85-99 are
no longer protected from deuterium. Such negative allostery between the exosites has
been reported in the literature (70, 170). In order to test this hypothesis, a series of HDX
experiments at 40:1 peptide to protein were performed.
Analysis of HDX Results (II): GpIbα (269-286) Interacts with a Unique Site in
Thrombin when Compared to the γ′ peptide (410-427). The HDX results for the γ′
peptide at 40:1 demonstrate similar effects on HDX as observed at 20:1 GpIbα. A
shoulder begins to appear at higher m/z for 85-99 (Figure 36J). An increase in protection
for the A-chain residues -13 to -4 at one minute, coupled with sustained protection for
202-207 over ten minutes of exchange are also evident in GpIbα (20:1). However, subtle
differences are apparent. Once again, the γ′ peptide slightly protects the autolysis loop
after one minute of deuteration. The ABE-I region 65-84 is slightly more protected at
one minute at 40:1 than at 20:1. Significant amounts of HDX protection are not observed
for 65-84 after ten minutes of exchange at both concentrations of the γ′ peptide.
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Figure 42: Crystallographic views of GpIbα bound to thrombin (II). A. The Dumas structure
(1P8V) and B. the Celikel structure (1OOK). Regions of HDX coverage are color-coded in both
structures: 1H-7 (red), 65-84 (blue), 85-99 (orange), 106-116 (yellow), 135-149D (purple), 173181 (brown), 202-207 (cyan), and 212-227 (green). Residues from the GpIbα peptide that interact
with thrombin are labeled without a colored background. Residues from thrombin that bind to
GpIbα or are mentioned in the text are labeled with a corresponding colored background.
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These results provide more evidence that these two peptides have slightly different
consequences on IIa dynamics when binding to ABE-II. The appearance of a similar
shoulder for the γ′ peptide at 40:1 as for GpIbα at 20:1 for residues 85-99 suggest that
perhaps higher concentrations of the γ′ peptide could drive the peptide to ABE-I as well.
Unfortunately, raising the concentration of the γ′ peptide to 80:1 over IIa significantly
suppresses peptide ionization in the MALDI-TOF MS. Therefore, further observing the
effects of concentration on this interaction was not possible with the HDX technique.
Eight peptide fragments were quantified at 40:1 GpIbα to IIa. The non-TCEP
digests did not yield any peaks in the mass spectra, thus the peptides -13 to -4, 106-116,
173-181, and 202-207 were unobserved. These HDX results suggest that the GpIbα
peptide is now interacting at ABE-I. Protection for 65-84 is doubled in magnitude from
20:1 (-18.3%) to 40:1 (-36.2%). The amount of HDX protection decreases after ten
minutes (-12.7). Unexpectedly, the autolysis loop shows quite a dramatic increase in
HDX protection at one minute of deuteration (-23.2%), disappearing within ten minutes.
Examining the Celikel X-ray structure illustrates that several residues within 65-84
and 135-149D are binding to GpIbα in a symmetry related IIa molecule: R73-E282, K145E281, and T147- YP279 (Figure 42B) (97).

These autolysis loop interactions suggest

stabilization of this region that is evident in the HDX results as well as in the Celikel
structure (97); however, these residues are significantly more disordered in the IIa
structures with the ABE-I binding thrombomodulin (260) and hirudin (72).

The

described interactions are not present in the Dumas structure, which only displays ABE-II
binding for GpIbα (269-286) and is lacking in electron density to model several of the
residues in the autolysis loop (96).
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The ABE-II fragment 85-94, with the ABE-II ligand-binding residue R93, is no
longer protected from HDX after one minute. The observed protection for residues 95-99
(within 85-99) may be a result of allostery due to binding at ABE-I, which is also evident
with thrombomodulin interactions with IIa’s ABE-I (173). Curiously, fragments -3 to 7
and 212-227 are initially protected from HDX at one minute, then dramatically increase
in the amount of HDX at ten minutes. In fact, the regions -3 to 7, 85-94, and 212-227 are
more exposed to deuterium at ten minutes when compared to IIa alone.
The 40:1 HDX studies suggest that GpIbα no longer interacts specifically at ABEII, but now binds at a unique interface on IIa, perhaps ABE-I. The interaction at the new
interface may be weaker than binding at ABE-II. Once bound, the GpIbα peptide can no
longer effectively interact at ABE-II; however, the peptide may retain the ability to bind
ABE-II through dimerization of IIa. Therefore, the concentration of IIa and GpIbα may
have an effect on the type of interaction under study and explain some of the divergent
results. The crystal structure reported by Celikel (97) was formed at a total concentration
of 25 mg/ml while the Dumas structure (96) was reported at 10 mg/ml. Unfortunately,
the individual concentrations of IIa and GpIbα within the crystallization solutions were
not reported. Regardless, the less concentrated Dumas structure (96) may be reflecting
the HDX data at 20:1, while the Celikel structure (97) reflective of the 40:1 results.
The same line of thought becomes more interesting as the competitive binding
studies determining where GpIbα binds to IIa are considered. One report declares that
ABE-I is the destination for GpIbα. The investigators used IIa at 0.42 nM and GpIbα at
50 µM to monitor the effect of the peptide on catalytic activity, 100,000 times the amount
of IIa (93). Conversely, a study proclaiming ABE-II as GpIbα’s site of interaction
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implemented much lower ratios of IIa (100 nM) to GpIbα (8 µM) when performing
competitive binding experiments (68). These observations suggest that protein/peptide
concentration plays an important role in determining the destination of GpIbα on IIa.
Physiologically, IIa interactions with platelets have been characterized by high
affinity binding (KD = 0.5 nM) and intermediate affinity binding (KD = 50 nM) (261,
262). An interesting paradox centers on the presence of 25,000 copies of GpIbα on the
surface of platelets (263), yet they provide only 105-1050 high affinity binding sites for
IIa (101, 262). The 40:1 HDX data suggest a situation where GpIbα no longer targets
ABE-II and instead binds ABE-I. In addition, research has shown that low levels of IIa
activate platelets in a GpIbα dependent manner, whereas higher levels of IIa perform this
function independent of GpIbα (94, 264).

These studies indicate that the binding

interface for GpIbα on IIa is concentration dependent.

It should be noted that IIa

interacts with other proteins on the surface of platelets, including PAR-I through ABE-I.
As Adam et al. suggests, the relative KD and concentrations of all IIa interacting partners
must be considered at the site of thrombus formation (265).
Conclusions.

These studies further characterize peptide binding to IIa’s anion

binding exosites. The NMR results suggest that the GpIbα peptide binds to IIa through
residues D274-E285 in an extended conformation. These investigations also imply that Y
phosphorylation is not a requirement for effective interaction with IIa. HDX data at 20:1
peptide to IIa demonstrate significant similarities between the GpIbα peptide and the γ′
peptide; however, at higher GpIbα concentrations (40:1), the peptide appears to interact
at a new interface. These results suggest that the concentration of the ligand and IIa
dictate where the peptide interacts with IIa as well as the corresponding allosteric effects.

118

CHAPTER VI
PERTURBATIONS IN FACTOR XIII RESULTING FROM ACTIVATION AND
INHIBITION EXAMINED BY SOLUTION BASED METHODS AND DETECTED
BY MALDI-TOF MS
Introduction
Along with converting fibrinogen to fibrin and activating platelets in preparation for
clot formation, thrombin also cleaves the activation peptide of Factor XIII (FXIII)
forming FXIIIa. FXIIIa is a transglutaminase that catalyzes the creation of covalent
crosslinks between adjacent fibrin molecules leading to the formation of the hard clot.
As mentioned in Chapter I, the similarity amongst the X-ray structures of zymogenic
(119), IIa activated (118), and Ca2+ activated (117) FXIII suggests two distinct
possibilities. First, the activated state of FXIII is not favored during the process of
crystallization (117). The other potential explanation is that substrate binding induces the
transition to the active conformation of FXIIIa (117).
Previous work by Brian Turner focused on implementing solution-based methods to
probe the conformational dynamics of FXIII activation that may be undetected in static
crystal structures (174, 175). Two useful techniques for observing protein dynamics are
HDX coupled with MALDI-TOF MS and differential chemical modification of C and K
residues (discussed in Chapter III). Figure 43 summarizes previous results using these
techniques. HDX studies have revealed potential allostery associated with Ca2+ binding
for both the β sandwich and β barrel 1 domains (174). Furthermore, activating FXIII was
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determined to expose regions within the proposed exosite peptides 4 and 7 (145), to
modify C409 at the A2 dimer interface, and to affect the conformation of β barrel 2 (174,
175). These studies highlight the subtle conformational changes that are associated with
the activation of FXIII.

Figure 43: Summary of previous results reported on Factor XIII dynamics (174, 175). Residues
and peptides experiencing conformational changes upon FXIII activation are highlighted in red.
The activation peptide is yellow. β sandwich (blue): 1. 98-104 large decrease in % deuteration
upon Ca2+ activation. 2. K73 acetylated within peptide 4 upon Ca2+ activation. 3. K156 acetylated
upon IIa activation. Catalytic core (green): 1. 220-230 increase in % deuteration. 2. K221
acetylated within peptide 7. 3. C314 is alkylated. 4. C409 alkylated at the dimer interface. β barrel
1 (cyan): 1. 513-522 small decrease in % deuteration. 2. 526-546 large decrease in %
deuteration upon Ca2+ activation. β barrel 2 (orange): 1. C695 is alkylated.
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The difficulties in crystallizing an active conformer of FXIIIa have led to the
prospect of designing an inhibitor for the TGase that may potentially trap the enzyme in
the active state. Once irreversibly inhibited, perhaps FXIIIa would be more amenable to
crystallization. Recently, Hausch et al. have reported inhibition of tissue TGase 2 with
gluten peptide analogs that replace glutamine with the Q isostere 6-diazo-5-oxonorleucine (DON) (176) (Figure 44A). The DON moiety has now been incorporated into
the FXIIIa substrate K9, which is a peptide derived from β-casein (177). By inhibiting
FXIIIa with a peptide (proposed mechanism in Figure 44B (266)), solution based studies
could potentially yield clues on how FXIIIa interacts with proteins containing a reactive
Q and how this TGase prepares for K substrate incorporation. Currently, a crystal
structure of an inhibited TGase or a TGase interacting with a ligand has not been solved.
The focus of this chapter is two-fold. First, conformational perturbations in FXIII
dynamics were further examined that result from proteolytic activation by IIa (FXIIIaIIa)
versus nonproteolytic activation with 50 mM Ca2+ (FXIIIaCa). IIa activation of FXIII led
to the increased exposure of residues within peptide 7, a putative FXIIIa exosite.
Regarding FXIIIaCa, unique changes in the dynamics of the β sandwich and the β barrel 2
may suggest the presence of additional Ca2+ binding sites. The second facet of these
studies concerned FXIIIa inhibition.

For the first time, the FXIIIa inhibitors

iodoacetamide (IAA) and K9 DON were investigated using the described techniques. A
TGase activity assay demonstrated that K9 DON inhibits FXIIIa with an IC50 in the high
nM range. HDX reveals that a β sandwich fragment and several regions within the β
barrel 1 are further stabilized by FXIIIa inhibition. Chemical modification shows that K9
DON inhibition impairs the conversion of several residues to the chemically altered state.
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These investigations have demonstrated the efficacy of the DON moiety as an inhibitor
specific for FXIIIa. More importantly, potential regions of plasticity resulting from
activation and inhibition of FXIIIa have been observed that appear static in the currently
available crystal structures.

Figure 44: K9 DON Inhibition of FXIIIa. A. The isosteres glutamine and 6-diazo-5-oxonorleucine. B. The proposed mechanism of inhibition proceeds through tetrahedral intermediate
formation resulting from cysteine attack at the carbonyl group. The methylene carbon then
abstracts a proton from the active site H373. Finally, a thioether is formed resulting in the release of
N2 and irreversible inhibition of FXIIIa (266).
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Materials and Methods
Factor XIII Preparation and Synthetic Peptides.

Recombinant human cellular

factor XIII (FXIII) was a generous gift from Dr. Paul Bishop (ZymoGenetics, Inc.,
Seattle, WA) (267). Lyophilized FXIII was reconstituted in 18 MΩ dI water. The
concentration of FXIII was determined with a Cary 100 uv-vis spectrophotometer
monitoring absorbance at 280 nm and using the FXIII extinction coefficient of 1.49
mL/mg-cm. Aliquots of 40 µM FXIII were stored at -70 °C.
K9 is a peptide substrate for FXIIIa that is derived from β-casein (177). The
sequence of K9 is Ac-LGPGQSKVIG-OMe and was synthesized by Peptides
International (Louisville, KY). The active site inhibitor Ac-LGPG-(DON)-SLVIG-OMe
(K9 DON) was custom synthesized by N-Zyme BioTec GmbH. The K9 DON inhibitor
is most soluble at high concentrations in DMSO, therefore this solvent was used to
prepare stock solutions. Experiments where K9 DON is absent contain an equivalent
amount of DMSO. Peptide concentrations were determined by quantitative amino acid
analysis (AAA Service Laboratory, Inc., Boring, OR).
TGase Assay. The Dade-Behring Berichrom Assay (177) utilizes coupled reactions
involving FXIIIa and glutamate dehydrogenase (GDH). As FXIIIa reacts with Q from
the peptide K9, NH3 is released. Next, the primary amine glycine ethyl ester (GEE)
concludes the TGase reaction through formation of an isopeptide bond with the K9
peptide. GDH converts α-ketoglutarate and NH3 into glutamate with the aid of reducing
equivalents from NADH. Thus, FXIIIa activity is directly related to NADH oxidation,
which results in decreasing absorbance at 340 nm.
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The FXIII activation mix consisted of 6.9 µM FXIII, 30 nM bovine IIa (purified as
described in (243)) , 1 mM CaCl2, in 20 mM borate, pH 8.3. After 12 min at 37 °C, IIa
activity was inhibited by 376 nM PPACK to prevent further proteolysis of FXIIIa. An
additional 12 min at 37 °C elapsed after which 19 µL aliquots of FXIIIaIIa were made and
stored at -70 °C.
Inhibition

of

FXIIIaIIa

with

either K9 DON or iodoacetamide
(IAA) was monitored with a modified
version of the Berichrom assay (200).
Figure 45 displays the mass spectrum
indicating K9 DON modification of
Figure 45: Mass spectrum of the K9 DON
modified C314 from a tryptic digest.

C314 (266). Irreversible inhibition is a
time and concentration dependent

phenomenon. Throughout each trial, the volumes of the detector reagent (250 µL) and
the activator reagent (163 µL), as well as FXIIIaIIa (218 nM) and K9 peptide (313 µM), in
100 mM bicine pH 8.3 were held constant. The amount of the inhibitor K9 DON or IAA
ranged from 0 to 5000 nM, resulting in inhibitor to FXIIIa active site molar ratios of 1:1
to 23:1. The assay contents were incubated in a Cary 100 uv-vis spectrophotometer for 5
min at 37 °C, then the substrate K9 was added. NADH oxidation was monitored for 10
min at 340 nm. Since 4% DMSO is present in the assay mix, a series of control
experiments were performed demonstrating that FXIIIaIIa in 4% DMSO possesses
identical activity to FXIIIaIIa with an equal amount of dI water (data not shown).

124

FXIIIaIIa activity was measured by determining the slope for the steepest part of the
curve. The slope represents the velocity of the reaction (Δabs/min). The resultant slope
of FXIIIaIIa activity in the absence of the inhibitor was assigned as 0% inhibition or 100%
activity. All reaction velocities calculated in the presence of K9 DON or IAA were
normalized with respect to the slope observed with 0% inhibition. As described in
Rajagopal et al. (268), IC50 values for inhibition of FXIIIaIIa were determined by plotting
the % inhibition versus the log of the inhibitor concentration, which produced an apparent
sigmoidal curve. Equation 8 was used to fit the sigmoidal with SigmaPlot and calculate
an IC50.

In this equation, a represents the minimal curve asymptote, b equals the

maximal curve asymptote, and c is the Hill slope which is an indicator of the steepness of
the inhibitor-response curve.

%inhibition = a +

(b + a)
" log([inhibitor]) %
1+ $
'
IC50
#
&

(8)
c

Activation and Inhibition of FXIII for HDX and NEM Experiments. IIa activation
of FXIII!proceeded as described for the TGase assay. Ca2+ activation of FXIII was
carried out in 50 mM CaCl2, 20 mM borate pH 8.3. The activation mix incubated for 2
hrs at 37 °C. The inhibitors K9 DON or IAA were added at a ten-fold molar excess to
FXIIIa and incubated at 37 °C for 30 min. The amount of inhibitor to FXIIIa (10:1) was
chosen based on the results of the TGase assay. Furthermore, the Berichrom assay
verified FXIIIa activation and inhibition. As with uninhibited FXIIIa, K9 DON and IAA
FXIIIa exhibited limited solubility. For the described experiments, enough FXIIIa is
present in solution to gather reliable and reproducible results.

125

HDX Sample Preparation. FXIIIa was exchanged into 6.67 mM borate, 0.33 mM
CaCl2, pH 8.3, removing excess inhibitor and/or Ca2+. The exception was the standard
for comparison, zymogenic FXIII without Ca2+, which was buffer exchanged into 6.67
mM borate, pH 8.3. The concentration of FXIII(a) (the (a) is shorthand for all forms of
Factor XIII: unactivated, activated, and inhibited) for all HDX preparations varied from
10-13 µM.

Aliquots (36 µL) of the buffer-exchanged FXIII(a) were evaporated to

dryness using a SpeedVac (Savant) and stored at -70 °C.
HDX Experiments. The HDX protocol is described in more detail in Chapter III.
Dry aliquots of FXIII(a) were allowed to come to room temperature before beginning the
experiment. 12 µL of 99.996% D2O (Cambridge Isotope Laboratories) was added to the
aliquot yielding 30-36 µM FXIII(a), 1 mM CaCl2, in 20 mM borate pH 8.3. The samples
were incubated in a desiccator at room temperature for 1 or 10 min. Adding 120 µL of
chilled 0.1% TFA pH 2.5 quenched HDX. Immediately, the entire quenched solution
was transferred to a tube of activated pepsin bound to 6% agarose (Pierce Chemical).
Digestion occurred on ice for 10 min. Centrifugation at 4 °C separated the digest from
the pepsin and 10 µL aliquots were immediately frozen in liquid N2 and stored at –70 °C.
Each time point was performed three times.
HDX Analysis. A HDX aliquot of FXIII(a) was thawed, immediately mixed with
an equal volume of 10 mg/mL α-cyano-hydroxycinnamic acid matrix (α-CHCA)
(Aldrich) in 1:1:1 ethanol/CH3CN/0.1% TFA, pH 2.2, and 0.5 µL spotted onto a chilled
stainless steel MALDI plate. The spotted MALDI plate was dried within a SpeedVac
unit and then inserted into the MALDI-TOF MS (Voyager DE-Pro, Applied Biosystems).
The entire procedure took about 5 min, limiting the amount of back exchange. Spectra
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were collected in the reflector mode over a mass range of 800-3500 m/z with 256 laser
shots per spectrum. All peptides in the peptic digest were previously identified by Brian
T. Turner, Jr. (174) (Figure 46). Data Explorer (Applied Biosystems) was used to
analyze the spectra. Calibration of the spectra involved two singly protonated reference
peptides, the monoisotopic mass of 850.4787 Da (residues 535-541) and the
quadraisotopic mass of 1375.7097 Da (residues 220 -230). The amount of deuterium
uptake by each peptide and the % difference in deuteration relative to zymogenic FXIII
was quantified as described by Sabo et al. (167) and discussed in Chapter III.

Figure 46: Sequence Coverage Map of FXIII. Pepsin fragments monitored during HDX
experiments are underlined (45% sequence coverage). Residues highlighted in red
represent trypsin coverage (68%), in blue indicates chymotrypsin coverage (48%), and in
green displays regions where the proteases overlap (81%).

Cysteine Modification with NEM. FXIII(a) at 10 µM was incubated with 50 µM
NEM (stock in 50% CH3CN) for 60 min at room temperature.

The reaction was

quenched with the addition of dithiothreitol. In either trypsin buffer (100 mM NH4HCO3,
pH 8) or chymotrypsin buffer (100 mM Tris-HCl, 10 mM CaCl2, pH 7.4), the quenched
samples were digested with 2 µL of 1 mg/mL chymotrypsin (25 °C) or 1 mg/mL trypsin
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(37 °C) for at least 4 hr. Proteolysis was quenched by acidification with 5% TFA.
Chymotrypsin cleaves primarily after the aromatic residues W, Y, and F.

Trypsin

hydrolysis occurs primarily after the positively charged R and K residues.
Lysine Acetylation and Limited Proteolysis Experiments. In 10 mM NH4HCO3 pH
7.4, FXIII at 10 µM was either activated with Ca2+ or with IIa. Inhibition of FXIIIa
occurred concurrently with the activation process in the presence of 20 µM IAA or K9
DON in DMSO. Ca2+ activation occurred in 50 mM CaCl2 for 2 hr at 37 °C. IIa
activation took place with 42 nM IIa and 1 mM CaCl2 for 12 min at 37 °C. PPACK was
used to inhibit IIa activity and the FXIIIa mix incubated for an additional 108 min.
After 2 hours, 5 µL of 600 mM acetic anhydride (AA) in DMF was added to
FXIII(a) and allowed to incubate for 1 hr. The acetylation mix was acidified with 1%
TFA. Residual AA and the byproduct acetic acid were removed by drying in a SpeedVac
concentrator device.

When performing limited proteolysis, AA was not added but

FXIII(a) was handled in a similar manner. The dry protein was reconstituted in dI water.
The modified protein was then split in half and addition of buffer yielded 10 µM FXIII(a)
in 100 mM NH4HCO3 pH 8.0 (trypsin) or in 100 mM Tris-HCl, 10 mM CaCl2 pH 7.4
(chymotrypsin). To 25 µL of the modified protein in digestion buffer, 2 µL of 1 mg/ml
trypsin (37 °C) or chymotrypsin (25 °C) was added and proteolysis occurred for 4 hr.
With limited proteolysis, the digest was quenched after 30 min with 5 % TFA.
MALDI-TOF Mass Spectrometry for Chemical Modification and Limited
Proteolysis. C18 ZipTips (Microcon) were used to concentrate and clean up the digested
FXIII(a) samples with elution into 50% CH3CN. The eluted peptides were mixed with 5
µL of either α-CHCA or ferulic acid MALDI matrix. The samples were spotted on a
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stainless steel MALDI plate and acquired in reflector mode using MALDI-TOF MS. The
mass range was from 550-4000 m/z and 256 shots per spectrum were collected. At least
three separate trials were performed for each state of FXIII(a) monitored and at least two
spectra collected for each trial. All spectra were analyzed as described by Turner et al
(175) and the FXIII sequence coverage produced with chymotrypsin and trypsin is
presented in Figure 46. For limited proteolysis, the intensity of a monoisotopic peak
representing FXIII(a) digest fragments was normalized with respect to the most intense
(abundant) monoisotopic peak. Differences in relative peak intensities greater than 20%
were considered significant for the limited proteolysis studies based on a comparative
standard employed by Ansong et al. (218).
Results
TGase Assay with FXIIIaIIa. A modified version of the Dade-Behring Berichrom
assay was performed to determine the potency of the irreversible inhibitor K9 DON for
FXIIIaIIa and the results compared to IAA. Figure 47A displays a series of progress
curves for inhibition of FXIIIaIIa with increasing concentrations of K9 DON and Figure
47B presents a plot of the data fitted to the Equation 8. The calculated IC50 was 816 ± 32
nM. The small molecular inhibitor IAA was slightly more effective with an IC50 of 539 ±
74 nM. The p value comparing the two inhibitors was p= 0.03. Briefly, the p value is a
statistical tool gauging the probability that the observed difference between two values
can be attributed to chance alone. Typically, p values less than 0.05 are considered to
reflect significant variance amongst two data sets.
Hydrogen Deuterium Exchange Coupled with MALDI-TOF Mass Spectrometry.
The solvent accessibility of IAA or K9 DON inhibited FXIIIa was compared to the
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zymogen, FXIIIaCa, and FXIIIaIIa. Table 10 contains the % differences in HDX for
FXIIIa relative to the zymogen. The table groups the data according to the activation
method observed. The amount of deuterium incorporated at each time point is presented
in Figure 48 (FXIIIaCa) and Figure 49 (FXIIIaIIa) as well as in Table 11.

Figure 47: TGase Assay and FXIIIa inhibition
by K9 DON. A. Eight separate trials were
performed at varying inhibitor concentrations:
FXIIIa in the absence of K9 DON (navy blue);
250 nM K9 DON (red); 400 nM K9 DON
(orange); 700 nM K9 DON (pink); 900 nM K9
DON (purple); 1500 nM K9 DON (brown);
2500 nM K9 DON (cyan); and 5000 nM K9
DON (blue). The assay components, FXIIIa,
and the indicated amount of inhibitor were
incubated for 5 min at 37 °C, at which point
the substrate K9 was introduced to the assay
mix. The graph depicts the oxidation of
NADH as a function of time. B. A plot of %
inhibition versus the log of inhibitor
concentration. Open and filled in circles
represent IAA and K9 DON, respectively.
Three separate trials were performed and the
plot was fit to equation 8. The IC50 was
determined as 815.5 ± 31.9 nM for K9 DON
and 538.8 ± 74.3 nM for IAA.

The β-sandwich residues 98-104 were only present in the FXIIIaCa spectra,
presumably due to pepsin’s inability to produce this peptide from FXIIIaIIa. Inhibition of
FXIIIaCa with K9 DON resulted in differences in the deuteration profiles for this peptide
at one and ten minutes. Whereas FXIIIaCa displayed an increase in solvent accessibility
after 10 minutes (from -24.3% at one minute to -15.3% after ten minutes), K9 DON
FXIIIaCa was observed to acquire less deuterium over a similar time span (from -15.5% at
one minute to -30.1% after ten minutes). As for IAA FXIIIaCa, inhibition with the small
molecular inhibitor leads to sustained stabilization over ten minutes of HDX (-31.9% at
one minute to -35.0% after ten minutes).
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Within the catalytic core, several fragments were observed as displaying similar
differences in deuterium exchange, regardless of the FXIIIa state monitored. For residues
220-230, deuterium incorporation varied from 4.5-7.0% more exposure relative to the
zymogen at one minute and at ten minutes the range was 6.2-9.7%. The only exception
was with IAA FXIIIaCa where one minute of exposure to deuterium did not yield a
significant difference in deuteration when compared to the zymogen (1.7%). Similarly,
the results for residues 240-247 were within the standard deviation for all FXIIIa
conditions examined: one minute, 6.0-7.3% and ten minutes, 5.9-10.4%. Only FXIIIaIIa
presented reliable isotopic clusters for quantification of 248-264. Once again, the type of
inhibition when compared to FXIIIaIIa had little effect on deuterium exchange. In this
case, significant protection was observed initially at one minute (5.9%-6.7%) and within
ten minutes, the exchange began to approach zymogenic FXIII (2.2%-3.1%).
Table 10: Changes in % Deuteration for Factor XIII-Inhibitor Complexes at One and Ten Minutes
Relative to Unactivated Factor XIIIa
Theo.
FXIIIaCa
K9 DON FXIIIaCa
IAA FXIIIaCa
Residues
Dmax b
1m
10m
1m
10m
1m
10m
c
98-104
6.5
-24.3
-15.3
-15.5
-30.1
-31.9
-35.0
220-230
10.8
5.4
9.7
7.0
7.3
1.7
6.2
240-247
7.5
6.0
7.1
7.2
5.9
6.9
8.5
513-522
9.7
-11.6
-10.6
-10.0
-11.4
-15.6
-15.6
526-546
21.2
-24.1
-25.8
n/ad
-32.7
n/a
n/a
535-541
6.5
1.8
2.4
2.6
2.7
1.3
4.2
Theo.
FXIIIaIIa
K9 DON FXIIIaIIa
IAA FXIIIaIIa
Residues
Dmax
1m
10m
1m
10m
1m
10m
220-230
10.8
4.5
7.2
5.9
6.3
6.6
7.5
240-247
7.5
6.0
6.8
6.5
6.7
7.3
10.4
248-264
15.9
6.0
3.1
5.9
2.2
6.7
n/a
513-522
9.7
-5.4
-5.3
-7.3
-10.3
-8.0
-9.4
526-546
21.2
-2.6
-2.4
-10.0
-11.8
-4.0
-9.0
535-541
6.5
1.8
4.2
2.8
4.9
2.3
5.1
a
The % change for a particular peptide is calculated by Equation 7 (Chapter III). bThe maximum
number of exchangeable protons within the indicated peptide, assuming 100% deuteration.
(Chapter III). A fully deuterated peptide would theoretically have acquired this amount of
deuterons. cThe values in bold represent significant changes in deuteration of greater than ± 4.5%.
d
n/a refers to a peptide that was either not observed in the peptic digest or was not of sufficient
intensity to quantify.
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Figure 48: Graphs of deuterium incorporation for FXIIIaCa. A. 1 min and B. 10 min of HDX.
The bars in the graph correspond to the following conditions: zymogenic FXIII (red), FXIIIaCa
(orange), K9 DON FXIIIaCa (yellow), and IAA FXIIIaCa (pink). Errors correspond to standard
deviation of the mean for three independent trials.

The final region of FXIII investigated with HDX was the β barrel 1. Considering
all FXIIIaCa states, two of the three regions observed, 513-522 (-10.0% to -15.6%), and
535-541 (1.3% to 4.2%), were similar in regard to the dynamics of deuterium exchange at
one and ten minutes.

However, the presence of the K9 DON peptide protects the

fragment 526-546 by 6.9% after ten minutes of HDX (-25.8% for FXIIIaCa and -32.7%
for K9 DON FXIIIaCa). Unfortunately, this region was unable to be observed in the IAA
FXIIIaCa spectra (Tables 10 and 11).

132

Table 11: Deuterium Incorporation for FXIII
Peptide

Theo.
Dmaxa

Zymogen

FXIIIaCa

98-104
220-230
240-247
248-264
513-522
526-546
535-541

6.5
10.8
7.5
15.9
9.7
21.2
6.5

4.4 ± 0.0
2.4 ± 0.1
1.2 ± 0.0
2.9 ± 0.0
3.8 ± 0.0
12.8 ± 0.1
0.6 ± 0.0

2.9 ± 0.1
2.9 ± 0.1
1.7 ± 0.1
n/ab
2.7 ± 0.0
7.7 ± 0.2
0.7 ± 0.1

One Minute
K9 DON
IAA
FXIIIaCa
FXIIIaCa
3.4 ± 0.1
3.1 ± 0.1
1.7 ± 0.0
n/a
2.9 ± 0.0
n/a
0.8 ± 0.1

FXIIIaIIa

K9 DON
FXIIIaIIa

IAA
FXIIIaIIa

2.4 ± 0.1
2.5 ± 0.1
1.7 ± 0.1
n/a
2.3 ± 0.1
n/a
0.7 ± 0.1

n/a
2.8 ± 0.1
1.6 ± 0.0
3.8 ± 0.0
3.3 ± 0.1
12.3 ± 0.1
0.7 ± 0.1

n/a
3.0 ± 0.0
1.7 ± 0.0
3.8 ± 0.0
3.1 ± 0.0
10.7 ± 0.3
0.8 ± 0.1

n/a
3.1 ± 0.1
1.7 ± 0.1
3.9 ± 0.1
3.1 ± 0.2
12.0 ± 0.5
0.8 ± 0.1

Ten Minutes
Peptide

Theo.
Dmaxa

Zymogen

FXIIIaCa

K9 DON
FXIIIaCa

IAA
FXIIIaCa

FXIIIaIIa

K9 DON
FXIIIaIIa

IAA
FXIIIaIIa

98-104
220-230
240-247
248-264
513-522
526-546
535-541

6.5
10.8
7.5
15.9
9.7
21.2
6.5

4.8 ± 0.1
2.9 ± 0.1
1.4 ± 0.0
3.5 ± 0.0
3.9 ± 0.0
13.0 ± 0.1
0.7 ± 0.0

3.8 ± 0.1
3.9 ± 0.3
1.9 ± 0.1
n/a
2.8 ± 0.1
7.5 ± 0.2
0.8 ± 0.0

2.8 ± 0.1
3.7 ± 0.1
1.8 ± 0.0
n/a
2.7 ± 0.0
6.1 ± 0.3
0.8 ± 0.0

2.5 ± 0.0
3.6 ± 0.2
2.0 ± 0.1
n/a
2.3 ± 0.2
n/a
0.9 ± 0.1

n/a
3.7 ± 0.0
1.9 ± 0.0
4.0 ± 0.1
3.3 ± 0.0
12.5 ± 0.2
0.9 ± 0.0

n/a
3.6 ± 0.1
1.9 ± 0.1
3.9 ± 0.0
2.9 ± 0.3
10.5 ± 0.8
1.0 ± 0.0

n/a
3.7 ± 0.1
2.1 ± 0.2
n/a
2.9 ± 0.0
11.0 ± 0.2
1.0 ± 0.1

a

The maximum number of exchangeable protons within the indicated peptide, assuming 100%
deuteration (Chapter III). A fully deuterated peptide would theoretically have acquired this amount of
deuterons. bThese clusters were unable to be quantified under these conditions.

When considering the various forms of FXIIIaIIa (Tables 10 and 11), residues 513522 experience slightly more protection from solvent in both inhibited forms of FXIIIaIIa.
At ten minutes, FXIIIaIIa had incorporated 3.3 deuterons (-5.3%) and both types of
inhibited FXIIIaIIa integrated 2.9 deuterons (-9.4% and -10.3%).

The amount of

deuteration in FXIIIaIIa for 526-546 was comparable to FXIII (-2.4% to -2.6%). For the
same span of residues, K9 DON FXIIIaIIa exhibited an immediate decrease in solvent
accessibility after 1 minute (-10.0%); conversely, IAA FXIIIaIIa affected the dynamics of
HDX in a gradual manner, reaching a statistically significant difference following ten
minutes of HDX (-9.0%). Lastly, the fragment 535-541 became more exposed to solvent
at ten minutes in all forms of FXIIIaIIa (4.2% to 5.1%).
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Figure 49: Graphs of deuterium incorporation for FXIIIaIIa. A. 1 min and B. 10 min of
HDX. The bars in the graph correspond to the following conditions: zymogenic FXIII
(red), FXIIIaIIa (blue), K9 DON FXIIIaIIa (green), and IAA FXIIIaIIa (cyan). Errors
correspond to standard deviation of the mean for three independent trials.

The isotopic clusters representing 526-546 for FXIIIaCa and K9 DON FXIIIaCa were
of an uneven distribution with a small rise in peak intensity toward higher m/z (Figure
50). This observation led to a separate series of HDX experiments to be performed on
the zymogen in the presence of 1 mM Ca2+. The rationale for these HDX trials was to
differentiate the effects of Ca2+ concentration on deuterium exchange. Figure 50 shows
an expanded isotopic cluster for FXIII in 1 mM Ca2+, intermediate between the zymogen
and FXIIIaCa, as well as, the spectra for the states of FXIIIaIIa in the same region.
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Figure 50: Mass spectra of FXIII residues 526-546 after ten minutes of HDX. All D-on
experiments are in 20 mM borate and 1 mM CaCl2 pH 8.3, except the zymogen in the absence of
Ca2+ where the buffer was 20 mM borate pH 8.3. The FXIII state illustrated in each spectrum is
listed in the figure. This peak cluster contains β-barrel 1 residues and displays drastically
varying degrees of deuteration between FXIIIaCa and FXIIIaIIa. In both types of activation states,
inhibition provides protection from solvent amounting to around 1-2 deuterons.

N-ethylmaleimide Modification of FXIII. Digesting FXIII with the proteases trypsin
and chymotrypsin provided a total of 81% sequence coverage (Figure 46). As previously
reported (175), seven of the nine cysteine residues were able to be observed in the tryptic
digests of FXIII: C152, C188, C238, C314, C327, C409, and C695. Unfortunately, chymotrypsin
did not produce additional proteolytic peptides containing C374 or C423.

All NEM

modification experiments are summarized in Table 12.
The only consistently unmodified cysteine was C152 within the β-sandwich. For the
zymogen, C188 was the lone residue to react with NEM. Once FXIII was activated, NEM
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modified the active site residue C314. Regarding the inhibited forms of FXIIIa, IAA
modified C314 was observed in the mass spectra (data not shown) and a weak peak for K9
DON covalently linked to C314 was infrequently apparent at 2900 m/z (Figure 45),
probably due to difficulties in ionization.
Table 12: Cysteine Alkylation Results at pH 8.3
Cysteine Residues
152a 188
238
314c

327

374

409

Zymogen

X

FXIIIaCa

X

X

IAA FXIIIaCa

X

IAA

K9 DON FXIIIaCa

X

695

X
X

weak

K9 DON

FXIIIaIIa

X

X

X

X

IAA FXIIIaIIa

X

IAA

X

X

X

K9 DON

X

weak

K9 DON FXIIIaIIa

423

b

X

X
X

X

a

A blank space indicates that the modified peaks were not observed in the mass spectra.
NEM modification of cysteine was identified. cCysteine 314 in the activated state reacted
with NEM in the uninhibited forms. The presence of the inhibitor covalently linked to
cysteine 314 prevented NEM from modifying the active site and the NEM peak was
unobserved in the mass spectra.
b

In the β-sandwich, C188 was altered by NEM in all three FXIIIaCa states. Moving to
the catalytic core, the residue C238 was weakly modified in K9 DON FXIIIaCa, while C409
reacted with NEM only when IAA inhibited FXIIIaCa. C327 remained unmodified after
Ca2+ activation. The β-barrel 2 residue C695 was available to NEM in all three forms of
FXIIIaCa. Turning to IIa activation, K9 DON FXIIIaIIa was the only form of FXIIIaIIa to
display modification of the β-sandwich residue C188 and the β-barrel 2 residue C695. Two
cysteine residues located near the activation peptide, 238 and 327, were consistently
labeled in all forms of FXIIIaIIa. Finally, the catalytic core C409 was modified in FXIIIaIIa
and IAA FXIIIaIIa, but K9 DON FXIIIaIIa severely weakened chemical modification.
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Acetic Anhydride Modification of FXIII. There are 38 lysine residues in FXIII
spanning all four domains. Only 10 of the 38 lysine residues were unable to be observed
as acetylated in the mass spectra: K61, K269, K363, K366, K418, K445, K446, K462, K467, and
K657. Residues always accessible to acetic anhydride included K54, K133, K534, K623, K635,
and K704. Additional labeling of the zymogen involved K129, K583, K584, and K621. Lysine
residues K73, K113, K156, K199, K221, K257, and K531, were exposed to acetic anhydride only
after activation of FXIII.

The modifications recorded from both trypsin and

chymotrypsin digests will be combined and the data separated into tables concerning
FXIIIaCa (Table 13) and FXIIIaIIa (Table 14).
Table 13: Lysine Acetylation Results for FXIIIaCa
β sandwich
Residues

54

a

68

73

b

113
c

129

133

X

X

151

156

199

221

257

482

503

504

513

?

?
?

Zymogen

X

FXIIIaCa

X

X

X

X

?

X

X

X

X

X

?

?

X

X

X

X

?

X

X

X

X

X

?

?

X

X

X

X

?

X

X

X

X

583

584

621

623

635

X

X

X

X

X

?

?

X

X

X

X

X

X

X

?

?

X

IAA
FXIIIaCa
K9 DON
FXIIIaCa

?

Catalytic Core

β barrel 1
569
570

β barrel 2
677 678

Residues

531

534

Zymogen

?

X

Ca

X

X

X

X

X

?

?

X

X

X

X

X

X

?

?

X

X

X

X

?

?

X

X

X

X

X

?

?

X

FXIIIa

IAA
FXIIIaCa
K9 DON
FXIIIaCa

565

?

?

704

a

Residues displaying modification regardless of FXIII activation or inhibition are referred to as always
solvent exposed. bThe letter X represents lysine modification of the indicated residue. cA question
mark denotes ambiguous data and the possibility exists for modification of the lysine residue. The first
possibility is when two peptides have similar masses and both possess lysine residues. Alternatively, a
peptide with two or three lysine residues may be observed as acetylated once, thus presenting ambiguity
in assigning the modified lysine.

In the β sandwich, K68 and K129 were not accessible to acetic anhydride
modification in all forms of FXIIIaCa. Interestingly, the catalytic core K482 was labeled in
FXIIIaCa and IAA FXIIIaCa, yet unmodified in K9 DON FXIIIaCa. For all three states of
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FXIIIaCa, the β barrel 1 residues K583, K584 and K621 were modified, while both K565 and
K570 could not be unambiguously assigned as always labeled.

Acetylation results

revealed that six residues spanning the β sandwich and catalytic core displayed consistent
labeling in FXIIIaIIa: K68, K129, K482, K503, K504, and K513 (Table 14). Like FXIIIaCa,
K565, could not be unambiguously assigned. K583 and K584 did not react with acetic
anhydride when IIa activated FXIII, however, general inhibition of FXIIIaIIa resulted in
protection from acetic anhydride for the β barrel 1 residue K621.
Table 14: Lysine Acetylation Results for FXIIIaIIa
β sandwich
Residues

54a

Zymogen

X

b

IIa

X

X

X
X

FXIIIa

IAA
FXIIIaIIa
K9 DON
FXIIIaIIa

68

73

113

Catalytic Core

129

133

151

156

199

221

c

?

X

X

X

X

X

X

?

X

X

X

X

X

X

X

X

X

X

?

X

X

X

X

X

X

X

X

X

?

X

X

X

X

β barrel 1
Residues

531

534

Zymogen

?

X

FXIIIaIIa

X

X

X

X

X

X

X

X

?

IAA
FXIIIaIIa
K9 DON
FXIIIaIIa

565

569

?

?

570

257

482

503

504

513

?

?

X

X

X

X

X

X

X

X

X

X

X

β barrel 2
583

584

621

623

635

677

678

704

X

X

X

X

X

?

?

X

X

X

X

?

?

X

X

X

?

?

X

X

X

?

?

X

?

?

a

Residues displaying modification regardless of FXIII activation or inhibition are referred to as always
solvent exposed. bThe letter X represents lysine modification of the indicated residue. cA question
mark denotes ambiguous data and the possibility exists for modification of the lysine residue. The first
possibility is when two peptides have similar masses and both possess lysine residues. Alternatively, a
peptide with two or three lysine residues may be observed as acetylated once, thus presenting
ambiguity in assigning the modified lysine.

Limited Proteolysis of FXIII.

Variations within the mass spectra of FXIII(a)

provide insight into subtle alterations in conformational dynamics that affect
chymotrypsin’s ability to hydrolyze backbone amide bonds of the TGase. For example,
during IIa activation of FXIII, the amide bond between R36-G37 is cleaved and a
chymotryptic digest of FXIIIaIIa does not produce the fragment Q32-F44. Proteolysis of
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FXIIIaIIa by chymotrypsin produces a significant amount of the activation peptide
residues G9-L31. By contrast, the digests of the zymogen and FXIIIaCa displayed the
peptide Q32-F44 and less G9-L31. In our studies with FXIII(a), significant variation within
thirty minutes of trypsin proteolysis was not observed (data not shown), thus the focus
was centered on chymotryptic digests of FXIII(a).

Selected data for chymotrypsin

proteolysis is summarized in Figure 51. Within the β-sandwich, two peptides were
cleaved more effectively with FXIIIaCa: 75-83 and 104-125. FXIIIaIIa displayed a large
abundance of the catalytic core fragment 207-214. Finally, two fragments in the β barrel
2, 681-691 and 692-698, were more susceptible to chymotrypsin in FXIIIaCa.

The

inhibitor K9 DON did not significantly affect the chymotryptic digests profiles.

Figure 51: Graph of limited chymotryptic proteolysis of FXIII. Only
differences in proteolysis larger than ±20% were considered significant. The
colored bars refer to the zymogen (red), FXIIIaCa (orange), K9 DON FXIIIaCa
(yellow), FXIIIaIIa (blue), and K9 DON FXIIIaIIa (green). Errors correspond to
standard deviation of the mean for three independent trials.

Discussion
At the present time, an X-ray structure of FXIIIa interacting with a substrate or
inhibitor has not been solved. Furthermore, limited evidence exists on how Q containing
substrates access the active site, interact with the catalytic core, and alter the dynamics of
FXIIIa in preparation for the K containing substrate. An effective peptide inhibitor for
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FXIIIa has now been developed that incorporates the Q isostere 6-diazo-5-oxo-norleucine
into the FXIIIa substrate peptide K9. The focus of the work has proceeded to observe in
solution the conformational changes associated with inhibition by K9 DON compared to
IAA (178). In addition to probing FXIIIa inhibition, new insight has also been obtained
regarding the conformational features associated with the activation of FXIIIa by Ca2+
and by IIa, thus augmenting our previous investigations (174, 175). The current studies
thus provide valuable information about events occurring to the β sandwich, the
activation peptide, the dimer interface, the catalytic core, and β barrels 1 and 2 (178).
DON Inhibition of FXIIIaIIa. A modified version of the Dade-Behring Berichrom
assay (177) was used to determine that K9 DON is a slightly less potent inhibitor of
FXIIIaIIa as compared to IAA. A longer peptide derived from the natural substrate α2antiplasmin has been reported to be an even better FXIIIa substrate model. α2AP (1-15)
shows improved kinetic parameters, maintains a preference for Q2 over Q4, and suggests
the existence of additional substrate specificity determinants within the active site (137).
Incorporation of DON into such a longer peptide sequence could later offer more potent
inhibition of FXIIIa as well as contribute to further understanding FXIIIa-ligand
interactions. The research with K9 DON provides our first successful application of such
a peptide inhibitor to probe changes occurring to FXIIIa conformation in solution.
The β sandwich and Proteolytic Versus Non-proteolytic Activation.

The β

sandwich residues 72-97, also known as peptide 4, are hypothesized to be involved in Q
substrate recognition (Figure 52A) since synthetic peptides derived from this sequence
compete for Q substrate binding to FXIIIa (145). An earlier report demonstrated that K73
was acetylated in FXIIIaCa only (175). The present results confirm this finding as well as
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showing that FXIIIaIIa is also modified at this position. The current research further
indicates that FXIIIaCa exhibits increased chymotryptic proteolysis of residues 75-83
within this peptide 4 region. Together these results suggest increased exposure of 73-83
upon activation, especially for FXIIIaCa. These events could signal FXIIIa preparation
for Q substrate interaction with the β sandwich (145).

Figure 52: Correlating results with X-ray structure of Factor XIII (I) (1FIE). A. β sandwich
region: Depicted are the activation peptide (cyan), peptide 4 fragments 72-74/84-97 and K73 (blue),
limited proteolysis fragments 75-83 (pink) and 104-125 (yellow), L125-Q126 (purple), K129 (orange),
the HDX fragment 98-104 (red), and C152/C188 (yellow). B. Activation peptide/dimer interface:
residues N18/S19/N20/A21 (cyan), K156 (pink), D243 (red), R252 (dark green), M242 (green), C238/C327
(orange), the HDX fragments 240-247 and 248-264 (purple), K113/K257/R260 (yellow), D367′ (green),
and E401′/D404′ (blue). C. Zymogen crystal structure 1GGT displaying activation peptide (red)
extending away from the dimer. D. FXIIIaIIa crystal structure 1FIE (orange) displaying activation
peptide resting across the surface of the dimer.
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Other unique properties related to FXIIIaCa include an increase in proteolysis of the
104-125 segment, a loss of the ability to acetylate K129, and a protection from solvent for
residues 98-104.

As the L125-Q126 peptide bond becomes more accessible to

chymotrypsin, it may be at the expense of K129 solvent exposure. Between peptide 4 (7297) and the chymotryptic cleavage region (104-125) is the segment 98-104. Previous
HDX studies have demonstrated that residues 98-104 of FXIIIaCa exhibited a significant
decrease in deuteration that may be localized to L98 and F99 (Figure 52A) (174). IAA
inhibition of FXIIIaCa further stabilizes this short segment from deuteration. K9 DON
FXIIIaCa requires more time to achieve significant stabilization of this fragment
conceivably due to allostery related to peptide binding within the catalytic core.
Interestingly, residues 98-104 are not observed peptic digests of FXIIIaIIa.
The differences in proteolysis observed for FXIIIaCa versus FXIIIaIIa are important
to consider. With both chymotrypsin and pepsin, fewer cleavages are detected within the
β sandwich region of FXIIIaIIa. Cleavage of the activation peptide by IIa may thus
protect certain regions within the β sandwich. Alternatively, the potential presence of
low affinity Ca2+ binding site(s) within this domain could aide in creating a more
accessible environment for the proteases to cleave FXIIIaCa. An earlier study ascertained
that IAA FXIIIaIIa possessed a higher affinity for fibrin II than IAA FXIIIaCa (269).
Another investigation found that FXIIIaCa was unable to crosslink fibrin α chains, while
retaining the ability to crosslink fibrin γ chains (270). Perhaps several fibrin-binding sites
are located in or influenced by the β sandwich and only cleavage of the activation peptide
is able to properly orient or expose residues related to fibrin α chain binding.
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FXIII Activation Peptide and the Dimer Interface. Located in close proximity to
the activation peptide (AP) and the dimer interface, FXIIIa fragments 240-247 and 248264 became more exposed to deuterium when compared to FXIII (Figure 52B). In
addition, acetylation of K113, K156, and K257 only occurred when FXIII was activated.
Several electrostatic and water mediated interactions are apparent between the AP
residues N18-A21 and main chain residues K156, D243, and R252. The crystal structures of
FXIII (1GGT) (119) and FXIIIaIIa (1FIE) (118) display the AP in similar conformations
except for one key stretch. The N-terminus of the zymogen (F8-P16) is extended away
from the dimer, while in FXIIIaIIa these same residues are depicted as resting on the
dimer’s surface (Figure 52C and D). Perhaps this emphasizes the importance of N18-A21
in anchoring the AP to FXIII through interactions with K156, D243, and R252.
Alkylation of the adjacent residues C238 and C327 occurred only with FXIIIaIIa
(Figure 52B). C238 is involved in main chain H-bonding with M242, adjacent to D243.
Cleavage of the activation peptide could conceivably weaken the aforementioned
electrostatic interactions involving residues within 240-264 and the activation peptide,
essentially perturbing the dynamics of this region. In fact, limited proteolysis of FXIIIaIIa
shows a large abundance of the fragment 9-31. As stated in the previous section, these
observations could signal FXIIIaIIa preparation for efficient interaction with the α chains
of fibrin. The FXIII mutations M242T, R252I, and G262E further highlight the structural
and functional importance for this stretch of catalytic core residues (271-273).
Intersubunit H-bonding among K113-D367′, K257-E401′, and R260-D404′ emphasize the
role these residues play in maintaining dimer integrity (Figure 7B and 52B). Acetylation
of K113 and K257 and the increased exposure of 248-264 insinuate an opening of the dimer
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space. Yee et al. predict a possible mode of the K substrate accessing the active site
through the opening of the dimer interface (119). Our results suggest activation of FXIII
weakens the interactions between residues at the dimer interface. These observations are
consistent with K-containing substrates accessing the active site from the dimer interface,
where, as previously suggested, the acyl acceptor is directed to the active site by residue
D343 and the H342/E434 diad (119). Three reported mutations resulting in congenital FXIII
deficiency, R260L, R260C, and R260H, signify the essential nature of the R260-D404′
interaction for proper FXIII functioning (274-277).
Cis-trans Isomerization Within the Catalytic Core and the Secondary IIa Cleavage
Site. NEM modification of C409 was severely impaired by the covalent linkage of K9
DON to C314 in FXIIIaCa and FXIIIaIIa (Figure 53B). Two non-prolyl cis bonds, Q425-F426
and R310-Y311, reside near C314 and C409. These unusual cis peptide bonds may possess
ample potential energy that FXIIIa could use to fuel catalysis and/or open access for
substrates within the active site (278). The Ahvazi group, through molecular modeling
studies on the related species tissue TGase 1 and 3, suggest that Ca2+ binding stabilizes
the non-prolyl cis bonds in preparation for catalysis and that Q substrate binding results
in the cis-trans isomerization (279, 280). C409 may no longer be available for alkylation
due to Q425-F426 isomerization, which resides about 6.5 Å from C409. Another explanation
could be that K9 DON interacts near or with C409. The distance from C314 to C409 is ~13
Å indicating that the 5 C-terminal residues (SLVIG) of K9 DON would have to exist in
an extended conformation (~20 Å in length) toward the dimer interface. This hypothesis
is supported by trNOESY data that suggest the K9 peptide and an α2-antiplasmin peptide
adopted extended conformations within the active site of FXIIIaIIa (137).
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Figure 53: Correlating results with X-ray structure of Factor XIII (II) (1FIE). A. β barrel 2:
the 5A2 binding epitope (red), the limited proteolysis fragment 681-698 (blue), W691-E692
(cyan), and C695 (red). B. Catalytic Core I: the activation peptide (cyan), D342/H343/E434
(blue), Y560 (light blue), C314/H373/D396 (red), C409 (yellow), and the non-prolyl cis bonds R310Y311 (red) and Q425-F426 (orange). C. β barrel 1: The HDX fragments 526-534/542-546
(green), 535-541 (red), and 513-522 (orange), K583/K584 (blue), K565/K621 (yellow), Y560 (light
blue), 561-564 (red), and the Ca2+ binding site (pink). D. Catalytic Core II: HDX fragment
220-230 (red), limited proteolysis fragment 207-214 (orange), and residues K199 (green), K221
(purple), K68 (red), T206 (yellow), Y204/R333 (yellow), and 466-472 (blue).

Another interesting observation was that K482 and K503 were not modified in K9
DON FXIIIaCa. K482 is located near the Ca2+ binding site and K503 resides on a fragment
leading to β barrel 1 near the FXIIIa secondary cleavage site (K513-S514). Unfortunately,
fragments resulting from tryptic proteolysis of K513-S514 rarely appeared in the mass
spectra after a thirty minute digest. Nevertheless, the acetylation results suggest that K9
DON inhibition may act in concert with Ca2+ binding to protect against further proteolysis
at the secondary cleavage site by IIa.
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FXIIIaIIa: the Peptide 7 Region and Catalytic Core. The fragment 220-230 within
the potential Q substrate recognition site known as peptide 7 (190-230) (145) experienced
similar levels of deuterium incorporation upon inhibition, as also seen with activation.
Furthermore, acetylation of both K221 and K199 only occurs in FXIIIa. Inhibition of
FXIIIa did not result in hindering the modification of these residues. These findings are
consistent with any of the following conclusions: residues 220-230, K199, and K221 are
not involved in substrate recognition, ten residues are not long enough to reach peptide 7,
and/or Q containing substrates do not lead to allosteric effects within these regions.
Unique to FXIIIaIIa was the increased proteolysis of the peptide 7 residues 207-214
by chymotrypsin and acetylation of K68 (Figure 53D). The distance from the K68 side
chain to the backbone carbonyl of L206 is 3.8 Å suggesting H-bond disruption concurrent
with IIa activation. A highly conserved loop amongst all TGases exists between residues
467-472 which appear to shield a portion of peptide 7. The previous observation that
K467 was acetylated upon activation (175) indicates a possible rearrangement of this loop.
Curiously, Fox et al. noticed a highly conserved water at a fork between two β
strands (117), which is situated within a pocket formed by the conserved residues Y204,
R333, T466, and K467. The same group also observed that the strand containing R333 runs
anti-parallel to the strand with H373 and that T466/K467 are downstream of A457 a Ca2+
binding site residue (117). This potential K467 loop repositioning could be associated
with the increased exposure of peptide 7 and proper orientation of residues involved in
catalysis. A study examining the consequences of TGase 1 mutations resulting in rare
skin disorders commented on the significance of an R395L (R333 in FXIII) mutant on
impairing TGase 1 activity (281). Also, the FXIII polymorphism Y204F leads to higher
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occurrences of recurrent miscarriage, probably due to conformational changes resulting
from the disruption of Y204-R333 H-bonding (282).
Ca2+ Concentration and FXIIIa Inhibition Affect Dynamics of β barrel 1. The
current HDX results confirm an earlier report of Ca2+ protecting the fragments 513-522
and 526-546 from deuterium exchange (174), however FXIIIaCa displayed significantly
more protection from solvent within this region than FXIIIaIIa.

Fragment 535-541

remained at similar deuterium levels compared to the zymogen, which enabled the
observed changes in dynamics to be localized to the two flanking loops, 526-534 and
542-546 (Figure 53C). The isotopic cluster for FXIII residues 526-546 exposed to 1 mM
Ca2+ appears to be an amalgam of the zymogen and FXIIIaCa (Figure 50). This isotopic
cluster possibly illustrates a concentration of Ca2+ where the cation binding site(s) is not
fully occupied. Analysis of these results could be interpreted to signify allostery within
the TGase. Ca2+ binding could potentially direct β barrel 1 to “roll away” from the
catalytic core to allow Q substrate access, as previously hypothesized (118).
Interestingly, the presence of K9 DON results in increased protection for 526-546
from solvent after ten minutes in both FXIIIaCa and FXIIIaIIa . Even residues 513-522,
though only in FXIIIaIIa, were slightly more protected in the presence of either K9 DON
or IAA. Both these inhibitors also blocked lysine acetylation of K621 in FXIIIaIIa. These
results suggest that Q substrate binding further stabilizes β barrel 1, perhaps restricting
access to additional Q substrates in preparation for covalent crosslinking to the acyl
acceptor.
Is the β barrel 2 the Location of a Lysine Containing Substrate Recognition Site?
Within β barrel 2, chemical modification studies have provided evidence for the C695
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exposure concurrent with activation (175). In the current work, only FXIIIaCa was
always alkylated at C695 regardless of inhibition, while FXIIIaIIa alkylation occurred when
K9 DON was present at the active site. The discrepancy in our results is likely due to the
amount of NEM used in our earlier report (200 mM versus 50 mM) (175). Further
supporting this finding was the limited proteolysis studies demonstrating that FXIIIaCa
resulted in increased chymotryptic proteolysis (chymotrypsin cleaves after W, F, and Y)
of W691-E692, which may be related to C695 exposure (Figure 53A).
As illustrated in Mitkevich et al., the antibody 5A2 that targets the FXIIIa epitope
646-658 displays uncompetitive inhibition toward the Q substrate and competitive
inhibition against the K substrate (146). In fact, 5A2 binding is enhanced when the acyl
donor binds to the active site (146).

The K9 DON FXIIIaIIa results suggest that the Q

substrate creates a more solvent accessible region within the β barrel 2, potentially
involved in K substrate recognition. This hypothesis is in line with competitive inhibition
of the acyl acceptor reaction when 5A2 binds to the FXIIIa epitope 646-658 (146).
Conclusions
The main objectives of this project were to demonstrate the applicability of DON
based peptides in FXIIIa inhibition and to explore perturbations associated with
activation and inhibition on FXIIIa dynamics.

For the first time, our chemical

modification and newly implemented limited proteolysis studies utilized the protease
chymotrypsin in addition to trypsin. These results corroborate and further augment
previous FXIII studies from our lab (174, 175).
New insight was obtained into the conformational variance amongst FXIIIaCa and
FXIIIaIIa. Chymotrypsin proteolysis supplied evidence of additional peptide 7 exposure
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resulting from IIa activation: the fragment 207-214 is cleaved more efficiently and K68 is
acetylated in FXIIIaIIa. Also with FXIIIaIIa, increased proteolysis of 9-31 and alkylation
of the nearby residues C238/C327 suggest unique events associated with activation peptide
cleavage. FXIIIaCa revealed amplification in proteolysis of the peptide bond L125-Q126
and suppression of nearby K129 acetylation. The β barrel 2 peptide bond W691-E692 and
C695 in FXIIIaCa were more solvent accessible than with FXIIIaIIa. These results perhaps
indicate allostery associated with Ca2+ binding or the presence of additional Ca2+ binding
sites within these domains. General activation of FXIII led to an increase in deuteration
for 240-268, as well as acetylation at K113, K156, and K257. These events could indicate
opening of the dimer interface for K substrate access to the active site.
With regard to FXIIIa inhibition, the results demonstrate that K9 DON is an
effective inhibitor of FXIIIaIIa.

Furthermore, the solution studies reveal potential

conformational features of FXIIIa trapped in the active state by K9 DON and IAA.
Specific to K9 DON inhibition was the cessation of C409 alkylation within the active site,
unique perturbations in HDX for 98-104 within the β sandwich of FXIIIaCa, increased
accessibility of C695 with FXIIIaIIa, and blocked K482/K503 acetylation in FXIIIaCa.
General inhibition resulted in FXIIIaIIa residue K621 no longer being available for
acetylation and β barrel 1 fragments 513-522 and 526-546 becoming more protected from
deuteration. These observations provide subtle glimpses into how substrate bound FXIIIa
prepares for the incoming lysine containing substrate. The current work focuses on the
consequences of interactions at the active site of FXIIIa. Future endeavors into FXIII
dynamics will examine larger more physiologically based substrates potentially evoking
greater conformational changes and further targeting of putative binding exosites.
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CHAPTER VII
RESEARCH SUMMARY AND FUTURE DIRECTIONS
The primary focus of this dissertation has been ligand-protein interactions. For the
research projects, two blood coagulation enzymes with very divergent catalytic activities
were studied to enhance understanding of the consequences of ligand binding on protein
dynamics. Chapters IV and V describe work performed on the serine protease thrombin
and peptide interactions at the anion binding exosites. The peptides represent binding
sites for thrombin found in fibrinogen and in the platelet receptor GpIbα. Thrombin
hydrolyzes peptide bonds, converting fibrinogen to fibrin and activating platelets.
Another substrate for thrombin is Factor XIII. Instead of catalyzing proteolysis, the
transglutaminase FXIIIa serves to crosslink adjacent proteins through the formation of a
covalent bond between a glutamine and lysine residue.

The studies in chapter VI

illustrate the effects of an irreversible peptide inhibitor on the conformational dynamics
of the transglutaminase.
Two types of instrumental approaches were employed as the primary methods for
examining ligand binding to proteins in these projects: nuclear magnetic resonance
(NMR) and matrix-assisted laser desorption-ionization mass spectrometry (MALDI-TOF
MS). In the studies with thrombin, NMR experiments described details regarding which
protons within the peptide interact with a protein and secondary structural elements the
peptide assumes when bound to protein. MALDI-TOF MS proved to be an indispensable
tool when investigating ligand binding from the perspective of thrombin and FXIIIa.
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Hydrogen deuterium exchange can yield information concerning sites of peptide-protein
interactions.

The technique can also probe the perturbations in the conformational

dynamics of a protein resulting from peptide binding to a site unaffiliated with the
binding interface.

Two methods that provide similar information as the HDX

experiments are differential chemical modification and limited proteolysis. These two
techniques elucidated some of the subtle conformational transitions resulting from the
activation and inhibition of FXIII.
The following sections in this chapter summarize the findings described in chapters
IV, V, and VI. In addition, some preliminary work with isothermal calorimetry (ITC) has
been performed to thermodynamically characterize the interactions of thrombin with the
GpIbα peptide. Based on these results and conclusions, new avenues will be discussed
for investigating ligand binding to thrombin and the mechanisms of FXIII activation and
substrate recognition.
γ′ Peptide (410-427) Binding to Thrombin
NMR and HDX coupled with MALDI-TOF MS were utilized to describe the
structural and conformational features associated with ligand binding to IIa anion binding
exosite-II (ABE-II) (167). In the absence of a crystal structure, the main impetus for
these investigations was to gain insight into the mode and consequences of γ′ peptide
interactions at ABE-II. Many observations discussed in chapter IV correlate extremely
well with the recently reported X-ray structure of the γ′ peptide bound to thrombin (242).
The research employed 1D and 2D NMR to characterize the structural features of
the bound γ′ peptide (410-427) and to evaluate the requirement of sulfonation for
effective thrombin interaction.

The results indicate the γ′ residues 414-427 make
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significant contact with thrombin; however, removing one phosphate from either tyrosine
lessens the amount of observed line broadening. Interestingly, the unphosphorylated
peptide does not show any 1D line broadening suggesting that at least one tyrosine must
be phosphorylated to bind thrombin. The 2D trNOESY spectra illustrate the presence of
a turn structure involving YP422-D425 and a trans configuration for the YP422-P423 that are
only evident when bound to thrombin. Once again, these structural elements require at
least one phosphotyrosine. Further evidence for the turn structure at the C-terminus of
the peptide is provided by the abundance of inter-residue long range NOEs,
predominately centered at the aromatic rings of both phosphotyrosines.
The NMR data (167) predict many of the features depicted in the solved X-ray
crystal structure (242). Only residues 413-426 were modeled in the X-ray structure,
supporting the NMR data suggesting that the first few N-terminal residues were not
necessary for interacting with thrombin. Finally, the two structural elements predicted
from the 2D trNOESY, the turn structure YP422-D425 and the trans YP422-P423 bond are
both present in the X-ray structure.
HDX coupled with MALDI-TOF MS was implemented to examine the location of
the γ′ peptide-thrombin interface and to screen for changes in solvent exposure at distant
sites. The HDX results indicate that residues within the thrombin fragments 85-99 and
173-181 interact with the γ′ peptide. The binding of the γ′ peptide also protects other
regions of thrombin from deuterium exchange. Affected regions include segments of
ABE-I, the autolysis loop, the W215/Na+ binding site fragment, and the A-chain. The
investigation also determined that thrombin forms a ternary complex with the γ′ peptide
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and the active site inhibitor PPACK.

This interaction generates an enzyme whose

solvent-exposed regions are even further stabilized from backbone amide HDX.
When comparing the data (167) to the reported crystal structure (242), the ABE-II
regions 85-99 and 173-181 that were predicted to engage with γ′ peptide contain two
residues (R93 and N179) that appear to bind the peptide. These observed interactions in the
X-ray structure serve to further expand the interpretations of the HDX data. The crystal
structure depicts electrostatic interactions involving R93T-S420γ′ and N179T-D419γ′.
Furthermore, the γ′ peptide appears to dimerize thrombin with many of the described
secondary features observed in the NMR data forming as a result of this dimerization. In
the X-ray structure, R93 of a symmetry related thrombin molecule interacts with two
residues in the γ′ peptide: D425 and D426. The N-terminus of the γ′ peptide fits into a
hydrophobic pocket formed by several thrombin residues, one of which is F181 and
several neighboring residues of the HDX protected fragment 173-181.
Another aspect of peptide interactions with thrombin’s ABE-II revealed by the
HDX studies concerns allostery connected to ligand binding. Quite a few residues that
participate in substrate binding are contained in the coverage from a peptic digest of
thrombin. In particular, residues L99, I174, and W215 are present in segments that are
significantly protected from deuterium incorporation after one minute. These results
support a connection from ABE-II to the active site that has been previously described
from kinetic studies (113). The reduced rate of HDX for residues at ABE-I advocates the
presence of an interexosite linkage. Similar conclusions were reached in HDX studies
with ABE-I ligand binding (172, 173) and fluorescent work (70, 170).
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GpIbα Peptide (269-286) Binding to Thrombin
Two crystal structures have been published illustrating the GpIbα-IIa interaction
(96, 97). Whereas the γ′ peptide-IIa interface has been localized to ABE-II, the binding
site for GpIbα is more ambiguous and may be at ABE-II or ABE-I. The C-terminal tail
of GpIbα (269-286) shares similar sequence elements with the γ′ peptide. Both GpIbα
X-ray structures (96, 97) display comparable ABE-II interactions for the C-terminal tail;
however, the Celikel structure (1OOK) shows the C-terminal tail dimerizing thrombin
through binding with ABE-I in a symmetry related thrombin molecule (97). Curiously,
the γ′ peptide-IIa structure (242) also illustrates ligand-induced dimerization of thrombin,
but in this instance the γ′ peptide binds to both thrombin molecules through ABE-II
interactions.
The research performed in chapter V further characterizes the features of peptide
binding to thrombin, building upon similar work in chapter IV on fibrin(ogen)’s γ′
peptide. Peptides were synthesized based on the C-terminal GpIbα residues 269-286.
Utilizing the same techniques as in chapter IV, perhaps the elements that distinguish γ′
peptide versus GpIbα peptide binding to thrombin can be discerned in more detail.
Furthermore, an additional study employed analytical ultracentrifugation to determine the
behavior of thrombin in the presence of both the GpIbα and γ′ peptides.
1D line broadening and 2D trNOESY NMR spectra indicate that GpIbα (269-286)
YP276YP278YP279 binds too tightly to thrombin for structural information to be obtained
from these techniques. Removing phosphorylation from Y278 weakens the interaction to
a certain extent and line broadening begins to be observed for the GpIbα YP276/YP279
peptide. The largest degree of line broadening and of NOEs in the 2D trNOESY appears
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with the unphosphorylated GpIbα peptide. The NMR results indicate that the N-terminal
residues 269-273 and the C-terminal residues 284-286 are not essential for binding
thrombin.

Furthermore, the GpIbα peptide interacts with thrombin in an extended

conformation, without significant secondary structural features.
As with the γ′ peptide, the NMR data compares very well to the X-ray structures.
The residues 269-273 in the two reported GpIbα crystal structures are in two different
conformations, which correlates to the lack of line broadening for these residues in the
1D spectra. Additionally, the extended conformation predicted by the 2D trNOESY data
is also evident for the C-terminal residues in both X-ray structures. Interestingly, the line
broadening observed for residues Y279-D283 and E285 may exist due to dimerization of
thrombin and peptide interactions with ABE-I. The NMR data compared with the crystal
structures of both GpIbα and the γ′ peptide indicate that these thrombin ligands possess
unique modes of binding to the serine protease.
For the HDX experiments, the GpIbα YP276YP278YP279 peptide was used because the
triply phosphorylated peptide binds tighter to thrombin. At a ratio of 20:1 peptide to
enzyme, the results compare well with the data from the γ′ peptide study, suggesting that
the GpIbα binds primarily to ABE-II.

More protection is observed for the ABE-I

residues 65-84, perhaps stemming from ABE-I interactions with dimerized thrombin.
Strikingly, after ten minutes of deuteration with the GpIbα peptide, the appearance of a
mixed isotopic cluster for ABE-II residues 85-99 is evident. Increasing the ratio of the
GpIbα peptide to thrombin (40:1) during the HDX experiment leads to ABE-II fragment
85-99 experiencing a drastic reduction in protection, while ABE-I residues are now
significantly protected from solvent. These results indicate that the GpIbα peptide is now
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binding exclusively to ABE-I. The new binding interface leads to different consequences
on the dynamics of HDX for other fragments observed in the HDX experiments when
compared to ABE-II binding.
The studies with analytical ultracentrifugation were performed to screen for
peptide-induced dimerization of thrombin. The concentration of IIa was kept between
4.5-7 µM to avoid saturation of the uv-vis absorbance. Both the GpIbα peptide and the γ′
peptide (4.5-140 µM) did not exhibit dimerization of thrombin at the concentrations
employed for the experiments. It should be noted that the NMR and HDX results were
performed at higher concentrations of protein (50-150 µM) and peptide (1-2 mM).
These studies suggest a concentration dependent binding scheme for the GpIbα and
IIa. This observation is not surprising given the low number of high affinity GpIbα
binding sites on platelets (105-1050) (101, 262) compared to the amount GpIbα present
on the surface of platelets (~25,000 copies) (263). In addition, low levels of IIa activate
platelets in a GpIbα dependent manner, while high levels of IIa can perform this task
without GpIbα (94, 264). One possibility could be that GpIbα binding to ABE-II serves
the function of activating platelets at the initiation of blood coagulation. After the burst
of IIa generation, GpIbα may no longer be needed to recruit IIa to the surface of platelets
to effectively interact with substrates like PAR-1. In the following sections, ongoing and
future studies are described to better understand the consequences of ligand binding to
ABE-II.
Preliminary Results from Isothermal Calorimetry of GpIbα Binding to Thrombin
Isothermal calorimetry (ITC) was performed to thermodynamically analyze the
GpIbα-IIa interaction. A significant advantage of this technique rests in the ability to
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directly measure ligand-protein interactions without the need for extraneous labeling,
such as fluorophores or chromophores (283). By titrating a ligand into a cell containing
an interacting partner, i.e. protein, heat will be either released to the environment or
absorbed from the surroundings (283, 284). The calorimeter measures the heat effect
upon binding, which can be used to calculate the dissociation constant (KD), the enthalpy
(ΔH) and the stoichiometry of interaction. The Gibbs free energy of an interaction
determines the binding affinity: ΔG = RT ln KD = ΔH - TΔS. For an optimal interaction,
ΔH must be negative and/or the entropy, ΔS, must be positive. Thus, these types of
experiments can provide insight into the thermodynamic driving force for the interaction.
When analyzing the results from ITC experiments, careful consideration must be
given to the interpretation of the thermodynamic parameters. Deviations in the value of
ΔH may not be directly correlated with changes in ΔG (284).

Enthalpy/entropy

compensation (285) is evident in a study of glycocalicin binding to thrombin (256).
Glycocalicin (140 kDa) is the extracellular fragment of GpIbα resulting from proteolysis
of the receptor near the cell membrane by a protease, such as calpain (286, 287). By
performing ITC on glycocalicin at a range of temperatures, the authors found that at
lower temperatures (4-10°C) the dominant driving force was entropic, while at higher
temperatures (20-37°C) the reverse was observed with enthalpy the major contributor to
binding (256). All the while, the ΔG remained relatively constant from -8.6 to -9.6
kcal/mol (256). The authors concluded that binding was favored due to the removal of
non-polar surface area from the solvent, termed the hydrophobic effect (288).
Another contribution to favorable ligand-protein interactions could be exclusively
entropic in nature. In the case of thrombomodulin binding to thrombin, the interaction
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has a favorable ΔG of -11.9 kcal/mol; however, ITC experiments demonstrated that ΔH
did not contribute to the favorable binding event (289). Thus, entropy was driving the
interaction, through an increase in protein mobility and/or the release of solvent
molecules from the binding interface. The authors found that 1H-15N HSQC NMR work
predicted a restriction in the configurational entropy once thrombomodulin bound to
thrombin (290). The increase in entropy was primarily assigned to the displacement of
water from the surface of the protein to the bulk solvent (289).
As mentioned previously, ITC has also characterized the interaction of glycocalicin
and IIa (256). The authors demonstrated that the favorable binding affinity results from
the burial of nonpolar surface area (256). The residues of GpIbα and glycocalicin
targeted by thrombin are located within the segment 269-286 (as discussed in Chapter V).
In an attempt to understand the thermodynamic contribution of residues 269-286 when
binding IIa, ITC was performed with the GpIbα (YP276YP278YP279) peptide and IIa.
The active site inhibitor PPACK was allowed to inhibit IIa for 30 min at a 2:1 ratio.
An assay involving the chromogenic substrate S2238 was employed to ensure that IIa
was inactive.

PPACK-IIa was then subjected to dialysis in 150mM NaCl, 25mM

phosphate, pH 7.4. The GpIbα peptide was lyophilized and reconstituted in the excess
buffer from dialysis. The ITC experiment attempted to characterize both the KD and ΔH,
with the GpIbα peptide at 450 µM and PPACK-IIa at 26.1 µM. PPACK-IIa was in the
cell and the peptide was titrated in as 5 µL aliquots every 5 minutes. The experiments
were carried out at 25°C in a VP-ITC from Microcal. The following controls were also
performed: buffer titrated into buffer, GpIbα peptide (450 µM) titrated into buffer, and
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buffer titrated into IIa (36.4 µM). The data was analyzed with the ORIGIN software
supplied by MicroCal.
The data from the first ITC experiment in Figure 54A shows that the GpIbα
(YP276YP278YP279) peptide binding saturated thrombin too quickly to accurately observe
the full sigmoidal titration curve. Thus, accurate modeling of the data by the program
Origin was not possible due to the absence of the initial plateau that represents the
enthalpy of binding. The experiment did indicate that GpIbα peptide binding to thrombin
was endothermic.

A

B

Figure 54: Isothermal calorimetry of the GpIbα peptide and thrombin. A. Top panel is the raw data
showing the measured heat change of GpIbα peptide titrated into IIa. Bottom panel is the integrated
heat of binding for GpIbα peptide-IIa without subtraction of the heat measured from the controls. B.
Top panel is the raw data from the “model free” ITC experiment with GpIbα peptide titrated into
thrombin. The bottom panel is the uncorrected integrated heat of binding for GpIbα peptide-IIa. The
experiments were conducted at 298 K in 150 mM NaCl, 25 mM H3PO4, pH 7.4.
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The second type of ITC experiment was performed in order to assess the enthalpy
of interaction in a “model free” manner where saturation of PPACK-IIa (30.1 µM) by the
GpIbα peptide (30 µM) is not achieved (291). In order to calculate the ΔH, the GpIbα
peptide was titrated into thrombin at much lower concentrations (Figure 54B), where
each injection yields an independent “model-free” measurement of the ΔH. The results
indicate that the average ΔH for the interaction is about +5.4 kcal/mol (291). The
controls measuring buffer into buffer and buffer into thrombin did not display any heat
evolution or absorption, discounting these possible contributors to the observed ΔH (data
not shown). The heat of dilution for the GpIbα peptide into IIa was around -0.5 kcal/mol,
thus ΔH for GpIbα peptide binding to IIa is closer to +4.9 kcal/mol (data not shown).
The data from the ITC experiments indicate that the binding of the triply
phosphorylated GpIbα peptide is endothermic with ΔH of +4.9 kcal/mol. Bothrojaracin
is a thrombin inhibitor found in snake venom that binds to both ABE-I and ABE-II (292).
ITC studies measuring the thermodynamics of bothrojaracin binding to ABE-I in
prothrombin described a positive value for the enthalpy (13.5 kcal/mol) (293). It should
be noted that ABE-II is not available in prothrombin due to binding by prothrombin
fragment II (169). The report concluded that the interaction was entropically driven, but
the reasons why were unclear. The authors suggested that either the release of water
from a non-polar binding interface or an increase in conformational mobility of
prothrombin leads to the observed positive enthalpy (293).
Both of these proposals from the bothrojaracin work seem to be unlikely
explanations for the GpIbα peptide studies (293). First, the electrostatic nature of the
glycocalicin interaction with thrombin was measured by Li et al. giving a Γsalt = -4.2 (68).
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In addition, the GpIbα peptide is highly anionic and, as demonstrated by the crystal
structures, interacts with a complementary cationic binding exosite on the IIa surface (96,
97). Thus, these observations seem to indicate that the GpIbα peptide is not releasing
water from a non-polar binding interface. Second, the HDX results at 20:1 GpIbα to
thrombin indicate that the protein is quite protected from HDX when compared to
thrombin alone (chapter V). These results suggest a restriction of the conformational
ensembles sampled by IIa and a restriction of protein mobility, at least for the regions of
HDX coverage.
Curiously, the ΔH of glycocalicin binding to IIa at 25 °C was found to be -11.10
kcal/mol (256).

At the present time, the discrepancy between the thermodynamic

behavior of glycocalicin and the GpIbα peptide is unknown. A possible explanation may
be that the GpIbα peptide, at the concentrations employed for ITC, dimerizes thrombin.
This dimerization is observed in the Celikel crystal structure and may result in the burial
of solvent accessible non-polar residues at the thrombin dimer interface (97).
Future ITC work will endeavor to further characterize the GpIbα peptide-IIa
interaction thermodynamically. The data from Figure 54 suggests that the top and bottom
of the sigmoidal binding isotherm has been observed during the course of the two
experiments. By using the concentrations employed in these experiments, perhaps an
experiment can be designed to generate the whole binding isotherm. If successful, these
experiments could yield more detailed thermodynamic information, such as the
stoichiometry of binding and the binding affinity.

In addition, performing ITC

experiments with the γ′ peptide could provide important clues as to whether the positive
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enthalpies associated with the GpIbα peptide are a general feature of ABE-II association
and possible dimerization of thrombin.
Future Directions for the Study of Ligand Binding to Thrombin
As with any endeavor, important discoveries and insights regarding the system
under study generate more paths for investigation. In this section, new NMR, HDX, and
AUC experiments will be suggested to help further elucidate the effects of ligand binding
to thrombin. More than likely, these potential studies will lead to even more questions to
be addressed in the future.
An unresolved issue from chapters IV and V (and further probed in the new ITC
data of this chapter) has been whether the GpIbα or γ′ peptides dimerize thrombin. The
crystal structures of these ligands bound to IIa display dimerization through a symmetry
related thrombin molecule.

In addition, the NMR data appear to require thrombin

dimerization in order to explain the observed effects. Unfortunately, peptide induced
dimerization has not been independently confirmed by another solution-based method.
An NMR technique was developed in 1965 to measure the diffusion constants,
termed NMR pulsed field-gradient (PFG) spin-echo technique (294).

Briefly, as

discussed by Stejskal and Tanner (294), during a 1D NMR spin-echo experiment, two
additional gradient pulses are applied that surround the 180° spin echo pulse. The first
pulse dephases the transverse magnetization along the z-axis and the second pulse
rephases the magnetization. While the nuclear spins are dephased, the molecules will
diffuse along the z-axis. The speed of diffusion will determine the degree of attenuation
required to refocus the resonances once the second pulse rephases the magnetization.
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Translational self-diffusion is related to measurable NMR parameters as described by
Stejskal and Tanner (294).
The method has been used to distinguish between RNA in a duplex or RNA
forming a hairpin turn and thus monomeric (295). Also, the aggregation state of the
protein myosin light chain 2 has been determined employing this technique (296). By
comparing the diffusion of an NMR sample of IIa alone with IIa in the presence of both
peptides, the pulsed field-gradient (PFG) spin-echo technique (294) could help determine
if peptide induced IIa dimerization is occurring in the NMR tube.
Another

method

for

determining

thrombin

dimerization

is

analytical

ultracentrifugation. AUC experiments were described in chapter V at significantly lower
thrombin concentrations than required for NMR and crystallization. A less accurate
AUC experiment could utilize the absorbance of proteins at 300-310 nm, where
saturation of the signal at 280 nm can be avoided when analyzing high concentrations of
protein. In this case, an AUC experiment can be performed at 150 µM IIa just for the
express purpose of determining if two macromolecular species are dimerizing in solution.
Concerning the work with HDX, the leech derived inhibitor hirudin is known to
bind to ABE-I of thrombin with a tight affinity. The 40:1 HDX results with GpIbα
suggest that the peptide is binding presumably at ABE-I. By performing HDX with a
peptide that targets ABE-I, perhaps the results from studies with hirudin will mirror the
results with GpIbα at 40:1, further supporting the concept of ABE-I binding. At the same
time, the allosteric consequences of ligand binding to ABE-I can also be observed and
compared to work performed with fragments of the ABE-I binding protein
thrombomodulin. The HDX results in chapter V imply that simultaneous occupation of
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both ABE-II and ABE-I by the GpIbα peptide is not possible.

Negative allostery

between the two exosites is supported by fluorescent work (70, 170). Thus, an HDX
experiment could be designed at lower GpIbα peptide concentrations (i.e. 20:1) in the
presence of hirudin to observe whether protection is observed at both exosites.
An additional HDX experiment would study full-length protein-thrombin
interactions. The peptides GpIbα and γ′ are derived from the larger parent proteins. By
attaching fibrinogen with the γ′ chain or GpIbα (1-290) to an agarose bead, HDX can be
performed to examine the effects on thrombin dynamics resulting from protein-protein
binding. An E.coli expression system has been recently developed for the γ′ chain
residues 148-427 (297).

As for GpIbα, residues 1-290 have been expressed in D.

melanogaster (97) and residues 1-288 have been expressed in Chinese hamster ovary
cells (96). Glycocalicin, the extracellular portion of GpIbα, could also be studied by
using a protease to cleave GpIbα at the platelet surface and then the extracellular portion
could be purified (287, 298).
For fibrinogen, the HDX projects could examine the effects of the whole fibrinogen
γ′ homodimer (AαBβγ′)2 versus the heterodimer (Aα)2(Bβ)2(γAγ′). Within the HDX
protocol, one more step would be added to separate the thrombin from the protein
attached to the agarose bead, perhaps involving an acidic quench (0.1% TFA) in a solvent
of lower polarity (i.e. propanol) to disrupt the interaction (299). This would be followed
by centrifugation, then peptic digestion. Finally, the binding could be studied from the
perspective of GpIbα (1-290), with IIa attached to the bead. Both of these proteins are of
similar length. In this case, the fragments from a peptic digest of GpIbα would have to
be identified by PSD and carboxypeptidase Y sequencing.
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HDX work has been

performed with a similar leucine rich repeat protein IκBα, which is involved in
transcriptional regulation of NF-κB (300).
FXIII Activation and Inhibition Studies
Another important substrate for thrombin is the transglutaminase Factor XIII. To
date, crystallography has been unable to accurately model the conformational transition
that occurs once FXIII is activated by thrombin (117-119). Therefore, solution based
techniques have been performed to characterize some of the subtle changes in FXIII
dynamics that results from activation. MALDI-TOF MS was utilized to observe the
effects of activation and inhibition on FXIII dynamics through HDX, differential
chemical modification, and limited proteolysis (178).
The work described in chapter VI further builds upon research performed by Brian
T. Turner, Jr. (174, 175) by increasing FXIII sequence coverage with the protease
chymotrypsin and by binding the irreversible peptide inhibitor K9 DON to the active site.
Previous HDX experiments demonstrated that FXIII activation protects regions within
the β sandwich (98-104) and the β barrel 1 (526-546) from deuterium, while exposing the
potential Q substrate recognition site (220-230) to deuteration (174).

Differential

chemical modification indicated the availability of several residues upon activation
including K73, K221, C314, and C409 (175). These initial forays into FXIII dynamics
supported the notion that conformational changes occur after FXIII activation that are
currently undetected in the crystal structures of the transglutaminase (117-119).
In the current work (178), activations of FXIII by thrombin and calcium were
further examined. New findings unique to FXIIIaIIa (thrombin activated FXIII) included
additional evidence for the exposure of peptide 7 with the acetylation of K68 and
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increased proteolysis of 207-214. Peptide 7 is hypothesized to be a potential substrate
recognition site accessible after FXIII activation (145).

Thrombin cleavage of the

activation peptide exposed resides C238 and C327 to alkylation by NEM, as well as
enhanced proteolysis of 9-31. By contrast, FXIIIaCa (calcium activated FXIII) led to
increased proteolysis of the β sandwich fragments 75-83 and 104-125 and a loss of K129
acetylation. In addition, several residues within the β barrel 2 were more solvent exposed
in FXIIIaCa including the peptide bond W691-E692 and C695. These observations may be
connected to the allosteric transmission of calcium binding at undiscovered sites
proposed by two independent groups (131, 132). Finally, activating FXIII with either
thrombin or calcium appeared to increase access within the dimer interface, as evidenced
by the enhancement of deuterium incorporation for residues 240-268 and acetylation of
K113, K156, and K257.
The investigation also examined FXIIIa inhibition by the K9 DON peptide (with the
glutamine isostere 6-diazo-5-oxo-norleucine) compared with the nonspecific alkylating
agent iodoacetamide (IAA).

The results illustrate, for the first time, irreversible

inhibition of FXIIIa with a peptide-derived inhibitor. K9 DON prevented alkylation of
C409 within the catalytic core perhaps a result of the inhibitor interacting near this residue
within the active site. Other observations related to K9 DON inhibition may signal
preparation for the incoming lysine containing substrate, including alkylation of C695 in
FXIIIaIIa and the cessation of K482-K503 acetylation in FXIIIaCa. Both inhibitors promoted
even greater protection from deuteration for the β sandwich (98-104) and the β barrel 1
(513-522 and 526-546).

The solution-based approaches reveal that activation and

inhibition lead to local and long range perturbations in the conformational dynamics of

166

the transglutaminase. Important glimpses are being provided on FXIIIa allostery and the
presence of putative FXIIIa exosites.
Future Research for the Study of FXIII Activation and Substrate Recognition
The development of a peptide-based inhibitor of FXIIIa has created new
possibilities for studying the conversion of FXIII to FXIIIa. The glutamine isostere 6diazo-5-oxo-norleucine may be incorporated into a better peptide substrate for FXIIIa α2antiplasmin (1-15) (137). Since the reactive glutamine is at position 2 in this 15-residue
peptide, inhibition of FXIIIa with α2-antiplasmin (1-15) DON will allow the C-terminal
13 residues to interact with a larger interface within the catalytic core than the four Cterminal residues of the K9 DON peptide. Similar HDX and chemical modification
experiments as described in chapter VI could be performed to assess the effects of a
different inhibitor on the dynamics of FXIIIa. Crystallization of DON peptide inhibited
FXIIIa should also be attempted. As has been already hypothesized, the binding of an
inhibitor to FXIIIa could favor crystallization of the transglutaminase in the active state,
revealing aspects of the FXIIIa conformation previously unobserved.
Non-proteolytic activation of FXIII by metals is another area that lends itself to
further exploration. An investigation could be conducted examining the activity of FXIII
in high concentrations (~50 mM) of divalent metals such as Mg2+, Mn2+, and Sr2+. A
question to be addressed is whether these metals can activate FXIII without the presence
of calcium, in the presence of 1 mM calcium (where the known Ca2+ binding site is
occupied), or substitute for 1 mM Ca2+ in thrombin activated FXIII. Since the secondary
reporter reactions typically used to study FXIIIa involve glutamate dehydrogenase, the
presence of a variety of metals may interfere with the catalytic activity of the reporter
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enzyme. A new fluorometric assay has been recently developed to study the kinetics of
the second part of the FXIII crosslinking reaction (lysine crosslinking to glutamine)
(301). The reported method may be better suited to study the effects of divalent metals
on FXIIIa activity since it does not rely on a secondary reporter enzyme (301).
Another aspect of FXIII that could be investigated by HDX and chemical
modification is the interaction of the regulatory B-subunits of plasma FXIII with the Asubunits and with the fibrinogen γ′ peptide. Research has shown that the B subunits of
plasma FXIII binds to the γ′ chain of fibrinogen (116). In addition, the binding interface
for the B dimer has not been identified on the A dimer. The catalytic A-subunits could
also be attached to agarose beads and HDX performed to study the effects of B-subunit
binding to the A-subunits. As with GpIbα (1-290), the fragments from a peptic digest of
the B subunits would have to be identified with PSD and carboxypeptidase Y sequencing.
Final Thoughts on the Investigations into Blood Coagulation Protein Interactions
The projects described in the preceding chapters have delved into further
understanding the dynamics of ligand-protein interactions. The binding of two peptides
with very similar sequences to thrombin leads to conformational differences in peptide
structure and affects thrombin dynamics in subtly unique ways.

Important insight

regarding FXIIIa substrate recognition and activation has been reported with the advent
of a peptide with a moiety that irreversibly inhibits FXIIIa. In the future, the specific
details of these peptide interactions could perhaps be exploited to develop drugs that
specifically target thrombin or Factor XIIIa in treatments for stroke, wound healing, and
coronary artery disease.
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APPENDIX A CHEMICAL SHIFT TABLES
(All Samples in Aqueous Solution and Referenced to EDTA)
Table A: 1H Resonance Assignments (ppm) of the γ′peptide (YP418 YP422) at 15°C.
Residue
P410
E411
H412
P413
A414
E415
T416
E417
YP418
D419
S420
L421
YP422
P423
E424
D425
D426
L427

NH
8.86
8.64
8.61
8.57
8.18
8.49
8.26
8.35
8.28
8.29
8.26
8.72, 8.65
8.38
8.36
7.80

CαH
4.40
4.25
5.00
4.43
4.31
4.35
4.33
4.28
4.59
4.60
4.36
4.25
?
4.42
4.31
4.63
4.67
4.17

CβH
2.45
1.95, 1.88
3.22, 3.13
2.32
1.43
2.11, 1.99
4.17
1.96, 1.86
3.13, 2.94
2.70, 2.60
3.84, 3.79
1.52
3.13, 2.86
2.29
2.10, 1.96
2.71, 2.64
2.76, 2.62
1.62

CγH
2.07, 2.01
2.26, 2.20
2.02, 1.98

CδH
3.42, 3.39

CεH

7.31
3.76, 3.58

2.32
1.13
2.20, 2.15

1.38
2.03, 1.99
2.36
1.58

7.19

7.14

0.88, 0.81
7.23
3.72, 3.62

7.13

0.92, 0.86

Table B: 1H Resonance Assignments (ppm) of the γ′peptide (YP418 YP422) bound to IIa at 15°C. The
assignments for this peptide bound to γ-IIa are not significantly different.
Residue
P410
E411
H412
P413
A414
E415
T416
E417
YP418
D419
S420
L421
YP422
P423
E424
D425
D426
L427

NH
8.86
8.66
8.61
8.57
8.19
8.49
8.25
8.36
8.26
8.29
8.26
8.73, 8.70
8.35
8.34
7.79

CαH
4.40
4.25
4.99
4.43
4.32
4.34
4.32
4.28
4.60
4.59
4.35
4.28
4.86
4.42
4.32
4.63
4.67
4.17

CβH
2.45
1.96, 1.88
3.23, 3.13
2.31
1.42
2.11, 1.98
4.17
1.96, 1.86
3.14, 2.93
2.70, 2.61
3.83, 3.79
1.52
3.14, 2.85
2.29
2.11, 1.97
2.71, 2.65
2.76, 2.61
1.64
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CγH
2.07, 2.00
2.25, 2.20
2.02, 1.98

CδH
3.42, 3.38

CεH

7.31
3.76, 3.58

2.32
1.13
2.21, 2.13

1.38
2.03, 1.99
2.35
1.57

7.18

7.08

0.88, 0.81
7.23
3.72, 3.62

7.11

0.91, 0.86

Table C:

1

H Resonance Assignments (ppm) of the γ′peptide (YP418) at 15°C.

Residue
P410
E411
H412
P413
A414
E415
T416
E417
YP418
D419
S420
L421
Y422
P423
E424
D425
D426
L427

NH
8.86
8.64
8.61
8.57
8.19
8.50
8.27
8.34
8.21
8.20
8.18
8.61
8.36
8.34
7.79

CαH
4.40
4.25
5.02
4.43
4.31
4.35
4.33
4.28
4.59
4.60
4.36
4.24
4.86
4.42
4.31
4.63
4.66
4.16

CβH
2.47
1.97, 1.88
3.23, 3.13
2.34
1.43
2.12
4.17
1.99, 1.88
3.13, 2.96
2.70, 2.60
3.84, 3.79
1.48
3.08, 2.83
2.28
2.12, 1.96
2.74, 2.65
2.76, 2.61
1.57

CγH
2.10, 2.03
2.24, 2.18
2.02

CδH
3.43, 3.39

CεH

7.30
3.76, 3.57

2.32, 2.00
1.14
2.20, 2.15

1.31
2.00
2.36
1.63, 1.60

7.18

7.11

0.87, 0.79
7.15
3.69, 3.57

6.82

0.92, 0.86

Table D: 1H Resonance Assignments (ppm) of the γ′peptide (YP418) bound to IIa at 15°C.
Residue
P410
E411
H412
P413
A414
E415
T416
E417
YP418
D419
S420
L421
Y422
P423
E424
D425
D426
L427

NH
8.86
8.66
8.61
8.58
8.20
8.50
8.25
8.34
8.21
8.20
8.19
8.63
8.35
8.33
7.79

CαH
4.40
4.25
4.99
4.43
4.33
4.36
4.36
4.29
4.60
4.60
4.36
4.24
4.86
4.42
4.31
4.64
4.68
4.17

CβH
2.45
1.96, 1.89
3.22, 3.13
2.32
1.43
2.11, 1.99
4.17
1.97, 1.87
3.13, 2.95
2.70, 2.62
3.85, 3.79
1.47
3.09, 2.81
2.28
2.10, 1.96
2.72, 2.67
2.75, 2.62
1.62
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CγH
2.08, 2.03
2.21, 2.26
2.03, 1.99

CδH
3.42, 3.38

CεH

7.30
3.77, 3.58

2.32
1.14
2.21, 2.14

1.32
2.01, 1.98
2.36
1.57

7.18

7.09

0.87, 0.79
7.14
3.69, 3.57

6.80

0.92, 0.86

Table E: 1H Resonance Assignments (ppm) of the γ′peptide (YP422) at 15°C.
Residue
P410
E411
H412
P413
A414
E415
T416
E417
Y418
D419
S420
L421
YP422
P423
E424
D425
D426
L427

NH
8.85
8.65
8.61
8.57
8.18
8.47
8.21
8.32
8.17
8.20
8.18
8.64
8.38
8.36
7.80

CαH
4.40
4.25
5.01
4.43
4.31
4.36
4.32
4.28
4.56
4.59
4.34
4.23
4.85
4.42
4.32
4.63
4.66
4.18

CβH
2.45
1.96, 1.88
3.24, 3.14
2.32
1.43
2.11, 1.99
4.16
1.96, 1.87
3.09, 2.92
2.71, 2.62
3.85, 3.79
1.51
3.13, 2.84
2.27
2.10, 1.96
2.74, 2.66
2.77, 2.63
1.64

CγH
2.07, 2.00
2.25, 2.20
2.02, 1.95

CδH
3.42, 3.39

CεH

7.32
3.76, 3.58

2.33
1.13
2.20, 2.15

1.34
2.01, 1.96
2.36
1.57

7.11

6.82

0.87, 0.80
7.21
3.67, 3.59

7.12

0.91, 0.87

Table F: 1H Resonance Assignments (ppm) of the γ′peptide (YP422) bound to IIa at 15°C.
Residue
P410
E411
H412
P413
A414
E415
T416
E417
Y418
D419
S420
L421
YP422
P423
E424
D425
D426
L427

NH
8.86
8.66
8.61
8.57
8.20
8.47
8.20
8.30
8.20
8.22
8.15
8.68
8.36
8.33
7.80

CαH
4.40
4.25
5.00
4.43
4.32
4.35
4.33
4.26
4.58
4.58
4.32
4.21
4.86
4.42
4.31
4.64
4.68
4.18

CβH
2.45
1.95, 1.88
3.23, 3.14
2.32
1.42
2.11, 1.98
4.18
1.97, 1.88
3.08, 2.90
2.72, 2.62
3.84, 3.79
1.50
3.12, 2.82
2.27
2.11, 1.96
2.73, 2.67
2.75, 2.61
1.64
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CγH
2.08, 2.00
2.24, 2.19
2.02, 1.95

CδH
3.43, 3.39

CεH

7.32
3.76, 3.58

2.32
1.14
2.19, 2.13

1.31
2.01, 1.95
2.36
1.59

7.11

6.78

0.84, 0.74
7.20
3.68, 3.61

7.11

0.90, 0.86

Table G: 1H Resonance Assignments (ppm) of the γ′peptide (No Phosphorylation) at 17°C. In the
presence of IIa, the peptide does not experience significant deviations in chemical shift.
Residue
P410
E411
H412
P413
A414
E415
T416
E417
Y418
D419
S420
L421
YP422
P423
E424
D425
D426
L427

NH
8.84
8.64
8.60
8.55
8.19
8.46
8.19
8.30
8.15
8.15
8.10
8.59
8.32
8.32
7.78

CαH
4.41
4.25
5.00
4.42
4.32
4.34
4.31
4.26
4.53
4.57
4.34
4.19
?
4.42
4.28
4.62
4.66
4.15

CβH
2.46
1.94, 1.88
3.23, 3.13
2.32
1.42
2.08, 1.98
4.16
1.96, 1.87
3.08, 2.92
2.68, 2.61
3.85, 3.80
1.45
3.07, 2.81
2.26
2.08, 1.94
2.70, 2.64
2.74, 2.60
1.61

CγH
2.08, 2.00
2.25, 2.19
2.02, 1.95

CδH
3.42, 3.39

CεH

7.32
3.74, 3.57

2.31
1.13
2.19, 2.14

1.27
2.00, 1.97
2.33
1.58

7.13

6.81

0.87, 0.78
7.14
3.65, 3.55

6.81

0.91, 0.86

Table H: 1H Resonance Assignments (ppm) of the GpIbα peptide (YP276 YP279) bound to IIa at 17°C.
Residue
D269
E270
G271
D272
T273
D274
L275
YP276
D277
Y278
YP279
P280
E281
E282
D283
T284
E285
G286

NH
?
8.95
8.67
8.14
8.22
8.44
8.13
8.14
8.23
7.97
8.20
8.56
8.49
8.55
8.22
8.46
8.11

CαH
?
4.27
4.03, 3.96
4.69
4.27
4.61
4.25
4.50
4.55
4.49
4.75
4.34
4.29
4.31
4.72
4.37
4.36
3.78

CβH
?
2.30
2.75, 2.73
4.24
2.71, 2.63
1.52
2.99, 2.89
2.60, 2.54
2.86
3.05, 2.83
2.26
2.35
2.29
2.79, 2.66
4.29
2.31
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CγH

CδH

CεH

0.87, 0.80
7.19

7.11

2.06, 1.99
1.17
1.44

1.95
2.07, 1.97
2.05, 1.95
1.22
2.13, 1.98

7.06
7.20
3.47

6.78
7.18

Table I: 1H Resonance Assignments (ppm) of the GpIbα peptide (No Phosphorylation) at 17°C.
Residue
D269
E270
G271
D272
T273
D274
L275
Y276
D277
Y278
Y279
P280
E281
E282
D283
T284
E285
G286

Table I:
17°C.

1

NH
?
8.94
8.65
8.13
8.21
8.39
8.04
8.05
8.15
7.82
8.09
8.48
8.44
8.51
8.20
8.44
8.08

CαH
?
4.28
4.02, 3.96
4.68
4.30
4.60
4.25
4.52
4.54
4.47
4.72
4.32
4.27
4.31
4.72
4.37
4.36
3.77

CβH
?
2.31
2.75, 2.73
4.25
2.67, 2.64
1.47
3.00, 2.83
2.57, 2.53
2.88, 2.81
3.00, 2.77
2.25
2.34
2.28
2.79, 2.66
4.28
2.30

CγH

CδH

CεH

0.87, 0.78
?

?

2.07, 1.98
1.20
1.40

1.94
2.07, 1.95
2.06, 1.93

?
?
3.48, 3.43

?
?

1.21
2.11, 1.97

H Resonance Assignments (ppm) of the GpIbα peptide (No Phosphorylation) bound to IIa at

Residue
D269
E270
G271
D272
T273
D274
L275
Y276
D277
Y278
Y279
P280
E281
E282
D283
T284
E285
G286

NH
?
8.94
8.64
8.13
8.19
8.39
8.01
8.01
8.15
7.82
8.02
8.47
8.42
8.48
8.17
8.38
8.07

CαH
?
4.28
4.04, 3.96
4.68
4.30
4.60
4.25
4.52
4.54
4.47
4.72
4.32
4.27
4.31
4.72
4.37
4.36
3.77

CβH
?
2.31
2.75, 2.73
4.25
2.67, 2.64
1.47
3.00, 2.83
2.57, 2.53
2.88, 2.81
3.00, 2.77
2.25
2.34
2.28
2.79, 2.66
4.28
2.30
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CγH

CδH

CεH

0.87, 0.78
7.04

6.77

2.07, 1.98
1.20
1.40

1.94
2.07, 1.95
2.06, 1.93
1.21
2.11, 1.97

7.02
7.09
3.48, 3.43

6.77
6.79

APPENDIX B INTER-RESIDUE NOE TABLE

Table J: Inter-residue NOEs for the γ′peptide (YP418YP422) bound to IIa at a mixing time of 400ms + 15°C.

Residue Proton
P410
CαH
NH
CαH
E411
CβH
NH
CαH
412
H
CβH
CδH
CαH
413
P
CγH
CδH
NH
CαH
A414
CβH
NH
415
β
C
H
E
γ
CH
NH
CαH
416
T
CβH
CγH
NH
CαH
417
E
CβH
CγH
NH
CβH
YP418
CδH
NH
D419
CβH
NH
CαH
S420
CβH
NH
CαH
L421
CβH
CγH
CδH
NH
YP422

NH
E411
412

CαH

Inter-Residue NOE
CβH
CγH

CδH

CεH

P410

H
H412
E411 P413

E411

P413
P413
P413
P413

A414
H412 A414 E415
A414
H412A414
E415
E415
T416
414 416
A T
A414 T416
E415 E417
E417
E417
417
E YP418
T416 YP418
YP418
YP418
YP418
417 419
E D
D419
D419
YP418
S420

A414
H412
P413

H412
H E415

P413
P A414

E415
A414
A414
A414
E415

E415

E415
T416
YP418

E415
T416

E417

T416 E417

E417 D419
YP418

T416 E417

413

416

T

E417
E417
416 417
T E

L421 D425

CδH

L421

CεH

L421

415

E

T416
T416
E415

421

L
L421

CβH

P

413

D419
L YP422

421

YP422

412

S420

YP418
YP418
YP418
YP418
YP418

L421
YP418
YP418
L421 YP422
YP422
YP422
YP422
YP422
YP422
418
YP YP422

S420 YP422

S420
S420
L421
420 423
S P
E424
420 421
S L
P423 D425
S420 L421
P423 D425

H412
P413

P423

P423

S420 L421
E424

L421 P423
E424

L421 P423

S420 L421

L421

L421 P423
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YP422
YP422
YP422
YP422
YP422
YP422
YP422

Table J: Inter-residue NOEs for the γ′peptide (YP418YP422) bound to IIa at a mixing time of 400ms + 15°C
(continued).
Inter-Residue NOE
Residue Proton

P423

424

E

D425

CαH
CβH
CγH
CδH
NH

NH

D

425

CH

D

425

CβH
CγH

D425
D425

P423

NH

E424

P423 E424

α

CβH

E424 D425
E424 D425

CH
CβH
NH

L427

D426

CαH

L427

427

CH
NH
CβH
CγH
CδH

427

P

423

Cγ
H

CδH

CεH

YP422 E424

YP422

YP422

YP422
YP422
P423

YP422
YP422

YP422

YP422D425L427

YP422 P423 E424

L42
7

E42

YP422
YP422
YP422

424

E

L
D426

L427

4

α

β

L

CαH

L427
D426
E D426
E424D426
E424

D426

424
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L42
7

YP422

Table K: Inter-residue NOEs for the γ′peptide (YP418) bound to IIa at a mixing time of 400ms + 15°C.

Residue Proton
P410
CαH
NH
CαH
E411
CβH
NH
α
C
H
H412
CβH
CδH
CαH
P413
CδH
NH
CαH
A414
CβH
NH
CβH
E415
CγH
NH
α
C
H
T416
CβH
CγH
NH
CαH
417
E
CβH
CγH
NH
CβH
YP418
CδH

D

419

S420

L421

Y

422

NH
E411
412

Inter-Residue NOE
CβH
CγH

CαH

CδH

CεH

P410

H
H412
E411 P413

E411

P413
P413
P413
P413

A414
H412A414 E415
H412A414
E415
E415
T416
T416
T416
415 417
E E
E417
E417
E415E417YP418
T416 YP418
YP418
YP418
YP418
417 419
E D
D419 S420

H
P413

A414
H412
H412

P413
P413 A414

A414

T416

E415

E415

T416

T416
YP418

T416

E417
E417

E417

T416 E417

T416E417 D419
S420
416 420
T S
YP418

T416 E417
L421

412

E417 D419 L421

T416 E417

CεH
NH
CαH
CβH
NH
CαH

D419
YP418 S420
S420
S420
D419

T416E417

CβH

L421

D

419

YP418D419
421
L

NH
CαH
CβH
CγH
CδH
NH
CβH

E424D425

CδH

L421 E424 D425

CεH

L421 D425

Y

H412
P413

YP418
YP418
YP418
YP418
YP418
YP418
YP418

YP418

206

S420 L421
P423E424
S420 L421

YP418

YP418
L421

S420
S420 Y422
S420
S420
L421
421 423
L P
S420L421
P423E424D425
S420L421E424

YP418

L421

L421 Y422
YP418Y422

422

YP418
YP418

YP418Y422
Y422
Y422
418 422
YP Y
YP418 Y422
P423
P423
L421 P423

L421 P423

L421

L421 P423

Y422
YP418
Y422
Y422
Y422
Y422
Y422
Y422

Table K: Inter-residue NOEs for the γ′peptide (YP418) bound to IIa at a mixing time of 400ms + 15°C
(continued).
Residue Proton
CαH
CβH
P423
CγH
CδH
NH
CαH
424
E
CβH
CγH
NH
D425
CβH
NH
CαH
D426
CβH
NH
β
C
H
L427
CγH
CδH

NH
E424 D425
E424 D425
E424Y422
D425
D425
D425
D425
E424
L427
L427
L427
L427
D426

CαH

P

423

P

423

P423 E424
E424

Inter-Residue NOE
CβH
CγH
422 424
Y E

Y422
Y P423
D425L427

L427

Y422 P423 E424

E424

L427

L427

422

D426
E D426
E424D426
E424

D425D426

424
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CδH
Y422
Y422
Y422
Y422
422 423
Y P
Y422L427
Y422
Y422
Y422

CεH

Y422

Y422

Table L: Inter-residue NOEs for the γ′peptide (YP422) bound to IIa at a mixing time of 400ms + 15°C.

Residue Proton
P410
CαH
NH
CαH
E411
CβH
NH
CαH
412
H
CβH
CδH
CαH
413
P
CγH
CδH
NH
CαH
A414
CβH
NH
415
β
C
H
E
γ
CH
NH
CαH
416
T
CβH
CγH
NH
CαH
417
E
CβH
CγH
NH
β
C
H
Y418
δ
CH
CεH
NH
CαH
D419
CβH
NH
CαH
S420
CβH
NH
CαH
CβH
L421
CγH

NH
E411
412

YP422

Inter-Residue NOE
CβH
CγH

CδH

CεH

P410

H
H412
E411 P413

E411

P413
P413
P413
P413

A414
H412 A414 E415
A414
H412A414
E415
E415
T416
414 416
A T
A414 T416
E415 E417
E417
E417
415 417
E E
T416
Y418
Y418
Y418
D419
D419
417 419
E D
D419
Y418
S420
S420

A414
H412
P413

H412
H E415
412

P413
P A414
413

A

414

A414
E415

P

413

415

E

E415
T416
T416
T416
E415

E417
T416

E415
T416

E415
T416
T416

E417

E417

E417

T416 E417
T416 E417

E417 D419
E417
Y418

T416 E417
T416 E417

419

D
L421

L421

CεH

L421 E424D425

Y418
Y418
Y418
Y418
Y418

Y418

L421
L421
Y418

S420
S420
S420

Y418 YP422

S420

L421 E424D425

Y418

L421 YP422
YP422
YP422
YP422
YP422
YP422

L

CδH

Y418

Y418
Y418
Y418

Y418

419

421

E424D425

H412
P413

Y418
D

CδH
CβH

CαH

P423
S L421
P423 D425
P423
420

S

420

421

L
E424
S420 L421
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P423
L P423
E424
L421
421

P423
L421 P423
L421 P423

YP422
YP422
YP422
YP422
Y418
YP422

Table L: Inter-residue NOEs for the γ′peptide (YP422) bound to IIa at a mixing time of 400ms + 15°C
(continued).

Residue Proton
CαH
CβH
P423
CγH
CδH
NH
CαH
424
E
CβH
CγH
NH
CαH
D425
CβH
NH
CαH
D426
CβH
NH
β
C
H
L427
CγH
CδH

NH
E424 D425
E424 D425
E424

Inter-Residue NOE
CβH
CγH
422 424
YP E

CαH

425

D
D425
D425
D425
E424

P

YP422
YP422
YP422 P423
D425L427

P
L427

YP422 P423 E424

E424

423

423

P423
P423 E424

L427
L427
L427
L427
D426

E424
D425

D425
L427

D426
E D426
E424D426
E424

CδH
YP422

CεH
YP422

YP422
YP422
YP422
L427
YP422
YP422
YP422
YP422

YP422
YP422

YP422
YP422

L427

D425D426

424

Table M: Inter-residue NOEs for 1). free γ′peptides and 2.) unphosphorylated γ′peptide in the presence of
IIa at a mixing time of 400ms + 17°C. There are not many significant differences in NOE assignments
across this series of NMR experiments.
Residue Proton
E411
CαH
NH
H412
CαH
CαH
P413
CδH
NH
CαH
A414
CβH
NH
E415
CβH
NH
CαH
416
T
CβH
CγH
NH
CαH
E417
CβH
NH
CαH
Y418
CβH

NH
H412

CαH

Inter-Residue NOE
CβH
CγH

CδH

E411 P413
P413
H412 A414

415

E
E415
T416
T416
E415
E417
E417
E417
Y418
Y418
Y418
E417
D419
D419

H412
P413

P413

A414

A414
E415

T416

T416

E417

E417

209

T416

CεH

Table M: Inter-residue NOEs for 1). free γ′peptides and 2.) unphosphorylated γ′peptide in the presence of
IIa at a mixing time of 400ms + 17°C. There are not many significant differences in NOE assignments
across this series of NMR experiments (continued).
Residue Proton
NH
CαH
D419
CβH
NH
CαH
S420
CβH
NH
CαH
421
L
CβH
CγH
422
Y
NH
CαH
P423
CδH
NH
CαH
E424
CβH
NH
D425
CαH
NH
D426
CαH
L427
NH

NH
S420
S420
421

CαH
Y418

Inter-Residue NOE
CβH
CγH
418
Y

D419

D419

S420

S420

L421

L421

L
L421
422

Y
Y422
Y422
424

E
E424
D425
D425
D425
E424
D426
L427
L427
D426

P423

E424
D425
D426

210

L421

P423

E424

CδH

CεH

APPENDIX C LIST OF FRAGMENTS FROM PEPTIC DIGESTS OF FXIII(a) and IIa
Table N: Peak listing of fragments from a peptic digest of human FXIII(a).
Residues
Theo. m/z
Sequence
Theo. Dmaxa
4-20
1800.92
SRTAFGGRRAVPPNNSN
17.1
19-33
1558.77
SNAAEDDLPTVELQG
13.6
27-36
1038.58
PTVELQGVVP
7.4
31-41
1151.69
LQGVVPRGVNL
9.5
73-90
2212.24
KLIVRRGQSFYVQIDFSR
18.2
75-84
962.55
IVRRGQSK
7.5
88-99
1568.80
FSRPYDPRRDLF
11.9
89-99
1421.73
SRPYDPRRDLF
10.9
98-104
925.51
LFRVEYV
6.5
100-111
1508.79
RVEYVIGRYPQE
11.8
117-132
1680.93
IPVPIVSELQSGKWGA
13.5
125-136
1317.74
LQSGKWGAKIVM
11.6
133-145
1588.90
KIVMREDRSVRLS
13.0
137-144
1030.58
REDRSVRL
7.9
138-156
2101.13
EDRSVRLSIQSSPKCIVGK
18.1
171-180
1176.56
RTSRNPETDT
8.9
178-184
872.44
TDTYILF
6.4
207-218
1339.65
NDIGVIFYGEVN
11.5
220-230
1372.70
IKTRSWSYGQF
10.8
240-247
1013.45
YVMDRAQM
7.5
248-264
1712.94
DLSGRGNPIKVSRVGSA
15.9
298-305
980.54
ILLEYRSS
7.5
328-338
1216.70
LGIPARIVTNY
9.5
364-372
1125.62
PVPIVSELQSG
8.4
380-389
1132.58
MTRPDLPVGF
7.5
380-391
1246.68
MTRPDLPVGFGG
9.5
511-521
1281.59
VMKSRSNVDMD
10.7
513-522
1198.55
KSRSNVDMDF
9.7
526-546
2431.30
NAVLGKDFKLSITFRNNSHN
21.2
535-541
850.48
LSITFRN
6.5
576-592
1844.05
TLEPLSFKKEAVLIQAG
15.6
607-614
949.51
FVTARINE
7.5
607-619
1533.84
FVTARINETRDVL
12.8
617-624
888.52
DVLAKQKS
7.5
632-645
1484.88
IIIKVRGTQVVGSD
13.5
632-646
1615.92
IIIKVRGTQVVGSDM
14.7
a
The maximum number of exchangeable protons within the indicated peptide, assuming 100%
deuteration. This value accounts for all exchangeable backbone amide protons and a slight
fraction of N-terminal, C-terminal, and side chain exchangeable protons that are dependent on
the final percentage of D2O in solution under quench conditions (approximately 4.5%). A fully
deuterated peptide would theoretically have acquired this amount of deuterons. All peaks were
previously identified by Turner and Maurer (174).
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Table O: Peak listing of fragments from a peptic digest of bovine IIa.
Residuesa
Theo. m/z
Sequence
Theo. Dmaxb TCEPc
-13 to -4
1254.54
TSEDHFQPFF
8.5
n
-3 to 7
1924.92
NEKTFGAGEADCGLRPLF
16.9
y
46-52
888.49
(L)ISDRNV(L)
6.6
n
65-84
2586.48
LVRIGKHSRTRYERKVEKISM
21.8
n
85-94
1317.78
LDKIYIHPRY
8.8
y
85-96
1617.87
LDKIYIHPRYNW
10.9
y
85-99
2102.12
LDKIYIHPRYNWKENL
15.2
n
106-113
996.66
(L)KLKRPIE(L)
6.7
n
106-116
1311.80
LKLKRPIELSD
9.8
n
135-149D
2162.12
KGRVTGWGNRRETWTTSVA
19.4
n
173-180
1018.55
RIRITDNM
7.8
n
173-181
1165.62
RIRITDNMF
8.8
n
202-207
1064.53
KSPYNNRW
6.8
n
212-227
1788.80
IVSWGEGCDRDGKYGF
15.9
y
a
Residues are numbered according the chymotrypsin numbering scheme described in Chapter I.
b
The maximum number of exchangeable protons within the indicated peptide, assuming 100%
deuteration. This value accounts for all exchangeable backbone amide protons and a slight fraction
of N-terminal, C-terminal, and side chain exchangeable protons that are dependent on the final
percentage of D2O in solution under quench conditions (approximately 4.5%). A fully deuterated
peptide would theoretically have acquired this amount of deuterons. cIndicates whether IIa
reduction by TCEP is required to observe fragment in mass spectrum. Non-TCEP fragments were
identified by Croy et al. (233) and TCEP fragments were identified by both Sabo et al. (167) and
Koeppe and Komives (234).
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APPENDIX D ABBREVIATIONS
(In order of appearance)
Shorthand notation for blood coagulation proteins: FXIII = Factor XIII, etc.
Shorthand notation for activated blood coagulation proteins: FXIIIa=Factor XIIIa, etc
TF
Gla
IIa
TFPI
vWF
PAR
HK
PK
TAFI
PC
GAG
tPA
Gp
KD
ABE
LRR
Mac-I
FpA
YS
TGase
NMR
FXIIIaIIa
FXIIIaCa
AT
MALDI
TOF
MS
1D
2D
trNOESY
HDX
DON
IAA
FID
T1
T2
ω
τc
koff
TOCSY

Tissue Factor
γ-carboxyglutamic acid
Thrombin
Tissue Factor Pathway Inhibitor
von Willebrand Factor
Protease Activated Receptor
High Molecular Weight Kininogen
Prekallikrein
Thrombin Activatable Fibrinolysis Inhibitor
Protein C
Glycosaminoglycan
Tissue-type Plasminogen Activator
Glycoprotein
Dissociation Equilibrium Constant
Anion Binding Exosite
Leucine Rich Repeat
Macrophage Antigen-I
Fibrinopeptide A
Sulfotyrosine
Transglutaminase
Nuclear Magnetic Resonance
Thrombin Activated FXIII
Calcium Activated FXIII
Antithrombin
Matrix-Assisted Laser Desorption-Ionization
Time-of-Flight
Mass Spectrometry
One Dimensional
Two Dimensional
Transferred Nuclear Overhauser Effect Spectroscopy
Hydrogen Deuterium Exchange
6-diazo-5-oxo-norleucine
Iodoacetamide
Free Induction Decay
Spin-lattice Relaxation
Transverse Relaxation
Resonance Frequency
Rotational Correlation Time
Dissociation Rate Constant
Total Correlation Spectroscopy
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DE
m/z
α-CHCA
NEM
AA
ku
kf
kop
kcl
kobs
TCEP
PSD
YP
BSE
EDTA
MWCO
PPACK
TFA
AUC
KI
IC50
SV
S
DMSO
GDH
GEE
NADH
FXIII(a)
DMF
α2AP
AP
ITC
ΔH
ΔG
ΔS
R
T
HSQC
PFG

Delayed Extraction
Mass to Charge ratio
α-cyano-4-hydroxycinnamic acid
N-ethylmaleimide
Acetic Anhydride
Unfolding Rate Constant
Folding Rate Constant
Local Unfolding Rate Constant
Local Folding Rate Constant
Observed Rate Constant
Tris (2-carboxyethyl) phosphine
Post Source Decay
Phosphotyrosine
Barium sulfate eluate
Ethylenediaminetetraacetate
Molecular Weight Cut-Off
D-Phe-Arg-Pro-chloromethyl ketone
Trifluoroacetic acid
Analytical Ultracentrifugation
Inhibition Equilibrium Constant
Concentration Resulting in 50% Inhibition
Sedimentation Velocity
Svedberg Constant
Dimethylsulfoxide
Glutamate Dehydrogenase
Glycine ethyl ester
Nicotinamide adenine dinucleotide
Unactivated, Activated and Inhibited Factor XIII
Dimethyl formamide
α2-antiplasmin
Activation Peptide
Isothermal Calorimetry
Enthalpy
Gibbs Free Energy
Entropy
Gas Constant
Absolute Temperature
Heteronuclear Single Quantum Coherence
Pulsed Field-Gradient
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